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BPGAP1 (BNIP-2 and Cdc42GAP Homology (BCH) domain-containing, 
Proline rich and Cdc42GAP-like protein subtype-1) is a ubiquitously expressed 
protein that regulates cell signaling and cell motility via its multiple protein 
modules. It inactivates the molecular switch for cytoskeleton, RhoA through its 
Rho-GTPase-activating protein (RhoGAP) domain at the C-terminus and together 
with the N-terminal BCH domain and the Proline-rich region in between that 
targets cortactin, endhophilin, Mek2 and Pin1, these domains serve to regulate 
ERK activation, pseudopodia formation and cell migration in a concerted 
manner.  Interestingly, overexpression of the BCH domain also elicits sustained 
Ras/ERK although the underlying mechanism(s) remain largely unknown. 
 
Our proteomics-based affinity pulldown experiments revealed several 
novel interacting partners for BPGAP1, raising the possibility that BPGAP1, via 
its unique domain architecture, could be subjected to multitude levels of controls 
in space and time. This thesis therefore aims to examine how its interaction with 
one such partner, LanCL1 (Lantibiotic synthetase component C-like 1; whose 
function remains elusive until recently), would modulate BPGAP1 function in 
ERK signaling and neuronal differentiation. Through series of co-
immunoprecipitation studies using BPGAP1 and LanCL1, their interaction in vivo 






cells. Unexpectedly, BPGAP1 interacts with all three forms of Ras (K-, N- and H-
Ras) whereas LanCL1 is H-Ras specific and predominantly targeting the 
constitutively active H-Ras G12V. Further mutational studies revealed that the 
specificity of LanCL1 towards H-Ras may be due to the specific microdomian 
localization of the Ras isoforms. While a highly conserved Histidine-323 on 
LanCL1 was indispensable for its interaction with H-Ras (but not for BPGAP1), 
more than one site of LanCL1 and BPGAP1 appeared to be required for their 
interaction to each other, suggestive of complex protein-protein interaction 
network amongst the trio of BPGAP1, LanCL1 and Ras.  
 
To elucidate the physiological significance of their interaction, 
knockdown of LanC1 were generated and the extents of Ras/Erk activation were 
monitored in the presence of BPGAP1. Interestingly, LanCL1 knockdown in 293T 
significantly reduced Ras/Erk activation upon EGF stimulation but such effect 
was abrogated with BPGAP1 overexpression. Conversely, when either LanCL1 or 
BPGAP1 was overexpressed seperately, they activated Ras/Erk and potentiated 
PC12 differentiation. For BPGAP1, this induction was GAP-independent. 
However, such a stimulative effect was delayed when they were both co-
expressed, and such mutual neutralizing effect required the GAP activity of 
BPGAP1.  Taken together, despite acting separately as inducer for Ras/ERK, 
timely BPGAP1-LanCL1 interaction could act as a feedback loop to modulate 
their signaling output, the detailed molecular basis for this awaits further 
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1    INTRODUCTION 
 
1.1.   Small GTPases – The molecular switches of cell dynamics control  
 
Small guanine nucleotide triphosphate (GTP)-binding proteins or small GTPases 
constitute a large superfamily of more than 150 members and function as molecular 
switches regulating important signaling networks in almost all aspects of cell biology 
(Bernards and Settleman , 2007; Wennerberg et al., 2005). These proteins have 
evolutionarily conserved orthologues in Drosophila, Caenorhabditis elegans, 
Saccharomyces cerevisiae, Dictyostelium and plants and have been classified into the 
Ras superfamily of proteins (Wennerberg et al., 2005). 
 
This superfamily of small GTP-binding proteins (GTPases) are classified based on 
their sequence similarities and functions into subfamiles, which comprises the Ras, Rho, 
Rab, Ran and Arf. They regulate a wide variety of cell functions as biological timers 
(biotimers), that initiate and terminate specific cell functions and determine the periods 
of time for the continuation of the specific cell functions. They furthermore play key 
roles in not only temporal but also spatial determination of specific cell functions. The 
Ras family regulates gene expression, the Rho family regulates cytoskeletal 
reorganization and gene expression, the Rab and Sar1/Arf families regulate vesicle 
trafficking, and the Ran family regulates nucleocytoplasmic transport and microtubule 
organization (Takai et al., 2001).  
 
 




Variations in structure and post-translational modifications dictate specific 
subcellular locations and the proteins that serve as their regulators and effectors allow 
these small GTPases to function as sophisticated modulators of a remarkably complex 
and diverse range of cellular processes (Wennerberg et al., 2005). The first proteins to 
be characterized in this family were the Ras proteins. 
 
 
Figure 1.1: Dendogram of the Ras superfamily of small GTPases. Subfamilies are 
indicated by colored arcs. RAS (pink), RAB/RAN (BLUE), ARF (Yellow), G (orange) and 
RHO (green) (Adapted from Coliceli, 2004).  
 
 




1.1.1.   Ras subfamily of small GTPases K-Ras , N-Ras and H-Ras 
 
The Ras subfamily of small GTPases encompasses 36 genes, coding for 39 Ras 
proteins. The great fascination of cell biologists with Ras stems from the early 
association of the ras gene with cancer and the frequency of ras mutations being the 
highest amongst any genes in human cancers (Barbacid M., 1987 and Hunter T., 1997) 
Mutated ras genes were first identified by their ability to transform NIH/3T3 cells after 
DNA transfection. The cellular homologues of the viral Harvey and Kirsten transforming 
ras sequences were first identified in the rat genome in 1981 and were subsequently 
found in the mouse and human genomes (Rajalingam et al., 2007). N-Ras was then 
cloned from neuroblastoma and Leukemia cell lines in early 1980s. 
 
There are four mammalian Ras proteins, encoded by three ras genes: H-Ras, N-
Ras, K-Ras4A and K-Ras4B. The three isoforms of Ras, H-, N- and K-Ras, are all 
ubiquitously expressed in mammalian cells.  
 
1.2.   Mechanism of regulation and Biochemistry of GTPases control on  
          signaling pathways 
 
Small GTPases are regulated intricately by the action of various regulatory 
proteins. In addition to regulatory proteins, post-translational modification on the C 
termini determines their sub–cellular localization, providing an additional level of 
regulation. 
 




1.2.1.   Small GTPases – the binary regulatory switches of signaling 
 
Although similar to the heterotrimeric G protein subunits in biochemistry and 
function, Ras superfamily proteins function as monomeric G proteins. They share a set 
of conserved G box GDP/GTP-binding motif elements beginning at the N-terminus: G1, 
GXXXXGKS/T; G2, T; G3, DXXGQ/H/T; G4, T/NKXD; and G5, C/SAK/L/T (Bourne et al., 
1991). Together, these elements make up an 20 kDa G domain (Ras residues 5-166) that 
has a conserved structure and biochemistry shared by all Ras superfamily proteins, as 
well as G  and other GTPases (Biou and Cherfils, 2004).  
 
The small GTPases of the Ras superfamily mediate numerous biological 
processes through their ability to cycle between an inactive GDP-bound and an active 
GTP-bound form. Small GTPases can bind effectively to both GTP and GDP. When bound 
to the GTP, it is in the “switch on mode” which causes a conformational change allowing 
it to interact with downstream effectors activating a signaling cascade resulting in 
specific cellular effects. When bound to the GDP they exist in the “switch off mode” that 
turns off the signal by rendering the small GTPase inactive. The cycling between the 
“on” and “off” modes are regulated by two classes of regulatory proteins the Guanine 
nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). The GEFS 
turn on the signal by facilitating the exchange of the GDP with GTP and activating the 
small GTPase. Although G proteins are also called GTPases, the actual GTP hydrolysis 
reaction is in fact very slow, and efficient hydrolysis requires the interaction  
with a GAP that increases the intrinsic GTPase activity of the small GTPase thereby,  
 




hydrolyzing the bound GTP to GDP resulting in the termination of the signal. In addition 
the Rho and Rab family of proteins have an additional level of regulation through the 
guanine nucleotide dissociation inhibitors (GDIs), which complex with the GDP-bound 





















Figure 1.2:  The Binary switch. The small GTPase is in the inactive GDP bound form 
and upon an upstream stimulus; the GTPases are activated by GEFs that displace the 
GDP, resulting in GTP bound active GTPases that can elicit downstream responses. 
Intrinsic GTPase activity catalysed by GAPs hydrolyses the bound GTP to GDP resulting 
in the inactivation of the active GTPases. Certain GTPase families like Rab and Rho have 












1.2.1.1.   Regulation of GTPase activation- Role of GEFS 
 
The GEFs are often the targets of biological signals, which induce, inhibit, or 
modulate their catalytic activity. Almost all GEFs are multidomain proteins regulated in 
a highly complex fashion. The impressively large number of GEFs encoded by 
eukaryotic genomes, with their diverse combinatorial arrangement of functional 
domains, highlights the complexity of their regulation.  This regulation includes protein-
protein or protein-lipid interactions, binding of second messengers, and post-
translational modifications (Bos et al., 2007). 
 
1.2.1.1.a.   General Mechanism of GEFs 
 
The affinity of most small G proteins for GDP/GTP is in the lower nanomolar to 
picomolar range. The direct consequence of this high affinity is a slow dissociation rate 
of nucleotides with a half-life on the order of one or more hours. Because exchange of 
GDP for GTP and thus, activation of G proteins in biological processes occur within 
minutes or even less, exchange of GDP for GTP requires the activity of GEFs. Indeed, 
GEFs accelerate the exchange reaction by several orders of magnitude (Vetter I. R.  and 
Wittinghofer A., 2001). 
  
GEFs catalyze the dissociation of the nucleotide from the G protein by modifying 
the nucleotide-binding site such that the nucleotide affinity is decreased, causing the 
release and subsequent replacing of the nucleotide. In general, the affinity of the G  
 




protein for GTP and GDP is similar, and the GEF does not favor rebinding of GDP or GTP. 
Thus the resulting increase in GTP-bound over GDP-bound is due to the approximately 
ten times higher cellular concentration of GTP compared to GDP. Thus, the interaction 
of a GEF weakens the affinity for the nucleotide, and visa versa, the nucleotide weakens 
the affinity for the GEF. In the course of the exchange reaction, the GEF displaces the 
bound nucleotide, and subsequently a new nucleotide displaces the GEF. 
 
The G-protein-bound nucleotide is sandwiched between two loops called switch 
1 and switch 2. The switch regions together with the phosphate binding loop (P loop) 
interact with the phosphates and a coordinating magnesium ion. Both phosphates and 
the magnesium ion are essential for the high-affinity binding of the nucleotide to the G 
protein (I. R. Vetter and A. Wittinghofer, 2001).  
 
GEF binding induces conformational changes in the switch regions and the P 
loop, while leaving the remainder of the structure largely unperturbed. For instance, the 
CDC25-HD of SOS makes extensive contacts with switch 2 and uses an α-helical wedge 
to pry open the binding site (Boriack-Sjodin et al., 1998). Thus, although the various 
GEFs are not conserved, their common action is to deform the phosphate-binding site, 










1.2.1.1.b.   Conserved mechanisms  in GEFS (GTPase regulators) 
 
Analysis of several of the individual GEFs has also revealed a few conserved 
themes that may apply more broadly to these numerous and ubiquitous GTPase 
regulators:  
(1) GEFs tend to assume a conformationally auto-inhibited state that can be relieved 
through a variety of signal-induced biochemical “inputs”.  
(2) Many of the established regulatory mechanisms for GEF activation involve rapid 
stimulus induced recruitment to specific sub-cellular membrane regions where their 
target GTPases reside, as well as allosteric activation of the catalytic domain occurs. 
 (3) GEFs are likely to serve as “coincidence” detectors that can integrate signals by 
virtue of their ability to be influenced by multiple distinct types of biochemical inputs. 
The most thoroughly understood GEF, Sos, has been intensively investigated in a variety 
of experimental systems. (Bernards and Settleman, 2007). 
(4) GEFs, like GAPs, are also under negative regulatory control; primarily via the 
ubiquitin–proteasome system regulating growth factor signaling independent of their 
GTPase-related catalytic function. Negative regulation of GEFs can also be achieved 
through regulatory mechanisms similar to those that can promote GEF activation 
(Birkenfeld et al., 2007). 
(5) Cross-talk between signaling pathways at the level of GEFs also contribute to 
regulation. For example, there are several GEFs whose activity towards one Ras  
superfamily member is controlled by other Ras GTPases, or by heterotrimeric G protein 
alpha or beta gamma subunits. 
 




(6) Post-translational modification such as lipid binding, interaction with second 
messengers such as cAMP or by interaction with other proteins mediated by a variety 
of protein interaction domains. Indeed, many signaling GEFs are complex proteins, 
comprised of multiple functional domains (Bos et al. 2007). Moreover, the regulation of 
these proteins may be further complicated by the fact that some GEFs contain more 
than one GEF catalytic domain, or they contain a combination of GAP and GEF domains 
within a single protein. 
(7) Performing context-dependent functions. GEF activity may be determined by 
various regulatory inputs that impinge on a particular GEF in a given setting. Even 
within the same cell, a single GEF may play distinct roles that are dictated by regulatory 
mechanisms that affect, among other things, protein localization. (Hahn and Toutchkine, 
2002). 
 
1.2.1.1.c.   GEFs in disease 
 
While GEF function has been largely studied in the context of normal biology, 
accumulating evidence from genetic studies has revealed roles for both gain and loss-of-
function of specific GEFs in a variety of human diseases. Mutations that disrupt the 
function of the RasGAP NF1 and the RhebGAP TSC2 give rise to the common genetic 
disorders neurofibromatosis-1 and tuberous sclerosis, respectively (Bernards and 
Settleman 2005). Several other disorders have similarly been associated with mutations 
that either activate or inactivate Ras superfamily GEFs. 
 
 




1.21.2.   Regulation of GTPase inactivation - Role of GAPS  
 
GTPase-activating proteins (GAPs) are the key regulators of GTPase cycling, 
stimulating the weak intrinsic GTP-hydrolysis activity of the GTPases and inactivating 
them. GAP activity is regulated by several mechanisms, including protein–protein 
interactions, phospholipid interactions, phosphorylation, subcellular translocation and 
proteolytic degradation (Bernards and Settleman, 2005). 
 
The human genome predicts around 170 proteins that are structurally related to 
GAPs for Ras superfamily members. The fact that up to 0.5% of human genes may 
encode functional GAPs serves to highlight the likely importance of this class of 
regulators. Interestingly, 70 putative GAPs are predicted to be speciﬁc for Rho GTPases, 
whereas another 30 genes predict putative GAPs for members of the Ras branch, which 
in mammals include H-, K-, and N-Ras, three R-Ras paralogs (R-Ras, R-Ras2/TC21 and 
R-Ras3/M-Ras), ﬁve Rap-related GTPases, RalA and RalB, Rheb, as well as several less 
well studied proteins. Thus, although Ras and Rho GTPases together account for just 
one third of all mammalian Ras superfamily members, these proteins are potentially 











1.2.1.2.a.   Mechanism of GAPs 
 
The GTPase activating proteins (GAPs) prevents prolonged activation of RAS 
GTPases by stimulating the intrinsic GTPase activity of Ras and accelerating the 
cleavage step by several orders of magnitude (Donovan et al., 2002). This is an 
important aspect of regulation of Ras activity that is frequently deregulated in 
tumorigenesis. All oncogenic Ras mutations compromise its GTPase activity by  
preventing GAPs from stimulating the hydrolysis of GTP or by affecting GAP action, 
thereby maintaining Ras constitutively in the active GTP-bound conformation. Besides 
Ras mutations, prolonged activation of Ras in carcinogenesis may also occur from 
inactivation of RAS GAPs (Panagiotis A. et al., 2007). 
 
The catalysis of phosphoryl transfer by GAPs consists of 1) the proper 
orientation of the attacking water molecule and its polarization 2) occlusion of water 
from the active site and 3) the stabilization of the transition state. However, as with 
GEFs, GAPs for the different Ras-protein families are not conserved, approach the G 
protein from different angles, and use various ways to enhance the GTPase activity. 
 
The first insight into GAP-assisted GTP hydrolysis was obtained from the 
biochemistry and structure of the Ras-RasGAP complex (Klaus Scheffzek et al., 1997). 
Ras-GAP stabilizes the position of glutamine 61 of Ras, which in turn coordinates the 
attacking water. In addition, an arginine, called the arginine finger, is positioned into the 
phosphate-binding site and stabilizes the transition state by neutralizing negative  
 




charge at the γ-phosphate. The arginine finger fulfils a function very similar to the 
arginine found in the helical insertion of α-subunits of large G proteins. This mechanism 
of catalysis is supported by biochemical and mutational studies (Bos et al., 2007).  
 
A similar mechanism is found in RhoGAP-assisted hydrolysis even though 
RasGAP and RhoGAP are not related in terms of primary structure and are only 
distantly related in terms of tertiary structure (Rittinger et al., 1997). The catalytic 
glutamine of Ras and Rho is also conserved in Rab, and the arginine finger is observed 
in RabGAP, but the mechanism is somewhat different. In this case, the glutamine that 
orients the water is supplied by the GAP, and the glutamine of Rab is pointing away 
from the active site and is involved in the binding of GAP (Pan et al., 2006). Mutation of 
glutamine 61, which frequently occurs in human tumors, abolishes GAP-induced 
hydrolysis. Oncogenic mutations at position 12 and 13 of Ras stearically block the 
proper orientation of both the arginine finger and the glutamine 61 preventing 
hydrolysis (Scheffzek et al., 1997).  
 
1.2.1.2.b.   Regulation of GAPS 
 
Several factors may explain the existence of multiple Ras and Rho GAPs. 
Individual GAPs may function in speciﬁc cell types, target speciﬁc GTPases or control 
GTPases in the context of speciﬁc signaling pathways by associating with specific  
membrane compartments or signaling complexes. While several GAPs are widely 
expressed, some are restricted to speciﬁc tissues. Finally, many Ras and RhoGAPs  
 




include a variety of putative protein or membrane interaction domains in addition to 
their catalytic segments. These domains have been implicated in the formation of 
transient protein complexes in response to incoming signals.  GAPS can thus be 
regulated by protein complex formation, protein phosphorylation, proteolytic 
degradation or changes in subcellular localization (Bernards and Settleman, 2004).  
 
(a) Regulation by protein interaction 
 
The GAP activity of the p190-B RhoGAP is stimulated by direct interaction with 
the small GTPase Rnd3, suggesting the existence of ‘GTPase cascades’ that involve the 
regulation of one GTPase by another through a GAP. The GEFs have been also implicated 
in such cascades. For example, the Race Tiam1 can be activated by direct interaction 
with the activated Ras protein.  Some GAPs are also regulated by intramolecular 
interactions. For example, the PH domain of p120 RasGAP associates with and regulates 
the activity of its catalytic domain. 
 
(b)  Regulation by protein phosphorylation 
 
GAP phosphorylation has the potential to influence GAP enzymatic function 
directly through conformational effects on the catalytic site, and it can also affect GAP 
activity indirectly by regulating the subcellular localization, the targeted degradation 
and, as described above, the protein interactions. For example, the RasGAP 
neurofibromin (the product of the NF1 tumor suppressor gene) is phosphorylated at 
several sites in its carboxy (C)-terminal region by protein kinase A; this 
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phosphorylation promotes the interaction of neurofibromin with 14–3-3 proteins and 
correlates with a reduction in RasGAPactivity, but the mechanism is poorly understood  
(Feng  L. et al., 2004).  
 
(c)  Dephosphorylation-mediated GAP regulation  
 
Protein dephosphorylation, via the action of phosphatases, is also likely to have a 
regulatory role in GAP activity. Evidence suggests that dephosphorylation of p190-B 
RhoGAP by the SHP-2 tyrosine phosphatase downmodulates its RhoGAP activity 
(Sordella, R. et al., 2003). 
 
(d)  Regulation by lipids 
 
Activation of protein kinase C (PKC) by phospholipase Cg (PLCg)-mediated 
generation of diacylglycerol has been implicated in signaling by several of the Ras and 
Rho family GTPases. Lipids can influence GTPase signaling by affecting various protein 
components that function as upstream regulators or downstream targets of the GTPase. 
Moreover, because most small GTPases have covalently bound lipids at their C-terminus 
and are consequently targeted to membranes, they are located in close proximity to 
regulators and targets that are potentially influenced by membrane-bound lipids.  
 
Thus, lipids can modulate GTPase-mediated signaling at many levels. In the 
context of GAP regulation, several studies now point to a likely role for various lipids in 
the regulation of GAP catalytic function through direct interactions with GAP proteins 
(Bernards and Settleman, 2004). 




1.2.1.2.c.   Regulation of Ras GAPS 
 
Early studies suggested that lipids have a regulatory role in controlling the two 
RasGAPs neurofibromin and p120 RasGAP. Various acidic phospholipids and fatty acids 
have strong inhibitory effects on the catalytic activity of these proteins towards Ras-
mediated GTP hydrolysis (Tsai, M.H. et al., 1989; Bollag, G. and McCormick, F., 1991). 
Lipid micelles interact directly with the catalytic domain of these RasGAPs and 
potentially inhibit activity by simply sequestering the protein and reducing its 
accessibility to its GTPase substrate (Serth, J. et al., 1991). 
 
Analysis of three mammalian RasGAPs that are structural orthologs of 
Drosophila GAP1 suggests that highly related proteins with identical overall domain 
structures can be regulated in fundamentally different ways. GAP1-related RasGAPs are 
characterized by the presence of two phospholipid-binding C2 motifs, followed by a 
RasGAP catalytic segment and a PH-BTK domain. Mammalian GAP1m and GAP1IP4BP 
are constitutively associated with the plasma membrane and the former translocates to 
the plasma membrane after activation by PI3K (Lockyer, P. J. et al., 1997). This 
difference has been attributed to different phosphoinositide binding specificities of the 
PH domains of these proteins, which share 63% identity (Cozier, G. E. et al., 2003). 
 
A third mammalian GAP1 ortholog, termed Ca2þ-promoted Ras inactivator 
(CAPRI), undergoes Ca2þ-dependent membrane translocation, which activates its 
RasGAP activity through an unknown mechanism (Lockyer, P. J. et al., 2001). The PH  
 




domain of CAPRI does not bind phosphoinositides, and the C2 domains of GAP1m and 
GAP1IP4BP lack residues implicated in Ca2þ-dependent lipid binding. Thus, it seems 
that other closely related GAPs are likely to be regulated through distinct mechanisms. 
 
 
1.2.1.2.d.   GAPs and disease  
 
Two of the most common human genetic disorders associated with an increase 
in cancer risk, neuroﬁbromatosis type 1 (NF1) and tuberous sclerosis complex (TSC), 
are caused by mutations that disrupt the function of GTPase-activating proteins (GAPs). 
The NF1 gene encodes neuroﬁbromin, which functions as a GAP for Ras and its 
immediate relatives (Cichowski, K. and Jacks, T. ,2001), whereas mutations in TSC1 or 
TSC2 affect the function of a two-subunit GAP for the GTPase Rheb, which functions in 
the target of rapamycin (TOR) signaling pathway (Li et al., 2004). 
 
Mutations in the gene RASA1, which encodes the ﬁrst GAP to be identiﬁed, p120 
RasGAP, have been recently found in individuals affected with a capillary and 
arteriovenous malformation syndrome (Eerola, I. et al., 2003). Loss-of-function 
mutations in the murine ortholog of p120 RasGAP also cause vascularization defects 









1.3.   Post-translational Modification of small GTPases 
 
 RAS superfamily GTPases undergo extensive post-translational modifications 
that regulate protein–protein interactions, protect them from proteolytic degradation 
and most importantly, facilitate membrane attachment and determine their subcellular 
localization and function (Radhika, V. & Dhanasekaran, N., 2001). RAS GTPases are the 
founding members of CAAX proteins, (C denotes cysteine, A represents any aliphatic 
amino acid and X may be any amino acid in their carboxyl terminus). 
 
The CAAX motif serves as a substrate for a series of post-translational 
modifications that create a lipidated hydrophobic domain, which mediates attachment 
to specific proteins (for example, the interaction of RHO with GDI) as well as 
membranes. These modifications include the covalent attachment of a non-sterol 
isoprenoid (either farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate 
(GGPP)) to the cysteine residue of the CAAX motif by prenylation (farnesylation and 
geranylgeranylation, respectively) (Zhang et al., 1996) 
 
 Farnesylation occurs when the CAAX sequence ends in any amino acid other 
than leucine and is catalysed by farnesyltransferase (FTase), whereas  
geranylgeranylation occurs when the CAAX sequence ends in leucine (as in the case of 
RHO B) and is catalysed by geranylgeranyltransferase I (GGTase I)( Reid et al., 2004). H-
Ras is only farnesylated, whereas K-Ras4A, K-Ras4B and N-Ras can be farnesylated and 
geranylgeranylated. 
 




1.3.1.   Ras Small GTPases - Localization dependant functions 
 
H-Ras, K-Ras and N-Ras are expressed ubiquitously and almost identical in terms 
of structural, biophysical and biochemical properties. Despite their similarities, the Ras 
isoforms have differing functions in various tissues. These differences are proposed to 
be mediated by differential localisation, enabling isoforms to interact with different 
subcellular pools of effectors and activators (Daniels et al., 2006; Onken et al., 2006; 
Rocks et al., 2006). The first evidence to support this hypothesis was derived from the 
association between activated RAS oncogenes and specific human cancers. This 
association has been attributed to a large extent, to the preferential expression of 
specific Ras isoforms in the affected organs (Leon et al., 1987). 
 
 Experiments in mouse genetics have suggested that there are distinct functions 
of Ras isoforms in specific tissues throughout development. For example, K-Ras-4B, but 
not K-Ras-4A, is essential for embryogenesis, as K-Ras-4B-deficient embryos 
succumbed to anemia, liver defects and cardiac abnormalities early in gestation 
(Johnson L. et al., 1997; Koera, K. et al., 1997). 
 
By contrast, H-Ras- and/or N-Ras-deficient animals develop normally and are 
viable (Luis M. E. et al., 2001; Umanoff H. et al., 1995) which suggests that their 
functions are mostly dispensable or at least redundant. Mice in which the H-Ras coding 
sequence was knocked into the locus of K-Ras (resulting in the loss of detectable K-Ras 
protein) were also shown to be viable (Potenza, N. et al., 2005) indicating that H-Ras  
 




can functionally replace K-Ras during embryogenesis when its expression is controlled 
by the K-Ras promoter.  
 
Most importantly, these findings suggest that the mortality of the K-Ras 
knockout mice might not result from the intrinsic inability of other Ras isoforms to 
compensate for K-Ras functions, but might rather derive from the inability of the other 
isoforms to be expressed in the same embryonic compartments as K-Ras (Karnoub and 
Weinberg,  2008). 
 
1.3.2.   Domain Architecture and Membrane targeting of Ras proteins. 
 
The G domain of Ras is >95% conserved between isoforms and binds the guanine 
nucleotides, the switch 1 and 2 loops undergo the major conformational changes on 
GTP-GDP exchange and is the binding surface for effectors, exchange factors and GAPs. 
In contrast the C terminal HVR (Hypervariable region comprising 24-25 aminoacids) is 
poorly conserved between isoforms (Figure 1.3) This region contain sequences that 
control post translational processing, plasma membrane anchoring and trafficking of 
nascent and processed Ras. Different HVR anchors may target the Ras isoforms to  
different microdomains and the different microenvironment may influence Ras signal 
output. This hypothesis can account for the extensive biological differences between 
Ras isoforms. 
 
The HVR comprises the well characterized anchor sequences that also operate as  
 




Ras trafficking signals. The minimal Ras anchor comprises the carboxy terminal CAAX 
motif in addition to a second signal. The second signal comprises a single palmitoylation 
site (C181) in N-Ras, two palmitoylation sites (C181, C184) in H-Ras and a polybasic 
domain of 6 contiguous lysine residues in K-Ras (K175-180). The protein sequence 
between the anchor and the conserved domain constitutes the linker domain (Figure 
1.4). 
 
 CAAX motif is the minimal Ras anchor (C is cysteine, AA is aliphatic and X is any 
amino acid) and mutation in this region abolishes plasma membrane association 
(Willumsen et al., 1984). Ras proteins initially synthesized as cytosolic precursors that 
undergo post-translational processing enabling them to associate with cell membranes. 
The modifications include Farnesylation (attachment of a farnesyl group) at the 
cysteine residue followed by removal of the AAX sequence, and then it is methylated. 
   
After methylation H-Ras and N-Ras undergo palmitoylation on cysteine residues 
181and C184 for H-Ras and 181 for N-Ras and enter the exocytic pathway, trafficking 
through Golgi to the plasma membrane and K-Ras which has a poly lysine sequence 
instead, bypasses Golgi and reaches the plasma membrane by yet unknown mechanisms 
(John F. Hancock, 2003). The two palmitoyl groups of H-Ras are not equally necessary 
for trafficking to the plasma membrane, palmitoylated Cys181 (C184S mutant) supports 
cell-surface localization, whereas mono-palmitoylation on Cys184 (C181S mutant) 
confines H-Ras to the Golgi (Roy S et al., 2005). 
 
 




Although based on mutagenesis studies, these observations are highly relevant 
to in vivo trafficking because Ras palmitoylation is labile. The measured half life is 10–
20% of that of the 21 h half-life of N- and H-Ras, and these cycles of acylation and 
deacylation are important regulators of global Ras compartmentalization by allowing 
recycling back to the Golgi complex for re-palmitoylation (Baker TL et al., 2003; Magee 
Al et al., 1987). When de-palmitoylation is inhibited, H-Ras is non-specifically localizes 
to all endomembranes (Rocks O et al., 2005). Thus, it is clear that the regulation of Ras 
palmitoylation would be an interesting way of modulating H-Ras and N-Ras localization 







 Figure 1.3:  Sequence alignment of Ras isoforms H, N, and K-Ras. 
The G domain –(Cyan) is >95% conserved contains switch I and II regions (highlighted 
in red ), the linker region (pink) and the C-Terminal HVR (green) are poorly conserved. 




(Modified from Hancock et al., 2003) 
Figure 1.4: Schematic representation of the conserved and hypervariable region 
of Ras isoforms.  All Ras isoforms have a CAAX tail that undergo farneselysation. K-Ras 
has a poly basic region containing 6 lysine residues .H-Ras has two cysteines at 181 and 
184 and N-Ras a single cysteine at 181 that undergo palmitoylation. 
 
1.3.3.   Importance of the Hypervariable region 
 
The plasma membrane being a complex dynamic structure provides platforms 
for the assembly of many signal transduction pathways, which have the capacity to 
impose an additional level of regulation on signaling networks (Hancock J.  F. and 
Robert G. Parton, 2005). The three isoforms of Ras, H-, N-and K-Ras, are all ubiquitously 
expressed in mammalian cells. They are highly homologous GTPases and interact with a 
common set of exchange factors and effector proteins to transduce signal from growth 
factor receptors, yet generate distinct signal outputs. These signaling differences are not 
reproduced in vitro, which indicates that the complexities of plasma-membrane 
microstructure, and exactly where on the membrane the signaling complex is 
assembled, are important factors in regulating signal output. 
 




1.4.   Plasma membrane signaling nanoclusters 
 
The plasma membrane has traditionally been viewed as a homogeneous 
organelle; in recent years, this model has been updated to incorporate a dense mosaic of 
signaling domains (Laude AJ and Prior IA, 2004). These incorporate nanoclusters of 
proteins and lipids that potentially facilitate signaling by selectively concentrating the 
components of effector cascades.  
 
Several laboratories using a combination of fractionation, chemical perturbation 
and advanced microscopy techniques, have characterized the association of Ras 
isoforms with different cell-surface nanoclusters that is driven by interactions of their 
HVRs with membrane proteins and lipids (Murakoshi H et al., 2004; Niv H et al., 2002; 
Prior IA et al., 2003). These nanoclusters are small (< 15 nm diameter) and short-lived 
(t 1/2 0.4 s) (Nicolau D. V., 2006). K (B)-Ras operates from actin-dependent, 
cholesterol-independent nanoclusters that are stabilized by galectin-3 and distinct from 
the H- and N-Ras signaling nanoclusters (Plowman SJ et al., 2008; Prior IA et al., 2003) 
 
The palmitoyl groups of H-Ras specify localization in cholesterol-dependent 
nanoclusters, however upon activation, H-Ras translocates into new cholesterol 
independent nanoclusters (Roy S et al., 2005; Prior IA et al., 2003). The activated H-Ras 
nanoclusters are stabilized by galectin-1 interactions with the C-terminal farnesyl group 
of the HVR (Prior IA et al., 2003; Belanis L et al., 2005; Paz A  et al., 2001).  However the 
clustering of GDP loaded H-ras C184S and GDP loaded N-Ras was unaffected by  
 




cholesterol depletion, suggesting that  H-Ras loses affinity for lipid raft domains on GTP 
loading  but N-Ras and monopalmitoylated  H-RasC184S behave in exactly the opposite 
manner and increase  affinity for lipid rafts on GTP loading (Roy et al., 2005). 
 
Ras activation might translate into differential nanocluster association. In 
addition, to characterizing the dynamic association of Ras with different nanoclusters, 
the functional consequences of these interactions have been analysed in silico and in 
vivo. Importantly, if nanocluster formation is inhibited, output is reduced to just 3% of 
maximal signalling (Tian T et al., 2007). 
 
Given that differential localization of Ras isoforms to distinct signaling 
nanoclusters underlies the lack of functional redundancy between Ras isoforms, 
effectors may have different affinities for each type of nanocluster. Recent high-
resolution microscopy analysis revealed that although both H and K-Ras can recruit Raf 
to the plasma membrane, the activated K-Ras nanoclusters retain Raf, whereas 
activated H-Ras–Raf interactions are transient (Plowman SJ et al., 2008). The 
biophysical and biochemical properties of different types of nanocluster are believed to 
regulate the variety and time course of effector interactions allowing different outputs 










1.5.   Compartmentalized signaling of Ras Isoforms 
Although all organelles have at least one Ras regulator in residence, the ER⁄Golgi 
and endosomes appear to be hotspots for controlling intracellular Ras signaling 
(Jasminka Omerovic and Ian A. Prior, 2008). 
 
 
1.5.1.   Endosomal signaling 
 
The initiation points of most signaling cascades are the cell-surface localized 
RTKs and G-protein-coupled receptors.  A proportion of activated receptors are 
internalized and sorted through the endosome for recycling back to the surface or 
delivered to lysosomes for degradation. Because the tails of early endosomal receptors 
are still exposed to the cytosol, they are also potentially able to initiate signaling 
cascades if still active. This observation, together with the localization of the Ras GEF, 
mSos, the activated Raf-MAP kinase cascade and scaffold proteins MP1 and APPL on 
endosomes, suggests that they are a viable platform for RTK–Ras signaling (Di 
Guglielmo  et al., 1994; Pol A et al., 1998). 
 
1.5.2.   ER ⁄ Golgi signaling 
 
Studies of ER⁄Golgi signaling provide some of the best evidence for isoform and 
compartment specific Ras signaling having phenotypic consequences. Ras GEFs and 
GAPs, the Ras effector Rain1 and the scaffold Sef have all been localized to the Golgi  
 




(Omerovic et al., 2007; Torii S et al., 2004; Mitin N. Y. et al., 2004).Although endogenous 
Golgi Ras activation has largely proved difficult to visualize (Augusten M. et al., 2006) an 
elegant bystander fluorescence technique revealed that delayed and sustained 
endogenous Golgi Ras activation could be stimulated by growth factors (Chiu V. K . et al., 
2002 ). Ras activation on the Golgi is mediated by calcium⁄diacylglycerol (Ca2+⁄ DAG) 
dependent stimulation of RasGRP1   and on the ER by lysophosphatidic acid dependent 
stimulation of RasGRF1 and Ras-GRF2 (Bivona T. G. et al., 2003). 
 
Finally, the Golgi also interestingly provides a site for negative regulation of Ras 
signaling and stimulation of cell proliferation and differentiation via the action of RKTG. 
This is a seven transmembrane protein that sequesters cytosolic Raf to the Golgi, 
competitively inhibiting interaction with activated Ras and the MAP kinase cascade 
(Feng L et al., 2007). 
 
 
1.5.2.1.   Acylation cycle regulates localization and activity of palmitoylated  
                 Ras isoforms  
 
Both the PM and the Golgi are sites of active Ras signaling. A constitutive de- and 
re-palmitoylation cycle maintains the specific compartmentalization (Rocks et al., 
2005). Golgi-localized Ras was thought to comprise nascent proteins trafficking to the 
PM (Plasma membrane).  Inhibition of protein synthesis, and thereby removing nascent 
proteins, still caused the H-Ras and N-Ras to be localized at the Golgi. Moreover,  
 




photobleaching and photo-activation studies showed that palmitoylated Ras cycled 
between the PM and the Golgi, and that Golgi Ras was replenished by retrograde 
transport of PM-localized Ras. Using a hexadecylated version of N-Ras-HDFar that could 
not undergo de- and re-palmitoylation, it was shown that the localization was not 
mediated by clathrin, caveolae or cholesterol, but that de- and re-palmitoylation events 
were required. Microinjected HDFar localized nonspecifically throughout the 
membrane system. 
 
The kinetics of H-Ras and N-Ras trafficking are different. H-Ras is palmitoylated 
on two cysteines, whereas palmitate moieties are added to only one cysteine in N-Ras. 
N-Ras is trafficked faster than H-Ras, so Rock et al. studied monopalmitoylated H-Ras 
mutants. C181S and C184S H-Ras had an increased preference for Golgi localization 
relative to wild-type H-Ras, and showed faster PM–Golgi exchange. By developing a new 
assay to compare the dynamics of Ras activation at the PM and Golgi, Rock et al. showed 
H-Ras to be rapidly and transiently activated at the PM in response to growth factor 
stimulation, and to have a delayed onset but to be sustained at the Golgi. By contrast, 
active H-Ras C184S and N-Ras were detectable much sooner at the Golgi. Total 
inhibition of palmitoylation blocked trafficking from the PM to the Golgi and therefore 
blocked Ras activation. 
 
So rapid exchange of palmitoylated Ras isoforms at the PM and Golgi is driven by 
de- and re-palmitoylation cycles. De-palmitoylation confers an equal distribution 
between the cytosol and membranes. Re-palmitoylation, which enables stable 
membrane anchorage, occurs at the Golgi; from here, Ras is redirected to the PM in the  




exocytic pathway. Since such a cycle extended to other proteins that have been reported 
to localize to the PM and the Golgi, this process may have a universal role in subcellular 
distribution (Katrin Bussell et al; Oliver Rocks et al., 2005). 
 
 
1.6.   Importance of the H-Ras isoform 
 
Mutations in the HRAS gene cause Costello syndrome. It is inherited in an 
autosomal dominant manner. Mutations that cause Costello syndrome lead to the 
production of a constitutive active form of H-Ras protein resulting in unchecked cell 
division  predisposing the development of benign and malignant tumors. The genetic 
mutation that causes Costello syndrome (CS), the H-Ras gene, was identified in 2005. 
This gene, along with mutations that cause cardiofaciocutaneous syndrome (CFC), 
found soon after, surprised the genetics world and changed how genetic syndromes can 
be grouped. 
 
The mutations that cause Costello syndrome, Noonan syndrome and CFC (cardio-
facio-cutaneous) syndromes are linked by their role in a cellular function, that links 
them together is a common signaling pathway-the Ras/MAP-kinase pathway (Yoko Aoki 
et al., 2008). 
 
Various groups have used mouse models to determine importance of Ras 
isoforms in embryogenesis. H-Ras -/- and N-Ras-/-mice are as viable as H-Ras or N-Ras  
 




single mutant mice, while K-Ras-/-mice are lethal at various embryonic stages. K-Ras-/- 
mice have abnormal hearts with thin ventricular walls on E15.5 (Koera et al., 1997). In 
situ hybridization analysis showed that all three ras genes are expressed in the heart on 
E13.5 and E15.5. These results suggest two possibilities.  
(1) Only K-Ras function is required while H-Ras and N-Ras cannot compensate 
for loss of K-Ras function during embryonic development of the heart.  
(2) The intrinsic activities of H-Ras and N-Ras do not differ substantially from 
those of K-Ras in embryonic development of the heart at this stage, but the activities of 
endogenous H-Ras and N-Ras are not sufficient for normal development of the heart due 
to their sub threshold amounts, timing and organ and/or tissue of expression or 
intracellular localization.  
 
However, introduction of the human H-Ras transgene rescued mutant  mice  
from the abnormal cardiac development and embryonic lethality of K-Ras, also mice in 
which the K-Ras gene was replaced with mouse H-Ras cDNA grew normally until term 
(Potenza et al., 2005) favoring the latter possibility. 
 
These, suggest that the functions of the ras genes overlap, at least partially 
during mouse embryonic development. Most importantly, these findings suggest that 
the mortality of the K-Ras knockout mice might not result from the intrinsic inability  of  
other Ras isoforms to compensate for K-Ras functions, but might rather derive from the  
inability of the other isoforms to be expressed in the same embryonic compartment 
(Potenza et al., 2005). 
 




In adult mice, the relative levels of expression of the three ras genes vary among 
different types of tissue (Leon et al., 1987). For example, in the adult  brain, where cell 
proliferation does not normally occur, the H-Ras gene was dominantly expressed, and 
analysis of H-Ras deficient mice revealed an important role for H-Ras in synaptic 
transmission (Manabe et al., 2000).  
 
Elevated p21ras expression is associated with tumor aggressiveness in breast 
cancer including the extent of invasion into fat tissues, infiltration into lymphatic 
vessels and tumor recurrence. H-Ras, but not N-Ras, induces an invasive phenotype in 
human breast epithelial cells (MCF10A) as determined by the Matrigel invasion assay 
(Aree Moon et al., 2000). Triple Ras mutant mice carrying an excisable H-ras transgene 
that can be conditionally inactivated by Cre-mediated recombination is being created. 
This new series of studies will help us address a number of questions, including 
whether ras genes are essential or dispensable for certain types of cell or tissue during 
embryonic development or in adulthood (Nakamura K. et al., 2008). 
 
 
1.7.   Ras-MAPK signaling pathway 
  
 The Ras/Raf/MEK/ERK cascade couples signals from cell surface receptors to 
transcription factors, which regulate gene expression. Furthermore, this cascade also  
regulates the activity of many proteins involved in apoptosis. Following binding of 
cytokines, growth factors or mitogens to their appropriate receptors, activation of the  
 




coupling complex Shc/Grb2/SOS occurs. Upon stimulation by Shc/ Grb2/SOS, the 
inactive Ras exchanges GDP for GTP and undergoes a conformational change and 
becomes active. (James A. McCubrey et al., 2006) 
 
Ras is the common upstream molecule of several signaling pathways including 
Raf/ MEK/ERK, PI3K/Akt and RalGEF/Ral.  The GTP bound active Ras can then recruit 
Raf to cell membrane. Of the members of the Ras-MAPK signaling pathway, Ras and Raf 
have been identified as proto-oncogenes. Gain of function mutations (activating 
mutations) of these genes drive a cell towards cancer. Oncogenic Ras has been 
identified in 25% of cancers. The most common cancers with oncogenic Ras are 
pancreatic (90%), thyroid (60%) and colorectal (45%) cancers (Bos 1989). 
Furthermore, 35% of cancers show increased MAPK activity (Hoshino et al., 1999). 
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(Modified from Kolch, 2000) 
Figure   1.5:  Schematic representation of the MAPK pathway. 




1.7.1.   Complex activation and inactivation of Raf by phosphorylation 
 
The mammalian Raf gene family consists of A-Raf, B-Raf and Raf-1 (C-Raf). Raf is 
a serine/threonine (S/T) kinase and is normally activated by a complex series of events 
including: (i) recruitment to the plasma membrane mediated by an interaction with Ras  
(J. Yan et al., 1998) ; (ii) dimerization of Raf proteins  (Z.Luo et al., 1996) ; (iii) 
phosphorylation/dephosphorylation on different domains (D.R Fabian et al., 1993);  




(iv) disassociation from the Raf kinase inhibitory protein (RKIP) (Yeung et al., 1999;  
Dhillon et al., 2002) and (v) association with scaffolding complexes e.g., kinase 
suppressor of Ras (KSR) (W. Blalock et al., 1999; JLee Jr et al., 2003; Chang et al., 2003). 
Raf activity is further modulated by chaperonin proteins including Bag1, 14-3-3 (Fantl 
et al., 1994) and heat shock protein 90 (Hsp90) (Blagosklonyy et al., 2002)  
 
 
1.7.2.   Activation of MEK1 by Raf 
  
Mitogen-activated protein kinase/ERK kinase (MEK1) is a tyrosine (Y) and 
(Serine/Threonine) S/T dual specificity protein kinase (D. R. Alessi et al., 1994). Its 
activity is positively regulated by Raf phosphorylation on S residues in the catalytic 
domain. All three Raf family members are able to phosphorylate and activate MEK but 
different biochemical potencies have been observed, (B-Raf > Raf-1 > A- Raf) (Alessi D. 
R. et al., 1994). The predominant downstream target of MEK 1 is ERK.  
 
 
1.7.3.   Activation of ERK1/2 by MEK1 and downstream targets of ERKs 
  
 Extracellular signal-regulated Kinases (ERK 1) and (ERK 2) were identified as 
protein kinases activated in response to growth factor stimulation (Raman et al., 2007). 
ERK 1/2, are S/T kinases and their activities are positively regulated by 
phosphorylation mediated by MEK1 and MEK2. ERKs have multiple downstream  
 




targets and can directly phosphorylate many transcription factors including Ets-1, c-Jun 
and c-Myc. They can also phosphorylate and activate the 90 kDa ribosomal S6 kinase 
(p90Rsk), which then leads to the activation of the transcription factor CREB (Steelman 
et al., 2004). Through an indirect mechanism, ERK can lead to activation of the NF-κB 
transcription factor (nuclear factor immunoglobulin κ chain enhancer-B cell) by 
phosphorylating and activating inhibitor κB kinase (IKK) (Nakano et al., 1998; O. Zhao 
et al., 2007). ERK1 and ERK2 are differentially regulated. There are over 160 targets for 
ERK1/2 (James A. McCubrey et al., 2007). They can enter the nucleus to phosphorylate 
many transcription factors (Steelman et al., 2004). And proteins involved in cell cycle 
regulation (Pouyssegur et al., 2002). Since ERK 1 and 2 are at the end of signaling 
cascade, any aberrant control or mutation of any of the upstream modulators will 
reflect on its activity. 
 
 
Table 1.1.  Phosphorylaion targets of ERK1/2 (Raman et al., 2007; Chuderland 
et al., 2005).  
 
 Phosphorylation Targets Function 
Elk -1, cFos,   cMyc Nuclear transcription factors 
Paxillin, Focal adhesion kinase, Calpain protein kinases 
P90 ribosomal S6 kinase (RSK), Mitogen 
and Stress activated Kinase (MSK) MAPK  
interacting kinase (MNK) 
 
Cell attachment and migration 
Cytosolic substrates SOS, MKPs  Negative feedback regulation 




1.8.   PC12 as a model to study  neuronal differentiation 
  
 The PC12 cell line was derived from rat pheo-chromocytoma, a tumor arising from 
chromaffin cells of the adrenal medulla. A key issue in signal transduction is how 
canonical signaling cassettes integrate signals from molecules having a wide 
spectrum of activities, such as hormones and neurotrophins, to deliver distinct 
biological outcomes. The PC12 cells provides an example of how one canonical signaling 
cassette-the Raf , mitogen-activated protein kinase kinase (MEK) 3 and extracellular 
signal-regulated kinase (ERK) pathway can promote distinct outcomes, which in this 
case include neuritogenesis, gene induction, and proliferation (Vaudry et al., 2002). 
  
 PC12 cells are responsive to several growth factors whose receptors are protein 
tyrosine kinases, such as nerve growth factor (NGF) and epidermal growth factor  
(EGF). It is a useful model for studying cell signaling for at least two reasons: (i) There 
are few growth factors, neurotrophins, and hormones to which it does not respond; and 
(ii) distinct responses of differentiation (halted proliferation and neurite outgrowth), 

























(Modified from Marshall, 1995) 
Figure 1.6: Schematic representation of PC12 cells under EGF and NGF 
stimulation. Sustained activation of the MAP kinase cascade may be required for MAP 
kinase to enter the nucleus, where it may initiate the gene transcription events required 
for neuronal differentiation of PC12 cells (D. Vaudry et al, 2002). 
  
  
 Stimulation of PC12 cells with nerve growth factor (NGF) increased mitogen-
activated protein kinase kinase (MAPKK) activity > 20-fold after 5min to a level that 
was largely sustained for at least 90min. MAPKK activity was stimulated to a similar 
level by epidermal growth factor (EGF), but peaked at 2min, declining thereafter and 
returning to basal levels after 60-90min. Activation of MAPKK by either growth factor 











The transient activation of MAPKK by EGF and its sustained activation by NGF underlies 
the transient and sustained activation of MAP kinase induced by EGF and NGF 
respectively (Sarah Traverse et al., 1992).  Stimulation with NGF caused a striking 
translocation of MAP kinase from the cytosol to the nucleus after 30min, but no nuclear 
translocation of MAP kinase occurred after stimulation with EGF. Thus, sustained 
activation of the MAP kinase cascade may be required for MAP kinase to enter the 
nucleus, where it may initiate the gene transcription events required for neuronal 
differentiation of PC12 cells (Vaudry et al., 2002). 
 
On the other hand, both growth factors induce the activation and nuclear 
translocation of ERK even though with different kinetics, being transient if induced by 
EGF, and prolonged if induced by NGF. The duration of ERK phosphorylation and 
activity has been shown to dictate the opposite effects (differentiation vs proliferation) 
elicited by these two growth factors (Cowley et al., 1994; Marshall, 1995; Chao, 1992). 
The prolonged activation of ERKs induced by NGF needs in turn the activation of both 
Ras and Rap1-dependent pathways (Vossler et al., 1997; York et al., 1998; Sasagawa et 
al., 2005). 
  
 A PC12 derivative cell line expressing  a Shp2 interfering mutant under an 
inducible promoter was generated to study the effects of EGF and NGF. Upon ligand 
stimulation a Gab2-Shp2 functional complex takes place. This complex is critical for ERK 
activation, and is required for NGF mediated differentiation and survival. The opposite 
effects induced by NGF and EGF, indicate a different usage of this phosphatase by the 
two growth factors receptors (Amelia D'Alessio et al., 2007). 







1.9.   BPGAP1 
 
 
BPGAP1 for BNIP-2 and Cdc42GAP Homology/Sec14p-like, proline–rich and 
GTPase activating Protein was identified by our co-workers (Shang et al., 2003) through 
a bioinformatics screening to identify novel GTPase activating proteins (GAPS) encoded 
in our genome. BPGAP1 is ubiquitously expressed and shares 54% sequence identity to 
Cdc42GAP/p50RhoGAP. 
 
p50RhoGAP, also known as Cdc42GAP, was isolated from human spleen tissue 
and from platelets, and is the founding member of the RhoGAP family of proteins 
(Garrett et al., 1989; Barfod et al., 1993; Lancaster et al., 1994). This ubiquitous protein 
contains a C-terminal RhoGAP domain and an N-terminal putative lipid-binding domain 
(Sec14), which may be required for its ability to bind to phos-phoinositides and possibly 
for membrane localization (Krugmann et al., 2002). In addition, it contains a proline-
rich region upstream from the GAP domain that binds to the SH3 (Src homology 3) 
domain of p85-α and c-Src in vitro, but the biological relevance of these interactions is 
unknown (Tcherkezian et al., 2007) 
 
It is also called as ARHGAP8 and is found to be up regulated in primary colorectal 
tumors and in six germline missense mutations in patients with colorectal or breast 
cancer (Jhonstone et al., 2004). A putative mouse ortholog to ARHGAP8 termed mouse 
arhgap8 having high homology to the human ARHGAP8 in its N-Terminal was identified 
and characterized by Shang et al., 2003. 
 






1.9.1.   Functional Domains of BPGAP1 
 
 
Figure 1.7:  Schematic representation revealing the multidomain nature of 
BPGAP1. 
 
BPGAP1 is a multidomain protein containing a N terminal BCH domain aa (34-167)  and 
a C terminal GAP domain aa (206-388) separated by a central  proline rich  region.  
 
 




(Shang et al., 2003) (Lua and Low., 2004) (Lua and Low., 2005)
morphogenesis
 
Figure 1.8: Effects of BPGAP1. BPGAP1 regulates the formation of pseudopodia and 
enhances cell migration through the concerted interactions of its BCH, GAP domains and 
the PRR region and EEN (Extra eleven endophillin) interacts with PRR enhancing EGF 




BPGAP1 causes morphological changes in MCF7 cells in a process that involves 
activation of Rac1 and Cdc42 and inactivation of RhoA. BPGAP1 interacts with RhoA, 
Rac1 and Cdc42, while selectively enhancing the RhoGAPGTPase activity alone without 
affecting the Rac1 and Cdc42 activity in vivo (Shang et al., 2003). 







The PRR of BPGAP1 interacts with cortactin - a cortical actin binding protein 
resulting in enhanced cell migration (Lua and Low,2004), while interaction of  PRR with 
EEN/Endophillin enhances the activation of the Ras/MAPK pathway via EGF receptor 
endocytosis (Lua and Low, 2005). BPGAP1 regulates the formation of pseudopodia and 
enhances cell migration through the concerted interactions of its BCH,GAP domains and 
the PRR region. Thus BPGAP1 plays a key role in stringently regulating the coupling of 
cell morphological changes to cell migration. 
 
1.9.3.   Multifunctional nature of BPGAP1 
 
1.9.3.1.   BPGAP1 couples morphological changes to cell migration 
 
BPGAP1 interacts with the three classic RhoGTPases: RhoA, Rac1 and Cdc42. 
However, it only inactivates Rho A in vivo. BPGAP1 causes morphological changes in 
MCF7 cells in a process that involves activation of Rac1 and Cdc42 and inactivation of 
RhoA. These effects are brought about by the concerted effects of the BCH domain and 
the GAP domain. The BCH domain is responsible for the formation of short pseudopodia 
and the GAP domain is responsible for the formation of long pseudopodia. The 
formation of long pseudopodia by the GAP domain requires inactivation of RhoA  and is 
inhibited by the dominant negative mutant Rac1T17N. However, formation of both long 
and short pseudopodia is inhibited by the mutant Cdc42 T17N. 
 
Thus, the cell morphological changes induced by BPGAP1 through the BCH and 
GAP domains are required but still not sufficient for mediating cell migration. It  







requires an additional input from the proline-rich region that specifically couples the 
control of cell movement to the morphological changes that precede the event. This 
stringent requirement of multi-domain interplay is different from several other 
RhoGAPs whose function is predominantly dependent upon the functional GAP 
domains. 
 
Various GAP proteins have been identified to regulate cell morphology but little 
is known about the coupling of cell morphology to cell migration via their protein 
domains in cis. BPGAP1 provides an example for such an intricate process. With 
multiple signaling modules, BPGAP1 is poised to target different classes of signaling 
molecules and thus could play a pivotal role in the integration of several signaling 
events (Shang et al., 2003). 
 
 







(Adapted from Shang et al., 2003) 
 
Figure 1.9:  Model for the effects of BPGAP1 on cell dynamics control.  
The three separate domains, BCH, proline-rich, and GAP domains of BPGAP1 
coordinately regulate distinctive yet concerted pathways in cell dynamics control. Its 
GAP domain specifically inactivates RhoA pathway and induces long pseudopodia 
whereas the BCH domain leads to the formation of short pseudopodia via a mechanism 
that is yet to be identified. Formation of pseudopodia can be inhibited at different points 
by mutants of Rho GTPases as indicated. It is believed that the GAP domain can cross-
talk to the BCH domain as exemplified by the ability of both domains to separately 
induce similar neurite-like features when Rac1 is active. Collectively, both BCH and GAP 
domains, but not the proline-rich region, confer unique pseudopodia, which are 
necessary but not sufficient to exert cell migration in the absence of a functional 
proline-rich region. It is therefore likely that protein(s) that harbor the proline-
targeting domains such as SH3 or WW domains is/are involved in linking cell 
morphological changes to its migration (Adapted from Shang et al., 2003). 
 
 







1.9.3.2.   BPGAP1 Interacts with Cortactin and facilitates its translocation  
                  to cell periphery for enhanced cell migration 
 
BPGAP1 was identified as a novel RhoGAP that coordinately regulated 
pseudopodia and cell migration via the interplay of its BNIP-2 and Cdc42GAP homology, 
RhoGAP, and the proline-rich domains. To further elucidate the molecular mechanism 
underlying cell dynamics control by BPGAP1,  protein precipitations and matrix-
assisted laser desorption/ionization mass spectrometry were carried out and identified 
cortactin, a cortical actin binding protein as a novel partner of BPGAP1 both in vitro and 
in vivo.   
 
Cortactin interacted directly and constitutively with the proline-rich motif 182-
PPPRPPLP-189 of BPGAP1 via its Src homology 3 domain independent of PDGF 
stimulation. Together, they colocalized to periphery and enhanced cell migration.  
Prolines   184 and 186 were indispensable for its interaction with cortactin. Mutating 
these residues to alaline abolished interaction with cortactin. The mutation did not 
inhibit translocation of BPGAP1 to cell periphery but failed to translocate cortactin to 
cell periphery. Consequently, no enhanced cell migration was observed. Thus, 
translocation of cortactin could be the cause for the enhanced migration observed in the 
presence of BPGAP1 and cortactin in epithelial cells. It also explains the requirement of 
the PRR for cell motility as observed by Shang et al., 2003. 
 
The findings corroborate well with observations by other groups  that 
subcellular localization of cortactin may be regulated by mechanisms  







independent of its tyrosine phosphorylation upon growth factor stimulation (Weed et 
al., 1998),  further supporting the notion that tyrosine phosphorylation of cortactin 
itself could not account fully for its role in conferring cell migration (Van Rossum et al., 
2003). 
 
BPGAP1 has been shown to be a key regulator of RhoGTPase  signaling involving 
Rac RhoA and Cdc42, with Cdd42 and Rac being involved with BCH and GAP domains in 
pseudopodia formation and BPGAP1 acting as a negative regulator of RhoA. This 
provides the first evidence that a RhoGAP functionally interacts with cortactin, and 
represents a novel determinant in the regulation of cell dynamics. This could potentially 
provide a link between the small GTPases and cortactin in regulating the spatial and 
temporal context of cell dynamics. (Lua and Low, 2004). 
 
 
1.9.3.3.   BPGAP1  interacts with EEN to activate EGF receptor endocytosis   
                   and ERK1/2 phosphorylation. 
 
 
  EEN Extra Eleven Nineteenth (EEN II) was identified as another interacting 
partner for BPGAP1 through protein precipitations and MALDI TOF analysis. EEN is a 
member of the endocytic endophilin family. EEN II colocalized with BPGAP1 and 
increased EGF receptor internalization following EGF stimulation. EEN interacted 
directly with BPGAP1 via its Src homology 3 (SH3) domain binding to the proline-rich 
region 182- PPPRPPLP-189 of BPGAP1, with prolines 184 and 186 being indispensable 
for this interaction. 







Over expression of EEN or BPGAP1 alone induced EGF-stimulated receptor endocytosis 
and ERK1/2 phosphorylation. The increase in ERKI/2 phosphorylation was augmented 
when EEN was present with BPGAP1 but not in the presence of EEN with the non-
interactive proline mutant of BPGAP1 where proline 184 1nd 186 are mutated (PP 
mutant). SH3 domain was indispensable for EGF receptor internalization, as the N 
terminal mutant lacking the SH3 domain served in a dominant negative manner 
inhibiting receptor internalization  and co-expressing BPGAP1 was unable to alleviate 
the inhibition.  
 
 Furthermore, BPGAP1 with a catalytically inactive GAP domain where the key 
Arginine residue was mutated (R232A) also blocked the effect of EEN and/or BPGAP1 
in EGF receptor endocytosis and concomitantly reduced their level of augmentation for 
ERK1/2 phosphorylation, showing that a functional RhoGAP domain was essential for 
the observed mechanism. BPGAP1 enhanced EEN mediated receptor endocytosis was 
also blocked by the EEN mutant that failed to interact with BPGAP. Thus, a concomitant 
activation of endocytosis and ERK signaling by BPGAP1 occurs via the coupling of its 
proline-rich region, which targets EEN and its functional GAP domain. The EGF receptor 
internalization was correlated to the activation of the Ras/MAPK pathway, using 
phosphorylation of ERK1/2 as a read off. 
 
However, a surprising observation was that the PP mutant that was unable to 
interact with EEN could still cause increased ERK1/2 activation but was unable  
 







to augment the ERK1/2 activation caused by EEN. Thus, BPGAP could cause increase in 
ERK1/2 activation in a mechanism independent of its interaction with EEN. The EGF 
receptor internalization was correlated to the activation of the Ras/MAPK pathway, 
using phosphorylation of ERK1/2 as a read off (Lua and Low, 2005). BPGAP1 could 
therefore provide an important link between cytoskeletal network, endocytic trafficking 
and Ras/MAPK signaling. 
 
 
(Adapted from Lua and Low, 2005) 
Figure  1.10: A model for the stimulatory effects by BPGAP1 and EEN on EGF-
stimulated EGF receptor endocytosis and ERK1/2 phosphorylation. Stimulation of 
cells with EGF triggers the internalization of the EGF-bound EGF receptor in the form of 
vesicles, leading to the phosphorylation of ERK1/2. This process is enhanced by 
BPGAP1 or EEN alone and augmented through their interaction via their PRR and SH3 
domain, respectively. The NT mutant of EEN, which lacks the SH3 domain, completely 
prevents the effects of BPGAP1 in both endocytosis and ERK1/2 phosphorylation, acting 
as a dominant negative mutant. The GAP mutant R232A devoid of the catalytic arginine 
finger motif also reduces basal and EEN-stimulated EGF receptor endocytosis, 
suggesting that functional RhoGAP activity is required to promote endocytosis and  







ERK1/2 phosphorylation. The PP mutant (devoid of the interaction with EEN) or the 
GAP mutant (R232A) can also stimulate ERK1/2 phosphorylation, which suggests a 
distinct regulatory pathway independent of BPGAP1’s stimulatory role in endocytosis. 
This could involve a different protein X possibly via its interaction with the BCH domain 
(Adapted from Lua and Low, 2005). 
 
 
1.9.3.4.   Active Mek2 promotes Pin1 binding to BPGAP1 to suppress BPGAP1- 
induced acute ERK activation and cell migration. 
 
RhoGAP domain of BPGAP1 interacts with the peptidyl-prolyl cis/trans 
isomerase (PPI) Pin1, leading to enhanced GAP activity towards RhoA. BPGAP1 also 
interacted with wild-type and constitutively active Mek2, and not with its kinase-dead 
mutant. 
 
Active Mek2 binds Pin1, acting as a scaffold to bridge Pin1 and BPGAP1 that 
involves the release of an autoinhibited proline-rich motif, 186-PPLP-189, proximal to 
the RhoGAP domain. This allows the non-canonical 186-PPLP-189 and 256-DDYGD-260 
motifs of the proline-rich region and RhoGAP domain of BPGAP1 to become accessible 
to concerted binding by the WW and PPI domains of Pin1.  Pin1 knockdown caused  
‘super-induction’ of BPGAP1-induced acute, but not chronic, ERK activation upon 
epidermal growth factor stimulation, in a process independent of GAP modulation. 
Reintroducing Pin1 reversed the effect and inhibited cell migration induced by 
coexpression of BPGAP1 and active Mek2. Thus, Pin1 was shown  to regulate BPGAP1 
function in Rho and ERK signaling, with active Mek2 serving as a novel regulatory 
scaffold that promotes crosstalk between RhoGAP, Pin1 and ERK in the regulation of 
cell migration. 







These findings provided the first evidence that BPGAP1 induces acute Erk 
signaling in response to EGF. This process is kept in check by a feedback mechanism  
involving Mek2 acting as a scaffold to recruit Pin1 to the BPGAP1-Mek2 complex. Pin1 
binding to the two unorthodox motifs of the PRR and RhoGAP domain is essential for 
regulating the acute enhancement of ERK, RhoGAP activity and consequently cell 
motility. This new signaling node provides an additional checkpoint for MEK/ERK 
signaling while opening up new avenues for probing the detailed functional coupling 
between Pin1, BPGAP1-Rho and Mek-Erk signaling (Pan et al., 2010). 
(Adapted from Pan et al., 2010). 
 
Figure 1.11: Pin1 and Mek2 are two newly identified modulators of BPGAP1 
function. A model depicting how Mek2 acts as a regulatory scaffold to 
promote Pin1 binding to BPGAP1 and suppress BPGAP1-induced acute ERK signaling. 
Regulation of the PRR and the C-terminal RhoGAP domain of BPGAP1 (PC) in the basal 
and Mek2-stimulated states. Step 1. Mek2 binds to PC independently of its active state, 
because non-active Mek2 and constitutively active Mek2 bind PC equally well. However, 
kinase-dead Mek2- K101A fails to interact with PC and also impairs the binding of Pin1 
and PC. The PRR is mainly autoinhibited and is not recognized by the WW domain, 
whereas binding of the PPI domain can only be observed after trapping it with the PPI-
H157A mutant at the 256-DDYGD-260 motif. Step 2. Upon Mek2 activation, the PRR is 
exposed as a result of a conformational change that is not linked to phosphorylation and 
is independent of its RhoGAP activity. Step 3. How such super-induction is triggered 
remains unknown, although Pin1 plays a crucial role in directly suppressing this effect. 
Step 4. After release of the PRR, active Mek2 becomes a target of Pin1, because Pin1 






does not recognize other forms of Mek2. This promotes concerted binding of the Pin1 
WW domain to the exposed PPLP motif and the PPI domain to the 256- DDYGD-260 
motif of the RhoGAP domain. Step 5. With active Mek2 acting as an atypical scaffold, this 
interaction provides a feedback loop that ensures that acute Mek2 and ERK activation is 
negatively regulated. This is supported by the loss of BPGAP1-induced super-induction 
of ERK and cell motility when key PC-Pin1 binding motifs become non-functional. Step 
6. This dynamic system helps ensure that Mek2 is recycled to promote the formation of 




1.9.3.5.   BPGAP1 exerts its effects through the Ras MAPK pathway 
 
 
Work by Lua B. L. (PhD thesis, 2005) and Soh F.L.(MSc Thesis, 2005) have shown 
that the BCH domain caused enhanced ERK 1/2 activation upon EGF stimulation 
(Figure 1.12). Aarthi R. (Ph D Thesis, 2010) has shown that  PC12 cells  when 
transfected with BPGAP1 and subjected to stimuation with 100ng/ml EGF resulted in 
the formation of protrusions indicating a shift from the expected EGF mediated 
proliferative  response to the beginning of differentiation a signature of NGF mediated 
response (Figure 1.13.) 
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Figure 1.12: BCH domain enhances ERK1/2 activation upon EGF stimulation. 
(Adapted from Soh, F. L. MSc thesis, 2005). 
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Figure1.13: The Ras/MAPK pathway is involved in the formation of the long        
 protrusions caused by BPGAP1.BPGAP1 expression causes PC12 cells to differentiate 
in the presence of EGF which is inhibited by MEK inhibitor U0126.  (Adapted from 
Aarthi R. PhD Thesis, 2010.) 
 
 
Figure 1.13 shows multiple long branched protrusions (≥ 1 cell body length / 10 
m or greater) in cells transfected with BPGAP1, indicating that the enhanced and 
sustained ERK1/2 activation by BPGAP1 could contribute to the formation of long 
protrusions in EGF stimulated PC12 cells, which are inhibited in the presence of MEK 
inhibitor, showing that the MAPK pathway is involved. BPGAP1 has also been shown to 
interact with the three important Ras is forms K, H, and N-Ras that are the key upstream 
activators of the Ras/MAPK pathway  (Soh, F. L. MSc thesis, 2005; Aarthi R. PhD Thesis, 
2010).  
BPGAP1 interaction with SmgGDS has also been recently implicated in the 
RAS/MAPK pathway (Aarthi Ravichandran PhD thesis 2010). The BCH domain of 
BPGAP1 enhances the activation of Ras/MAPK pathway by interacting with K-Ras  







resulting in increase in ER1/ERK2 phosphorylation resulting in protrusion formation in 
PC12 cells upon EGF stimulation. SmgGDS reduced BCH mediated K-Ras activation and 
blocked BCH- domain mediated protrusions of PC12 cells upon EGF stimulation. Thus 
SmgGDS has been shown to be a negative regulator of BCH domain (Aarhi R. PhD Thesis, 
2010) (Figure 1.14) 
HA-BCH DIC MergeFlag-SmgGDS Merge
 
(Adapted from Aarthi R. PhD Thesis, 2010.) 
Figure 1.14: Overexpressed SmgGDS reduced protrusions caused by BCH domain. 
.   
 
Cortactin, EEN, SmgGDS that were discussed here, are proteins that were 
identified as interacting partners for BPGAP1 by proteomics based affinity pull down 
and MALDI TOF. Thus, BPGAP1 is multifunctional in nature and intricately controls 
diverse aspects of signaling through various interacting partners.   
 
LanCL1 (Lanthionine synthetase C-like protein 1) is another  novel interacting 
partner for BPGAP1 identified in a similar way (Lua B. L. ,PhD Thesis 2005) and remains 
to be characterized. This thesis aims to examine the function of LanCL1 and how the 
interaction between LanCL1-BPGAP1 would modulate BPGAP1 function. 





1.10.   LanCL1 
 LanCL1 (Lanthionine synthetase C-like protein 1) was identified by Prohaska and colleagues as a mammalian homologue of bacterial   Lanthionine synthase–C (LanC) enzymes. LanCL1 polypeptide is approximately 30% homologous to prokaryotic LanC expressed by many Gram-positive bacteria (Mayer et al., 2000). It was initially proposed to be a G-Protein coupled receptor, which was later found not to be so. LanCL2 a homologue of LanCL1 was later identified. LanCL2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism (Soyeon Park and C. David James, 2003).  The bacterial homologue LanC has been characterized and shown to be involved in the synthesis of Lantibiotics. Though the bacterial enzyme has been studied and characterized, information on the mammalian homologue has been limited until recently when its crystal structure was solved in complex with and without GSH. It was also shown to interact with Eps8, a signaling molecule having an SH3 domain, through a non canonical site and involved the  NGF signaling pathway resulting in differentiation but the mechanism still remains unknown (Zhang et al., 2009).The two isoforms of LanC: LanCL1 and LanCL2 appear to be widely expressed, although the highest levels seem to be in the central nervous system and testis (Mayer et al., 2000, 2001).  The isoforms differ in their N-terminal with LanCL2 having an extra N-terminal peptide which may function as a switch to regulate its binding to different ligands (Zhang et al., 2009).  





1.10.1.   LancL1 highly conserved across different species   The degree of homology between LanCL1 and particular LanC polypeptides is in similar magnitude to the homology among different LanC polypeptides from different bacterial species, which can vary substantially in terms of primary sequence. Sequence alignment of selected LanC homologous proteins have been shown in Figure1. 15 Specific motifs within LanCL1 are highly conserved relative to LanC proteins, including a WC-X-G-X-PGV-X38-I/L-CHG motif containing two cysteine residues located 46 aminoacids apart near the C-terminal region are characteristic of both LanCL1 and all known bacterial LanC enzymes (Chatterjee et al., 2005). Among others, Histidine at 323 is also conserved. They also have seven conserved GXXG motifs that are exclusive to LanC and not found in other double helix barrel proteins such as Farnesly transferases.  














1.10.2.   Structure of LanCL1 
   Crystal structures of human LanCL1 both free of and complexed with glutathione, revealing glutathione binding to a zinc ion at the putative active site formed by conserved GxxG motifs were solved by Zhang et al. LanCL1 consists of two layers of 
α- helical barrels formed by 14 α-helices with inner and outer barrel each containing seven helices. Amino acid sequence alignment indicates that the N-terminal end of the inner barrel is the most conserved region among LanCL1 family members (Zhang et al., 2009). The overall folded structure of LanCL1 resembles that of its bacterial homolog LanC/NisC.  
Seven conserved GXXG motifs are located at the N-termini of the inner helices and are a signature feature of the LanCL1 family of proteins, since they are absent in other double helix containing proteins such as the farnesyl transferase (Park et al., 1997). These bulged loops reduce the entry size of the central cavity formed by the inner helix barrel by about one-third relative to other known double helix barrel proteins. Thus, LanCL1 is unlikely to use the central cavity as a substrate binding site as proposed for the farnesyl transferase (Zhang et al., 2009).  
 
 




GXXG containing motifs that 
bulges into the central cavity
Double helix barrel
 
Figure 1.16: Ribbon representation of human LanCL1. The outer helix barrel is depicted in red and the inner helix barrel is shown in yellow. The seven GxxG-containing bulges are colored blue. N-terminal and C-terminal regions are colored cyan and green, respectively. The Zn2+ ion is depicted with a magenta sphere. (Adapted from Zhang et al., 2009)  
  
Figure 1.17: Crystal structure of LanCL1. GSH is shown by a cyan stick model. LanCL1 is shown in a molecular surface model superimposed with selected residues depicted by gray stick models. Zn2+ ion is shown as a magenta sphere. Oxygen, nitrogen, and sulfur atoms are colored red, blue, and yellow, respectively. Hydrogen bonds (or salt bridges) are shown as dashed magenta lines. Amino acid residues surrounding and those of GSH are labeled as single letters. (Adapted from Zhang et al., 2009) 
 
 





1.10.3.   Known Interacting partners for LanCL1  
1.10.3.1.   LanCL1 binds Zinc 
 LanCL1 is known to bind Zinc ions (Chatterjee et al., 2005). The crystal structure showed that each LanCL1 moiety contains one Zn2+ ion, which is anchored in tetrahedral coordination. Three of the four Zn2+ binding ligands are provided by Cys276 (fifth GXXG motif), Cys322 and His323 (sixth GXXG motif) (Figure 1.17). The corresponding residues in LanC/NisC also participate in Zn2+ binding and are conserved in the LanCL1 family (Zhang et al., 2009). 
 
1.10.3.2.   LanCL1 interacts with Eps8  
 Eps 8 is a widely expressed, multidomain signaling protein that coordinates at least two disparate GTPase dependant mechanisms: EGF stimulated actin reorganization via the Rac pathway and /or the inhibition receptor internalization via inactivation of the Rab5 pathway (Mongiovi et al., 1999). Recently Zhang et al have provided evidence for a novel LanCL1- Eps8 interaction in the NGF receptor (Trk A) mediated neurite outgrowth and cell differentiation. 
   




 LanCL1 contains two PxxDY sequences (residues 9-13 and 252–256) and two PxxP motifs (residues 145–148 and 366–369), both of which are potential SH3-binding sites (Mongiovi et al., 1999). SH3 domains from Eps8, GRB2, and CIN85, which are known to function in various signaling pathways, were tested for its ability to bind LanCL1 in vitro by surface Plasmon resonance (SPR) binding assays. LanCL1 was specifically able to interact with SH3 Eps8 and not other proteins.    However, mutagenesis studies showed that D12A and Y13F variants of LanCL1 exhibited the same binding affinity for SH3 Eps8 as the wild-type protein suggesting that the P9xxDY13 motif was not a major SH3-binding site in LanCL1. The second such motif which occurs in the C terminal was speculated not to be involved in Sh3 binding as the crystal structure revealed that this region was solvent inaccessible.   The Eps8 SH3 domain employs a novel binding mode to interact with LanCL1. Mutants R4A, R4E, and H219F were defective in interaction with Eps8. The LanCL1–Eps8 interaction involves a three dimensional (3D) structural framework as opposed to a linear proline-rich sequence motif. Wild type LanCL1 did not affect neurite outgrowth caused by 50ng/ml NGF in PC12 cells but mutants defective in Eps8 interaction strongly inhibited NGF induced neurite outgrowth.   
  
 





Thus a direct and specific interaction between LanCL1/2 and the Eps8 SH3 domain, were identified through a screen of five SH3 domains from three adaptor proteins involved in EGF and other signal transduction pathways. LanCL1 normally targets to the plasma membrane, which may be a necessary step for LanCL1 to interact with Eps8 in the cell. In this regard, the LanCL1 mutants could compete with endogenous LanCL1 for the binding sites on the plasma membrane, thereby preventing the latter from binding to the membrane and its subsequent interaction with Eps8. The LanCL1–Eps8 interaction may directly contribute to neurite outgrowth, but the mechanism requires further investigation. In addition, LanCL1 may compete with E3b1 and RN-tre for interactions with Eps8, which all involve the Eps8 SH3 domain. The resulting inhibition of the latter pathways, which promote cell proliferation during EGF signal transduction, could also contribute to the neurite outgrowth and cell differentiation.  
 
Therefore, this suggests that the LanCL1–Eps8 interaction is involved in NGF signaling, and the LanCL1 mutants defective in Eps8 interaction may abrogate the endogenous LanCL1–Eps8 interaction, leading to inhibition of NGF signaling and neurite outgrowth. Interestingly, the LanCL1–SH3Eps8 interaction can be significantly inhibited by 1 mM GSH, which overlaps with the cellular concentration of GSH (Jacob et al., 2004). This type of negative regulation of protein–protein interactions by the free, reduced form of GSH would be potentially useful in vivo, in addition to glutathionylation, as a  





mechanism to regulate protein functions in response to cellular redox status (Zhang et 
al., 2009). 
 
1.10.3.3.   Interaction with Glutathione (GSH) 
 GSH is the most abundant cellular sulfhydryl-containing molecule responsible for maintaining a reducing intracellular environment, protecting against electrophilic toxins. GSH reacts with xenibiotics through glutathione S- transferase (GST) catalysed reactions to yield water soluble compounds that can be readily excreted. GSH also acts ubiquitously as a reducing equivalent to remove cellular peroxides through reactions mediated by glutathione peroxidase. 
  It has also been implicated as a mediator of redox signal transduction and cytoskeletal dynamics (Meister et al., 1983). GSH forms mixed disulphides with protein tyrosine phosphatases, transiently inactivating the enzymes and preventing irreversible oxidation of active site cysteines, which are later removed through the action of glutaredoxin and thioredoxin. Glutathionyaltion of actin has been recognized as a means of effecting reversible microfilament dissociation (Lee et al., 1998, Wang et al., 2001, Pastore et al., 2003). Many other proteins have been identified as targets for glutathionylation, although the significance of these posttranslational modifications   




 remains to be elucidated (Giustarini et al., 2002). Glutathione may have other functions  important to mammalian physiology that have yet to be discovered.   LanCL1 was identified as a binding partner for Glutathione (GSH) in a screen to identify novel GSH binding proteins from bovine brain lysate. Subsequent studies by the same group showed that LanCL1 was elevated 3 fold in the spinal cord tissue of presymptomatic SODI G93A transgenic mice, a murine model for amyotrophic lateral sclerosis (ALS). Amyotrophic lateral sclerosis is a neurodegenerative disease. SODI G93A mouse, used to study protein changes in ALS, ubiquitously expresses a mutant human Cu, Zn superoxide dismutase enzyme responsible for a hereditary from of ALS. In the affected animals, protein oxidation and neuroinflammatory gene induction occur in an accelerating fashion from 80 days until death at 120-130 days. Significant motor neuron loss and frank paralysis occurs between 100-120 days. This was the first report of an endogenous small molecule ligand for LanCL1 suggesting that the mammalian homologue may engage in sulphur chemistry analogous to the reactions of prokaryotic LanC enzyme. (Chung C. H. et al., 2007).  
 
1.10.3.4. LanCL1 oligomerization   A common feature of both GSH-complex crystal and GSH free crystal is the homo-oligomerzation of LanCL1 molecules. The GSH-complexed crystal formed a dyad   




 symmetrical dimer and in the free form, there were four LanCL1 molecules, which  formed two dyad symmetrical dimers. Consistent with the oligomerization observed in  the crystal structure, LanCL1 was also found to have detectable dimer population as measured by analytic ultracentrifugation (AUC) and interacted with itself as determined by surface plasmon resonance. LanCL1 was also found to bind to LanCL2 ∇18 in the SPR assay. The biological significance of this homodimer or heterodimer remains to be demonstrated (Zhang et al., 2009).   
1.10.5.   LanCL1 is a novel interacting partner for BPGAP1   Extensive work by our group has revealed that BPGAP1 plays important roles in many aspects of signaling owing to its multidomain nature. To characterize BPGAP1 and analyze the mechanisms involved in multiple signaling pathways, proteomics based affinity pull down experiments were carried out to identify novel interacting partners. As mentioned earlier Cortactin, EEN and SmgGDs are among the targets identified and studied by our group, while a few others remain to be characterized.    Proteomics based affinity pull down identified LanCL1 as another interacting partner for BPAGP1 (Lua B. L. PhD thesis, 2005). (Figure 1.16) GST tagged BPGAP1 specifically pulled down LanCL1. The bands were visualized using silver stain and desired bands were cut and analysed by MALDI-TOF. The band corresponding to LanCL1 is highlighted by red oval. 








Figure 1.18:   Silver stained gel of GST-precipitation assay. Full length BPGAP1 was used to crudely fish for novel interacting partners. ‘+’ and ‘-‘denote the presence and absence of incubation with cell lysate respectively. The intense bands shown are GST fusion proteins (Adapted from Lua B. L. PhD thesis, 2005).       





1.11.    OBJECTIVES   The bacterial homologue LanC and the murine homologue LanCL1 have been characterized, however its  significance in  humans remained enigmatic until its structure was solved recently by Zhang  et al. They also demonstrated a role for LanCL1 in neuronal differentiation arising from its interaction with EPS8 a well known signaling molecule. However, the precise mechanism still remains largely unknown. With  multiple signaling modules, BPGAP1 could target different signaling molecules eliciting diverse cellular responses, we  therefore wanted to examine how its interaction with LanCL1 would modulate BPGAP1 function. 
 This thesis aims to address the importance BPGAP1 and LanCl1 interactions, broadly 
•    Confirm interaction between BPGAP1 and LanCL1 and delineate binding regions by mutational studies.  
•   Identify the mechanism of BPGAP1- LanCL1 interaction using biochemical assays and knockdown studies.  





Materials and Methods 





2       MATERIALS AND METHODS  
 
2.1.   Generation of LanCL1 and H-Ras Constructs 
 Full length LanCL1, internal deletion mutants of LanCL1, truncation mutants of 
LanCL1, point mutations of LanCL1 and point mutants of H-Ras were generated using 
Polymerase Chain Reaction (PCR), gel extraction, restriction, ligation, transformation 
and plasmid extraction the protocols of which are detailed below. 
 
 
2.1.1.   Secondary structure analysis prior to designing primers for  
truncation and internal deletion mutants. 
 
 The secondary structure of the protein sequence of LanCL1(AJ were predicted 
with the NPS@ (Network Protein Sequence @nalysis) consensus secondary structure 
prediction web server (http://www.npsa-pbil.ibcp.fr) that incorporated 10 secondary 
structure prediction methods: SOPM, DPM, DSC, GOR-IV, HNNC, PHD, PREDATOR, 
SIMPA96, SOPM and Sec. Cons (Combet et al., 2000). The boundaries for the truncation 
and internal deletion mutants were designed such that there was no break in any 
recognizable secondary structural motifs like alpha helices or beta sheets. The predicted 









2.1.2.   Polymerase chain reaction (PCR) 
 
 LanCL1 cDNA was cloned using cDNA from SH-SY5Y cells and existing plasmid 
constructs were used in the case of truncation, internal deletion mutants or point 
mutants of LanCL1 and H-Ras. 
 
PCR was carried out with respective templates (Refer to Table 2.1 for templates 
used). A 50µl reaction was set up containing , 1U of high fidelity long template 
DyNAzyme EXT (Finnzyme, Espoo, Finland),10pmol each of specific forward and 
reverse primer oligonucleotides, 0.2mM dNTP mix and 1X DyNAzyme EXT Buffer (50 
mM Tris –HCl (pH 9.0 at 25:C), 1.5 mM MgCl2 , 15 mM (NH4)2SO4 and 0.1% Triton X-
100). Reactions where the template was longer than 1 kb or when the template was 
cDNA, DyNAzyme was substituted with 2.5 U of Pfu Turbo DNA Polymerase and 
corresponding 1 X Pfu Turbo DNA Polymerase reaction buffer (Stratagene, USA) was 
used. In the case of secondary PCR BD Advantage2 polymerase and corresponding SA 
PCR buffer was used to maximize efficiency of PCR. The PCR reaction was carried out in 
a BioRAD Thermocycler. The PCR protocol involves an initial denaturation step of 2 min 
at followed by 30 cycles: Denaturation 2 min at 95 : C; Annealing 0.5 min at 50-65 :C 
(depending on the Tm of the primer pair); Extension 1 min/kb at 72 :C. The primer 
sequences used for the generation of various constructs are given in Table 2.2.  
In the case of cloning of LanCL1 from cDNA of SH-SY5Y the product obtained 
from primary PCR was not sufficient for direct cloning thus a secondary PCR using 
primary PCR product in the ratio of 1:100 was used as template for secondary PCR 
using BD Advantage 2 Polymerase with LanCL1 specific forward and reverse primers. 




Table 2.1: Templates for generation of constructs used for cloning 
 
Template Construct 
Human cDNA  HA LanCL1 
HA LanCL1 Flag-LanCL1, GFP LanCL1,myc LanCL1 
internal deletion mutants of LanCL1, 
truncation mutants of LanCL1,point 
mutants of LanCL1 
HA H-Ras Flag H-Ras, Flag H-RasC184A 
 
 
Table  2.2: Primer sequences used for cloning of LanCL1 WT, deletion mutants, 
truncation mutants  point mutants and  HRAS point mutants. 
Construct  
name 
Primer name  Primer sequence 





5’ -CCGGATCCATGGCTCAAAGGGCCTTCCCGAATCC- 3’ 





360 REV     
5’ –CCGGATATCAGGTTCCCTGCATTTGAACTCTGA-  3’ 
5’ -GGGATATCTTCTCCATAC TCTAAGCACC ATTCAGC-  3’ 





LC 330 FW 
LC 271 REV 
5’ –GGGATATCTATGCCTTCCTGACACTCTACAACCTCACACAG-  
3’ 
 




LC 271 FW 
LC 234 REV 
5’ –GGGATATCCTTGTCCATTGGTGCCATGGCGCC-  3’ 





LC 234 FW 
LC 205 REV 
5’- CCGATATCGTGAGCCAAGGGAAGTTACATAGTTTGGTCAAG-  
3’  




LC 205 FW 





5’ - CCGATATCTCCAAAGTTC TTATTGACAA AAAGAAGAGC-  3’ 
 
 7T 170 FW 5’ –CCGGATCCGTGGAAAAGATTCCTCAAAGCCATATTCAGC- 3’ 















110 FW 5’ –CCGGATCCGCAGGCCCCCTGGCAGTG- 3’ 
 
 9 LC 61 FW  
LC 9 REV 
5’ –GGGATATCTACACTGGCTGGGCAGGTATTGCTGTG- 3’ 
5’ -CCGATATCAGGATTCGGG AAGGCCCTTT GAGCCAT-  3’ 
LANCL1  
R4A/E 
LC R4A FP  
LC R4A RP 
5’ – GGATCCATGGCTCAAGCCGCCTTCCCGAAT-  3’ 




LC H219F FP 
LC H219F RP 
5’ -GTAGGGGCTGCTTTCGGCCTGGCTGG 3’ 
5’ –CCAGCCAGGCCGAAAGCAGCCCCTAC-  3’ 
 
LANCL1  
 H 274F 
LC H274F FP 
LC H274F RP 
5’ –GCTTGTCTTCTGGTGCCATGGCGCC-  3’ 
5’ –GGCGCCATGGCACCAGAAGACAAGC-  3’ 
LANC 
H277F 
LC H277F FP 
LC H277F RP  
5’ –GCTTGTCCATTGGTGCTTCGGCGCC-  3’ 
5’ –GGCGCCGAAGCACCAATGGACAAGC- 3’ 
LANCL1 
H323F 
LC H323F FP 
LC H323F FP 
5’–GGATATGGGCTGTGCTTCGGTTCTGCAGG-  3’ 
5’ –CCTGCAGAACCGAAGCACAGCCCATATCC-  3’ 
LANCL1 
K317A 
LC K317A FP 
LC K317A RP 
 5’ –GGGTTGCTGAAGGCTGGATATGGGCTG-  3’ 
 5’ –CAGCCCATATCCAGCCTTCAGCAACCC-  3’ 
LANCL1 
R364E 
LC R364E FP  
LCR364E RP 
5’ –GGAGAACATGGATGCGAGACACCAGACAC-  3’ 
5’  -GTGTCTGGTGTCTCGCATCCATGTTCTCC-  3’ 
 LANCL1 
C276A 
LC C276A FW 
LC C276A REV 
5’ –GATCTGCTTGTCCATTGGGCTCATGGCGCC- 3’ 




LC C322A FW 
LC C322A REV 
5’ -GGG TTG CTG AAG AAG GGA TAT GGG CTG GCG CAC  
GGT TCT GCA GGG- 3’ 
5’ –CCC TGC AGA  ACC GTG CGC CAG CCC ATA TCC CTT CTT  










5’ -CTCGAGTCAGGAGAGCACACACTTTGCGCTCATGCAGCCG- 3’ 
 
 




2.1.3.   Agarose gel electrophoresis 
 
 Agarose gel electrophoresis was carried out to separate both the PCR products 
prior to cloning, as well as for separation of DNA fragments after restriction enzyme 
digestion. Agarose (1st Base) was dissolved in 1 X TAE buffer (40 mM Tris base, pH 8.0 
with glacial acetic acid, 10 mM EDTA) to generate 1-2% (w/v) agarose gels that were  
cast and run using 1 X TAE buffer. A 1 kb DNA ladder (Fermentas) was run together 
with the samples to be separated to aid in size determination. Agarose gels were run 
using SYBR®Safe DNA gel stain (Invitrogen) at a dilution of 1:50,000 to aid in 
visualization of DNA bands under ultraviolet radiation.  
 
2.1.4.   Gel extraction 
 
 After the separation of DNA samples by agarose gel electrophoresis, the gels 
were visualized under ultraviolet light and desired bands were excised using a clean 
scalpel. The excised bands were then subjected to an extraction procedure using 
QIAquick Gel Extraction Kit (QIAGEN) to elute the DNA. This DNA was then subjected to 
restriction digestion followed by cloning.  
 
2.1.5.   Restriction enzyme digestion 
 Inserts obtained from PCR followed by gel extraction were digested with 
appropriate enzymes prior to ligation into vectors cut with similar enzymes.  
 
 




Enzyme pairs were chosen based on their presence in the multiple cloning sites (MCS) 
of the vectors and their absence in the constructs to be cloned. LanCL1 and H-Ras 
constructs were cloned using BamHI and XhoI enzymes, where as for psilencer BamHI 
and HindIII were used. In general, restriction digestion was carried out using 4 U of 
each enzyme for every 1 μg of vector digested in a total reaction volume where the total 
enzyme composition was not more than 10%. Reactions were carried out in 1 X reaction 
buffer (according to manufacturer’s instructions) with bovine serum albumin (BSA) 
where required (dependent on the enzyme used). A notable exception to the above was 
in the case of the enzyme BamHI where NEB Buffer 2 was used instead of the 
recommended buffer as it was shown to provide the best results. For digestion of PCR 
products to generate inserts for cloning, 25 U of each enzyme was used for 28 μl of 
product eluted from the gel extraction step. Digestions were carried out for 4-8 hours at 
37°C for PCR products and digestion of empty vectors. Digestions of vectors with 
existing inserts was carried out for 1-2 hours at 37°C. 
 
2.1.6.   Cloning and expression vectors 
 
Various vectors were used for the purpose of cloning, as well as for expression of 
the cloned constructs in either bacterial or mammalian systems. Cloning vectors like 
pGEM-T Easy from Promega were used for the purpose of PCR cloning. Vectors like the 
pGEX-4T-1 and pXJ40 were used for PCR cloning, sub-cloning and also for expression of 
the cloned constructs. The pSilencer 2.1 U6 hygro vector was used for cloning shRNA  
 
 




constructs for the purpose of knocking down selected genes in mammalian cells. 
 
2.1.6.1.   pXJ40 Flag-tagged, HA-tagged, GFP-tagged mammalian expression  
                vector 
 
 The pXJ40 vector, kindly provided by Dr. E. Manser (Institute of Molecular and 
Cell Biology, Singapore) contains a Flag, hemagglutinin (HA) or green fluorescent 
protein (GFP) tag. This vector contains a cytomegalovirus (CMV) promoter and 
enhancer that flanks an MCS and an ampicillin-resistant gene and also harbors a β-
globin intron and either a HA epitope tagged sequence (YPYDVDYA), a flag epitope 
tagged sequence (DYKDDDDK) or a GFP sequence at the 5’ end. These vectors are 
extremely useful in various protein-protein interaction techniques that require one or 
both of the interacting partners to be expressed in a mammalian host.  
 
2.1.6.2.   pGEX-4T-1 GST-tagged bacterial expression vector 
 
 pGEX-4T-1 vector (Amersham Biosciences) is a 4.95 kb plasmid that is ampicillin 
resistant and contains an MCS downstream of a glutathione-S-transferase (GST) gene 
that serves as a tag. This GST gene contains an ATG start site as well as a ribosome-
binding site and is under the control of the tac promoter, which can be induced with 1-5 
mM isopropyl-B-thiogalactopyranoside (IPTG). Genes cloned into this vector are 
expressed as a fusion protein together with an N-terminal GST tag (~26kDa) upon 
induction with IPTG. In addition, this vector also contains an enzymatic cleavage site,  
 




which allows for the removal of the GST carrier protein from the fusion protein by 
thrombin. 
 
2.1.6.3.   pSilencer 2.1 U6 hygro siRNA expression vector 
 
The pSilencer 2.1 U6 hygro siRNA expression vector (Ambion) contains the 
human U6 RNA polymerase III promoter and hygromycin gene for antibiotic selection in 
mammalian expression as well as E. coli origins of replications and ampicillin resistance 
gene for cloning in bacterial systems.   
 
2.1.6.4.   mCherry-N1 mammalian expression vector 
 
mCherry-N-1 expression vector (Clonetech) contains a  mutant fluorescent 
protein derived from tetrameric Discosoma sp. red fluorescent protein ,DsRed. The 
vector backbone contains an SV40 origin of replication in mammalian cells expressing 
the SV40T antigen, apUC origin of replication for propogation in E.coli, and a  fi origin 
for single stranded DNA production. A Kozak consensus sequence is located 
immediately upstream of the mCherry gene to enhance translational efficiency in 
eukaryotic systems. A neomycin resistance  cassette allows stably transfected 
eukaryotic cells to be selected and a bacterial promoter upstream of the cassette 








2.1.7.   Ligation  
 
 For the purpose of cloning, subcloning and generation of internal deletion 
mutants of existing constructs, ligation was carried out with T4 DNA ligase (New 
England Biolabs) using 200 U (0.5 μl) at room temperature for 3-4 hours or overnight 
with comparable results, using twice the amount of ligase for blunt end ligation as 
compared to sticky end ligation. For pSilencer ligation reactions, only 20 U of ligase was 
used per reaction as detailed in section 2.2. 
 
2.1.8.   Competent Cells 
 
2.1.8.1.   Escherichia coli strain DH5 
 
This strain of bacteria was used for cloning (cDNA cloning, PCR cloning and sub-
cloning) purposes as it produces plasmid DNA of high yield and high purity due to a 
mutation in the endA gene that reduces the levels of endonuclease activity. 
 
2.1.8.2.   Preparation of competent cells 
 
 Bacterial E. coli DH5α cells were made competent using the calcium/manganese 
based (CCMB) method. E. coli DH5α cells were streaked onto an LB Agar plate from  
glycerol stock and incubated overnight at 37°C before one colony was picked and  
 
 




incubated in 5 ml of  LB broth overnight at 37°C with shaking. 50 ml of LB broth was 
then inoculated with this started culture and the culture was grown at 37°C with 
shaking till an OD measured at 600 nm reached 0.6. The culture was then chilled on ice 
for 10 minutes before it was pelleted at 2500 rpm for 10-15 minutes at 4°C. The 
supernatant was then decanted and the pellet re-suspended by gentle vortexing in 17 
ml (1/3 volume of original culture) of ice cold CCMB (80 mM CaCl2.2H2O, 20 mM 
MnCl2.4H2O, 10 mM MgCl2.6H2O, 10 mM KOAc pH 7, 10% (v/v) Glycerol; pH 6.4, 
filtered) followed by a 20-minute incubation on ice. The re-suspension is then pelleted 
by centrifuging at 3000 rpm for 10 minutes at 4°C. The supernatant is then decanted 
and the pellet is re-suspended in 4 ml (1/12 volume of original culture) of ice cold 
CCMB. The competent cells are then snap frozen in 100 μl aliquots using liquid nitrogen 
and stored in -80°C. 
 
 
2.1.9.   Transformation of ligated products into competent bacterial cells using 
heat-shock method of transformation 
 
 Frozen E. coli DH5α of competent cells were thawed on ice (50 μl per reaction) 
and the ligation product was added and mixed by pipetting. The mixture was then 
incubated on ice for 30 minutes followed by incubation in a water bath at a temperature 
of 42°C for 90 seconds after which it was immediately kept on ice for 2 minutes and 30 
seconds. 800 μl of LB broth was then added to each reaction and the samples were 
incubated in 37°C with shaking at 250 rpm for 1 hour for recovery. After recovery, the  
 




samples were pelleted for 1 minute at 800 rpm and re-suspended in 100 μl of broth  
before they were plated on LB agar plates containing 100 mg/ml ampicillin. The plates 
were then incubated overnight at 37°C. 
 
 
2.1.10.   Re-transformation of plasmid DNA using KCM method of transformation 
 
 For the purpose of re-transformation of plasmid constructs, 0.2-0.5 μl of plasmid 
DNA was incubated for 5 minutes on ice in a solution of KCM (100 mM KCl, 30 mM 
CaCl2, 50 mM MgCl2). 10-15 μl of thawed competent cells were added to the mixture and 
incubated on ice for 20-30 minutes before plating onto LB agar plates containing 100 
mg/ml ampicillin. The plates were then incubated overnight at 37°C. 
 
 
    2.1.11.   Plasmid extraction 
 
 Depending on the yield of plasmid DNA required, either a 5 ml or 50 ml 
overnight culture bacterial culture was used and the plasmid DNA extracted using 
either QIAGEN or AxyGen Mini/midiprep kits according to the manufacturer’s 
instructions. Once isolated, the concentration and purity of the plasmid DNA was 








2.1.12.   Spectrophotometric quantitation of plasmid DNA 
 
 The plasmid DNA samples were first diluted 1:150 with ddH2O before their 
absorbance at wavelengths 260 nm (OD260) and 280 nm (OD280) were measured  
spectrophotometrically using a blank of ddH2O. The DNA concentration of the samples 
were calculated using the following equation: 
DNA concentration (μg/ml) = OD260 X Dilution factor (150) X 50 μg/ml, whereby 1 unit 
of absorbance is taken to be equivalent to 50 μg/ml of double-stranded DNA. The purity 
of the DNA sample was determined by calculating the OD260:OD280 ratio. A ratio 
between 1.7-1.9 indicated DNA of good quality. 
 
 
2.1.13. Sequencing of DNA constructs 
 
 In order to confirm the presence of the insert after cloning, as well as to ensure 
that the amino acid encoding the construct is in the correct reading frame and 
mutation-free, the constructs were sequenced  in the forward and reverse reading 
frames with T7 forward and pXJ40R reverse (5’– GAG CGC AGC GAG TCA GTG AG – 3’) 
sequencing primers for the pXJ40 series of vectors, pGEXF and pGEXR sequening 
primers for the pGEX-4T-1 series of vectors or T7 forward and pSilencerR reverse (5’ – 
GAT GAC GGT GAA AAC CTC TGA C – 3’) sequencing primers for the pSilencer 2.1 U6 
hygro series of vectors. Automated sequencing was performed using the ABI PRISM  
 
 




BigDye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA) 
according to the manufacturer’s instructions. The 25-cycle-sequencing protocol 
involved the following steps: Denaturation of 30 seconds at 96°C; Annealing of 15 
seconds at 55°C; Extension of 4 minutes at 60°C. After the PCR sequencing reaction, the 
samples were purified by precipitation with 80 μl (3.0 μl of 3.0 M Sodium acetate pH, 
62.5 μl of 95% (v/v) ethanol, 14.5 μl ddH2O) of sodium acetate and ethanol mixture for 
15 minutes at room temperature. The DNA was then pelleted by centrifugation at  
14,000 rpm for 10 minutes. The supernatant was discarded and the pellet was washed 
using 500 μl of 75% (v/v) ethanol and centrifuging for 5 minutes at 14,000 rpm. The 
wash step was repeated and the pellet was then dried (30 seconds at 85°C or overnight 
at room temperature) till there was no residual ethanol. The DNA pellet was then 
dissolved in 10 μl HiDi Formamide and run using 96-well plates on the automated ABI 
3100 DNA Sequencer. The sequences obtained were then analyzed using the BLAST 
(Basic Local Alignment Search Tool) program on the NCBI (National Center for 
Biotechnological Information) website (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
 
 
2.1.14 .   Checking expression of cloned constructs using mammalian  
              (pXJ40 and pSilencer series) or bacterial (pGEX-4T-  1 series) 
 
 The successful expression of cloned constructs was first checked before they 
were used in subsequent experiments. For the pXJ40 series of clones, the expression 
was tested by transfection into 293T cells followed by western analysis using antibodies  
 




against the tag of the fusion protein. The pSilencer vector constructs were tested by co- 
transfection of GFP-tagged target protein, checking for the visual reduction of 
expression using fluorescence microscopy as well as confirmation of reduction by  
western analysis using protein-specific antibodies. The pGEX-4T-1 vector constructs 
were expressed as fusion proteins in bacterial cells, extracted, purified and expression 
analyzed by SDS-PAGE (Sodium Dodecyl Sulphate–Polyacrylamide Gel Electrophoresis) 










siRNA sites were selected to target the human LanCL1  by screening for overlapping 







The following sequences were chosen as targets: 
 
sh 1 : 5’ –AAG ATT GCA TCA CAC GGC TAA- 3’ (nt 392-412) 
 
sh2 : 5’ –AAG ATT GCA TCA CAC GGC TAA- 3’ (nt  586-606) 
 
sh3 : 5’ –AAG TGA GCC AAG GGA AGT TAC- 3’ (nt 701-721) 
 





sh4 : 5’ –AAG TAT CTC TGT GAT GCC TAT- 3’ (nt 889-909) 
 
sh5 : 5’ – AAA GCA AAG TCT GAA CTG CTT-  3’ (nt 276- 296) 
 
sh6 : 5’ –AAT  AGG CTA CAT CTA TGC TCT- 3’ (nt 465-485) 
 
sh7 : 5’  -AAT GGC TGG AAC AAT ATA TTT- 3’ (nt 1125-1145) 
 




After selecting siRNA target sites, shRNA insert sequences were generated 
together with 5’ overhangs and appropriate spacer sequences for the loop region 
using the program provided by the Ambion website 
:http://www.ambion.com/techlib/misc/psilencer converter.html) as single stranded 
complementary oligonucleotide sequences. Additional bases were then added to 
either ends to complete the  BamHI and HindIII cloning sites  to facilitate RE 
digestion and cloning. The target sequences were then synthesized and obtained 
from Sigma. The oligonucteotides were then diluted to a concentration of 
approximately 2.25 µg/µl in TE (10 mM Tris, 1 mM EDTA) buffer before 
complementary oligonucleotides were prepared for annealing. 3 µl  of each of the 
sense and antisense template nucleotide sequence  were diluted to  a final volume of 
30 µl  .The annealing mixture was first  heated for 3 minutes at 90 : C on a dry  heat 
block and then let to cool off to room temperature  gradually. 2 µg of annealed insert 
was then subjected to RE digestion with BamHI and Hind III enzymes  and  purified 
using pcr purification kit – refer to section 2.1.4.  
 
The insert was diluted to 8 ng/ µl , 1 µl  was used in a ligation reaction with 
80ng of pSilencer 2.1 U6 hygro vector (precut with corresponding RE enzymes refer  




to section (2.1.5) using 20 units of T4 DNA ligase (NEB).The ligation was carried out 
overnight at room temperature after which the ligation mixture was transformed 
into 50 µl  of DH5α competent cells by the heat shock transformation method. The 
ligation mixture was added to the competent cells and incubated on ice for 30 
minutes. This was followed by a heat shock of the sample at 42 : C for 90 seconds 
and immediate incubation in ice for 10 minutes. The sample was then recovered by 
incubation with 800 µl of LB broth for I hr at 37 : C in a shaking incubator. The 
sample was then pelleted and re-suspended in 100 µl of LB broth, which was then 
plated onto LB Agar plates containing 100 mg/ml ampicillin. The plates were then 
incubated overnight at  37 : C after which colonies were  picked, grown overnight in  
LB broth and subjected to plasmid extraction .The plasmids were then checked for 
the presence of insert by sequencing the plasmid with T7 forward primer and 
pSilencer R reverse primer. 
 
 
2.3.   Expression and purification of GST-fusion proteins in bacteria 
 
 Purified plasmids of constructs cloned into pGEX-4T-1 vectors were transformed 
into DH5α E. coli bacteria and plated on to LB Agar plate containing 100 ng/ml of 
ampicillin. Single colonies were picked and cultured overnight with vigorous shaking in 
5 ml of LB broth as a starter culture which was used to grow 200 ml of LB broth until an 
absorbance reading, OD of 0.3-0.6 at 600nm is reached. The culture is then pelleted (50  
ml per pellet) by centrifugation at 5500 rpm for 15 minutes in a refrigerated centrifuge.  
 




The supernatant is discarded and the pellets are stored in -80°C for a minimum of 1 
hour before lysis. The pellet was then re-suspended in 5 ml of ice-cold lysis buffer (1 X 
PBS, 1% Triton X-100, 100 mM (0.15g/10ml) of DTT and protease inhibitor cocktail 
(Roche Applied Science). All steps after this were carried out at 4°C. The suspension was 
transferred into a 15 ml Falcon tube and subjected to sonication (MISONIX Sonicator XL 
2020) at the following conditions: 3.0 minutes of 3.0 seconds pulses interspersed with 
9.9 seconds of lag time at 20% amplitude. The probe of the sonicator was cleaned with 
water before, between and after each sonication.  
 
 The lysed sample was then clarified by centrifugation at 5500 rpm for 30 
minutes at 4°C and the supernatant was transferred to a fresh 15 ml Falcon tube and 
incubated with 500 μl of Glutathione Sepharose 4B beads (Amersham Biosciences) by 
rotating overnight at 4°C. The bound beads were then washed 3 times with 10 ml of ice 
cold 1 X PBS containing 1% Triton X-100, followed by 2 washes with ice cold 1 X PBS. 
Beads were pelleted between washes by centrifugation at 500 rpm for 1 minute at 4°C. 
The beads were re-suspended in equal volume of 1 X PBS. For checking expression, 5-10 
μl of the re-suspension was boiled in Laemmli loading buffer (0.2 M Tris-HCl, pH 6.8, 
25% (v/v) glycerol, 25% (v/v) SDS, 12.5 (v/v) 2-mercaptoethanol, 0.005% (w/v) 
bromophenol blue) and resolved in an SDS-PAGE gel together with pre-stained protein 
marker (BioRAD) and 10, 25 and 50 μg of BSA similarly boiled in Laemmli loading  
buffer. The gel was then stained with Coomassie Brilliant Blue stain (0.2% Coomassie 
blue R-250, 40% methanol, 10% acetic acid) for 30 minutes before destaining with 
water until the desired resolution was reached.  
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2.4   Cell culture 
 
2.4.1   Cell lines and maintenance  
 
 For the purpose of the experiments in this thesis, the mammalian cells lines used 
were 293T and PC12. 
 
2.4.1.1.   293T 
 
 This cell line is a human embryonic kidney cell line that stably expresses the 
SV40 Large T antigen allowing the episomal replication of SV40 origin containing 
plasmids and therefore increasing the expression of the proteins coded by these 
plasmids. These cells can be easily grown and their ease of transfection and high  
expression of plasmids with SV40 origin made it an ideal choice for 
immunoprecipitation and other experiments. The cells were cultured in RPMI (Roswell 
Park Memorial Institute) 1640 media (Hyclone Laboratories) supplemented with 10% 
(v/v) defined fetal bovine serum (PAA Cell Culture), 2 mM L-Glutamine (Hyclone 
Laboratories), 10 mM HEPES (Hyclone Laboratories), 100 U/ml penicillin (Hyclone  
Laboratories), 100 U/ml streptomycin (Hyclone Laboratories) and 2 g/L sodium 










2.4.1.2.  PC12 
 
 The PC12 cell line is derived from a pheochromocytoma of the rat adrenal 
medulla and is a useful cell line for modeling neuronal differentiation. The cells were 
cultured in DMEM (Dulbecco’s Modified Eagle Medium) (high glucose) media (Hyclone 
Laboratories) supplemented with 10% horse serum (Gibco), 5% defined fetal bovine 
serum (PAA Cell Culture), 2 mM L-Glutamine (Hyclone Laboratories), 10 mM HEPES 
(Hyclone Laboratories), 100 U/ml of penicillin (Hyclone Laboratories), 100 U/ml of 
streptomycin (Hyclone Laboratories) and 3.7 g/L Sodium Bicarbonate (Hyclone 
Laboratories) and maintained at 37C in a 5% CO2 atmosphere. 
 
 
2.4.2.   Transfection of 293T cells 
 
293T cells were transfected using either FuGENE®6 (Roche Applied Sciences) or 
TransIT®-LT1 (Mirus Bio) transfection reagents at a ratio of 3:1 (volume of transfection 
reagent to μg of DNA). Prior to transfection, the medium of the cells to be transfected  
were replaced with serum-free RPMI medium for about 20 minutes. The transfection  
reagent was diluted in serum-free RPMI medium (100 μl for 3 μl FuGENE® 6 and 250 μl 
for 3 μl TransIT®-LT1) and incubated at room temperature for 5 minutes before the 
addition of plasmid DNA. Care was taken to make sure the transfection reagent was 
added into the media without coming into contact with the sides of the tubes. The 
mixture was then mixed by brief vortexing followed by an incubation of 15 minutes at  
 




room temperature before the complex was added drop wise to the media of the cells to 
be transfected. The plates were swirled to mix and incubated at 37°C in 5% CO2 
atmosphere for 3 hours before the cells were supplemented with RPMI medium 
containing 10% serum and returned to the incubator. 
 
 
2.4.3.   Transfection of PC12 cells 
 
 PC12 cells were transfected using Lipofectamine™ 2000 (Invitrogen Life 
Technologies) transfection reagent at a ratio of 4.5:2 (volume of transfection reagent in 
μl : μg of DNA) into antibiotic-free DMEM medium containing 10% serum. DNA was 
diluted in 150 μl of Opti-MEM® I Reduced Serum Media (GIBCO, Invitrogen) for every 2 
μg of DNA. The transfection reagent was also similarly diluted in 150 μl of Opti-MEM® 
and incubated for 5 minutes at room temperature before it is added to the diluted DNA 
and mixed, incubating further for 20 minutes before it is added to the cells. The cells 
were incubated for 3 hours at 37°C in 5% CO2 atmosphere before the medium 
containing the transfection complex is replaced, either with DMEM medium containing 
10% serum or DMEM medium containing 0.5% serum to prevent the toxic effects of the 










2.5.   EGF stimulation 
 
2.5.1.   Time-course EGF stimulation of 293T cells for endogenous      
              
             ERK1/2detection 
 
 
 293T cells were seeded in 6-well plates such that they reached ~50% confluency 
in 24 hours. At this time the cells were subjected to transfection as mentioned in section 
2.4.2. 24 hours after transfection, the cells were made quiescent for 24 hours by 
incubating in serum-free RPMI medium. These cells were then subjected to stimulation 
with 100 ng/ml Epidermal Growth Factor (EGF) (Sigma) in serum-free RPMI medium 
for 0, 2, 5 ,10 and 20 minutes before the samples were lysed, collected and separated on 









 293T cells were seeded in 6-well plates such that they reached ~50% confluency 
in 24 hours. At this time, the cells were subjected to transfection as mentioned in 
section 2.4.2. 24 hours after transfection, the cells were made quiescent for 24 hours by 
incubating in serum-free RPMI medium. These cells were then subjected to stimulation 
with 100 ng/ml Epidermal Growth Factor (EGF) (Sigma) in serum-free RPMI medium 
for 0, 5, 10, 20 and 30 minutes before the samples were lysed, collected and subjected to  
 
 








2.5.3.   Suboptimal EGF stimulation of PC12 cells for assessment of neurite  
              formation  
 
 PC12 cells were seeded at a confluency of 0.5 X 105 cells/ onto coverslips coated 
with Poly-D-Lysine. To coat the glass coverslips, they were incubated overnight at 4°C in 
a solution of 0.1 mg/ml Poly-D-Lysine (PDL) followed by five washes with autoclaved 
water and two washes with 95% ethanol before drying. PC12 cells were grown for 24 
hours in DMEM media containing 10% serum before they were transfected with 
plasmid constructs using Lipofectamine transfection reagent from Invitrogen according 
to manufacturer’s instructions in media free of antibiotics, containing 0.5% serum for 2 
hours before the cells were supplemented with 10% serum-containing media for a 
further 2 hours. The media was then completely replaced with media containing 10% 
serum for 21 hours before the cells were made quiescent by incubating for 24 hours in 
media containing 0.5% serum. The cells were then subjected to stimulation with 20 
ng/ml of EGF in 0.5% serum-containing media for 24 hours .The coverslips were then 









2.6.   NGF stimulation  
 
2.6.1.   NGF stimulation for immunoprecipitation 
 
PC12 cells were grown for 24 hours in DMEM media containing 10% serum before they 
were transfected with desired vectors using Lipofectamine transfection reagent from 
Invitrogen according to manufacturer’s instructions in media free of antibiotics, 
containing 0.5% serum for 2 hours before the cells were supplemented with 10% 
serum-containing media for a further 2-3 hours. The cells were made quiescent by 
incubating for 24 hours in media containing 0.5% serum. The cells were then stimulated 
with 100ng/ml NGF in 0.5% serum containing media for 24 hours before the samples 
were lysed, collected and subjected to immunoprecipitation and then separated by SDS-
PAGE and analyzed by Western blotting. 
 
 
2.6.2.   NGF stimulation of PC12 cells for assessment of potentiation of    
              neurite outgrowth with suboptimal NGF conc of 5ng/ml 
 
PC12 cells were seeded on to culture plates coated with Poly-D-Lysine. To coat the 
culture plates they were incubated at 37°C for 1 hour with ploy-D-Lysine and then 
washed 3-4 times with autoclaved water and two washes with 95% ethanol before 
drying. PC12 cells were grown for 24 hours in DMEM media containing 10% serum  
 
 




before they were transfected with GFP-LanCL1, pmCherry-BPGAP1, pmCherry-
BGAP1R232A, or GFP and pmCherry vectors as required using Lipofectamine 
transfection reagent from Invitrogen according to manufacturer’s instructions in media 
free of antibiotics, containing 0.5% serum for 2 hours before the cells were 
supplemented with 10% serum-containing media for a further 2-3 hours. The cells were 
made quiescent by incubating for 24 hours in media containing 0.5% serum. Before 
imaging, the cells were subjected to stimulation with 5ng/ml of NGF in 0.5% serum-
containing media. Live images were obtained at desired intervals using manual focus 
function on the Olympus live imaging system. 
 
 
2.7.   Co-immunoprecipitation, in vitro precipitation/pull down and semi-  
          endogenous pull down experiments 
 
2.7.1. Preparation of mammalian whole cell lysates 
 
 24 hours after transfection, the 293T cells were rinsed once with cold 1 X PBS 
and then lysed with 300 μl of SFB lysis buffer (50 mM Tris-HCl; pH 7.3, 150 mM NaCl; 5 
mM EDTA; 1.5mM MgCl2; 1% (v/v) Triton X-100; 10% (v/v)  Glycerol along  with 
freshly added protease inhibitors (Roche), 1% Sodium ortho vanadate; an 25mM β-
Glycerol Phosphate. The cells were scraped and centrifuged at 14,000 rpm for 10 
minutes to clear the lysate. The cleared whole cell lysate was then used for downstream  
 
 




protein quantification (Bradford assay) and protein-protein interaction 
(immunoprecipitation, pull down experiments) studies. 
 
2.7.2.   Bradford Assay for protein quantitation 
 
 Protein quantitation of whole cell lysates was carried out by spectrophotometric 
analysis using Bradford reagent (BioRAD) diluted freshly (1:5) before each experiment. 
Each sample and standard were analyzed in duplicate and the average value was used. 
Standards of 0, 2, 4, 6 and 8 μg were prepared using stock solution of BSA (10 mg/ml) in 
a total volume of 20 μl. 1 μl of whole cell lysate was mixed with 19 μl of water to 
prepare the samples. 980 μl of diluted Bradford reagent was then added to each sample 
sequentially, mixed and incubated at room temperature for 15 – 40 minutes. The 
absorbance at 595 nm was then taken for standards and sample sequentially and the  
protein concentration of the samples was calculated using the standard curve plotted 
with the standards. 
 
 
2.7.3.   Co-immunoprecipitation 
 
 For the purpose of co-immunoprecipitation, whole cell lysates from 293T cells 
that were co-transfected or singly transfected (controls) with appropriate constructs 
were incubated with 5 μl of anti-FLAG M2 beads for 3 hours of immunoprecipitation at  
4°C . The beads were washed 3 times with 750 μl of SFB (Special Formulation Buffer- 
 




(50 mM Tris-HCl; pH 7.3, 150 mM NaCl; 5 mM EDTA; 1.5 mM MgCl2; 1% (v/v) Triton X-
100; 10% (v/v)  Glycerol along  with freshly added protease inhibitors (Roche),1% 
Sodium ortho vanadate; and 25mM β-Glycerol Phosphate.) (Soh .F.L mSc Thesis 2005; 
Lua B.L PhD Thesis 2005) and the bound proteins were then boiled in Laemmli buffer 
before being separated by SDS-PAGE for Western analysis. 
 
 
2.7.4. Semi-endogenous immunoprecipitation experiments 
 
 These experiments were carried out in the same manner as for co-
immunoprecipitation with the exceptions that either single transfections of Flag-tagged 
LanCL1 or Flag- tagged LanCL1 and HA- tagged BPGAP1 were used and that for each 
sample, whole cell lysates from 2 wells of a 6-well plate were used, with an increase in 
the amount of M2 beads used to 10 μl ( with the exception of semiendogenous  pull 
down of  endogenous H-Ras using Flag –LanCL1 and HA-BPGAP1 co-trnsfection where 
in samples from 3 wells of a 6 well plate were pooled and lysates from 2 wells were 
used for endogenous pulldown of H-Ras and remaining lysate from 1 well of a 6 well  
was used for Co- immunoprecipitation of Flag-LanCL1 and BPGAP1. The samples were 
incubated overnight at 4°C, washed and boiled in Laemmli buffer before the bound 









2.7.5.   Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis  
            (SDS-PAGE) 
 
 Proteins were analyzed by separation on 10-15% SDS polyacrylamide gels with 
the use of a Mini Protean II electrophoresis apparatus (BioRad Laboratories). SDS-PAGE 
gels were cast according to the sizes of proteins to be separated. 15% gels were used to 
separate proteins with molecular weight less than 15 kDa whereas 12.5% gels were 
used to separate proteins of molecular weight around 20 kDa from the light chain; 10% 
gels were used in all other cases. The separating gel (10-15% (v/v) acrylamide, 0.48% 
(v/v) N-N’-methylbisacrylamide, 0.375 mM Tris-HCl, pH 8.8, 0.1% (w/v) SDS, 0.0075%  
(w/v) ammonium persulphate (APS) and 0.05% (v/v) TEMED (N, N, N', N'-
tetramethylethylenediamine)) was cast first and allowed to set before the stacking gel 
(5% (v/v) acrylamide, 0.133% (v/v) N-N’-methylbisacrylamide, 0.125 mM Tris-HCl, pH 
6.8, 0.1% (w/v) SDS, 0.0075% (w/v) APS and 0.08% (v/v) TEMED) was cast. Samples 
were boiled in Laemmli loading buffer for 3 minutes at 85°C, cooled and then loaded 
into the wells. 
  
The denatured samples were resolved in SDS-PAGE running buffer (25 mM Tris-base, 
0.19 M Glycine pH 8.3, 0.1% (w/v) SDS) at 50 mA for 1 hour. A pre-stained ladder of 
protein markers (BioRad) was used for estimation of protein sizes. After 
electrophoresis, proteins separated on the gels were immobilized onto PVDF  
membranes (Millipore) in transfer buffer (33.7 mM Tris, 0.256 M Glycine, 20% (v/v) 
methanol and 0.01% (w/v) SDS) at 100 V for 1.5 hours at 4°C with a Mini Trans-Blot 
Electrophoretic Transfer Cell (BioRad). 




2.7.6.   Western Blotting analysis 
 
 After transfer of the proteins to PVDF membranes, the membranes were blocked 
either overnight at 4°C or for 1 hour at room temperature in blocking buffer (1 X PBS, 
0.1% Tween-20, 1% BSA). After blocking, the blots were incubated in primary antibody 
(diluted in blocking buffer) either overnight at 4°C or for 1 hour at room temperature 
followed by 3 washes of 5 minutes each with wash buffer (1 X PBS, 0.1% Tween-20). 
This was followed by incubation with secondary antibody diluted in wash buffer for 1 
hour followed by 3 washes of 5 minutes each with wash buffer. The membranes were 
then treated for chemiluminescence detection using the ECL kit (Pierce).Primary 
antibodies used were polyclonal anti-Flag (Sigma) [1:10000], polyclonal anti-HA 
(Zymed) [1:2500], monoclonal anti-dualphospho-threonine-tyrosine (anti-phospho 
ERK1/2) (Sigma) [1:1000], monoclonal anti-ERK2 (anti-pan ERK) (Transduction 
Laboratories) [1:1000], anti-H-Ras (Santa Cruz Biotechnologies) [1:1000], and  anti 
LanCL1( Abnova)[1:1000]. Secondary antibodies used were anti-rabbit IgG and anti-
mouse IgG (both from Sigma)[1:2500]. 
 
 
2.8.   Staining of coverslips for indirect immunoflorescence detection 
 
 Coverslips were washed twice with 1 X PBS prior to fixing for 30 minutes at 
room temperature with 3.7% paraformaldehyde. After fixing, the coverslips were  
washed twice with 1 X PBS followed by 2 washes with 1 X PBS containing 4 mM  
 




ammonium chloride and 2 washes with 1 X PBS. The coverslips could be stored at this 
point at 4C till they needed to be stained. Coverslips were permeabilized for 15 
minutes at room temperature with 1 X PBS containing 0.2% (v/v) Triton X-100 prior to 
incubating with blocking buffer (1 X PBS containing 2% (w/v) BSA (Sigma) and 7% 
(v/v) defined fetal bovine serum (PAA Cell Culture)) for 1 hour at room temperature. 
After blocking, the coverslips were incubated faced down in 50 l of primary antibody  
(monoclonal anti-Flag (sigma) [1:100] or polyclonal anti-HA (Zymed) [1:50], diluted 
appropriately with blocking buffer) at room temperature for 1 hour. The coverslips 
were then washed, face up, 4 times with 1 X PBS containing 0.1% (v/v) Triton X-100; 
each wash lasting 2 minutes with shaking. Following this, the coverslips were incubated 
face down in 50 l fluorophore-conjugated secondary antibody (AlexaFluor® 488 
donkey anti-mouse [1:200] or AlexaFluor® 555 donkey anti-rabbit [1:100] (both from 
Invitrogen), diluted appropriately in blocking buffer) for 1 hour at room temperature. 
The coverslips were then washed face up 4 times with 1 X PBS containing 0.1% Triton 
X-100 followed by 2 washes with 1 X PBS (each wash lasting 2 minutes with shaking).  
 
The coverslips were then dipped in sterile water to remove any traces of salt 
from the PBS and then blotted dry before mounting face down on glass slides with 8 l 
of FluorSave (Calbiochem) mounting medium. Cells were viewed using confocal 









2.9.   In vivo RBD assay 
 
 The in vivo GTPase activity of H-Ras (endogenous and overexpressed) was 
examined by using GST-Raf-1 RBD fusion protein to bind to endogenous  active H-Ras.  
Transfected cells were lysed for the RBD assay using a HEPES based buffer (SFB buffer, 
50 mM HEPES; pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 5 mM EDTA, 10% (v/v) glycerol, 
1% (v/v) Triton X-100) with freshly added protease inhibitors and 5 mM sodium 
orthovanadate). 80 μg of total protein was incubated with 10 μg of GST-Raf-1 RBD for 
50 minutes at 4°C. Each set was also carried out using 10 μg of GST alone as a control. 
The bound proteins were then washed three times with 600 μl of SFB based buffer 
before they were boiled with Laemmli buffer and resolved on an SDS-PAGE gel for 
western analysis. The blots were stained with Amido Black to reveal equal loading of 
the GST-fusion proteins. 
 
 
2.9.1.   RBD assay in knockdown of endogenous LanCL1 with over-expression of 
BPGAP1 and time course EGF stimulation 
 
293T cells were transfected with 2ug each of pSilencer sh1, sh2 or pSilencer 
negative control either with or without BPGAP1 (1ug) for 24 hours along with 50ng 
LanCL1(to enhance detection with anti LanCL1 antibody). They were then allowed to 
grow in serum free medium for another24 hour, then  the cells were stimulated with 
100ng/ml EGF for 5 minutes, lysed and the cleared lysate was used for RBD analysis  
 




(Refer to section 2.7). The bound samples and whole cell lysates were then separated by 
SDS-PAGE and subjected to Western analysis to detect amount of endogenous H-Ras in 
the background of LanCL1 KD and BPGAP1 over-expression. 
 
 
2.9.2.   RBD assay under suboptimal NGF stimulation with overexpression   
               of LanCL1 and BPGAP1 
 
PC12 cells were grown in DMEM media containing 10% serum before they were 
transfected with Flag LanCL1, Flag BPGAP, Flag Vector or co-transfected with Flag 
LanCL1 and Flag BPGAP1 as required,  using Lipofectamine transfection reagent from 
Invitrogen according to manufacturer’s instructions in media free of antibiotics, 
containing 0.5% serum for 2 hours before the cells were supplemented with 10% 
serum-containing media for a further 2-3 hours. The cells were then made quiescent by  
incubating for 24 hours in media containing 0.5% serum. The cells were then subjected  
to stimulation with 5ng/ml of NGF in 0.5% serum-containing media for 1 hr, 4hr or 12 
hour respectively before being lysed. The cleared lysate was used for RBD analysis 
(Refer to section 2.8). The bound samples and whole cell lysate were then separated by 
SDS-PAGE and subjected to Western analysis to detect amount of bound active 









2.10   pSilencer sh Screening for Knockdown of endogenous LanCL1 
293T cells were transfected with pSilencer constructs along with GFP-LanCL1 for 
24 hours. They were then screened visually for drop in fluorescence and then lysed and 
were then separated by SDS-PAGE and Western analysis performed to detect LanCL1 












3      RESULTS 
 
3.1.   LanCL1 forms complex with BPGAP1 in cells 
  
LanCL1 (Lanthionine synthetase C-like protein 1)   was identified as one of the 
novel interacting partners for BPGAP1 by proteomics based affinity pull down using 
GST-tagged BPGAP1 to pull down interacting partners from cell lysates (Lua B. L. ,PhD 
thesis, 2005) (Refer Figure 1.18). LanCL1 is the human homologue for bacterial LanC 
enzymes. Though the functions and mechanisms of the bacterial homologue have been 
characterized its function in the eukaryotic system remained enigmatic until its 
structure was solved and a role in neuronal differentiation was demonstrated recently 
by Zhang et al.  Sine BPGAP1 could interact with multiple signaling molecules eliciting 
diverse cellular responses, its identification as a novel interacting partner for BPGAP1 
was intriguing. We therefore wanted to determine if LanCL1 was indeed a bona fide 
interacting partner for BPGAP1 in cells and how their association would modulate 
BPGAP1 function.  
 
 
3.1.1.   Molecular cloning of human LanCL1 cDNA   
 
MALDI TOF analysis of the excised band from the proteomics pull down revealed 
LanCL1 (Accession no: AJ289236) as an interacting partner. The accession number 
retrieved only a partial sequence corresponding to nucleotides 1 to 1140 from NCBI.  
 





Hence, nucleotide and deduced amino acid sequence of human p40 cDNA (LanCL1) 
were retrieved from EMBL, using the nucleotide sequence accession number Y11395 
(Appendix I) (Herbert Mayer et al., 1998)) and used for primer design.   
 
Initially cDNA synthesized by RT-PCR of mRNA obtained from human 293T cells 
were used as template, but the amplification was insufficient for use in downstream 
applications. Since LanCL1 was shown to have highest expression in the brain (Bauer et 
al., 2000), total human cDNA synthesized by RT-PCR of mRNA obtained from human SH-
SY5Y cells (neuroblastoma cells) were used as template for PCR amplification of human 
full length LanCL1 cDNA. The nucleotide sequence Y11395 from EMBL database was 
used to design forward and reverse primers with BamHI and XhoI sites respectively. 
PCR was carried out as described in “Materials and Methods”.  (Figure 3.1 A) PCR 
product of size 1200bp corresponding to full length human LanCL1. Since amplification 
was insufficient, a secondary PCR was set up as described in detail under “Materials and 
Methods”. (Figure 3.1 B) Relative amplification from cDNA and primary PCR 
respectively. The amplified product was used to generate clones with desired tags for 
further studies. The clones obtained were completely sequenced using T7 and PXJ40 
reverse primers along with various internal primers. The sequence alignment of the 
clone with the sequence corresponding to Y11395 is provided in Appendix I. No 


























































Figure 3.1:  Cloning of human LanCL1 cDNA. cDNA prepared from SHY5Y cells was 
used as template for PCR amplification with LanCL1 specific forward and reverse 
primers.  (A) The low intensity 1200bp band observed corresponds to full length 
human LanCL1 amplified from cDNA (lane 3 -red box); lanes 1 and 2 show marker 
bands and no template controls respectively. (B) Amplification from cDNA and primary 
PCR to compare the relative efficiencies. Weak band was obtained with cDNA (lane 2- 
red box), secondary PCR using primary PCR  product as template generated an intense 
band at 1200 bp corresponding to full length human LanCL1 cDNA. The amplified 












3.1.2.   Open conformation might be required for LanCL1 association 
 
Following the identification of LanCL1 as an interacting partner for BPGAP1 we 
wanted to determine if BPGAP1 and LanCL1  were bona fide interacting partners within 
cells. To determine this, co-immunoprecipitation experiments were carried out. 
HEK293T cells co-expressing  HA-epitope tagged full length BPGAP1 or its fragments 
and FLAG-epitope tagged full length LanCL1 were subjected to immunoprecipitation 
with mouse anti-FLAG® M2 beads. The bound proteins were then resolved in SDS-PAGE 
and subjected to Western blot analysis as described under “Materials and Methods”. 
(Figure 3.2  A) Diagrammatic representation of the various HA-epitope tagged BPGAP1 
constructs used.   
 
LanCL1 forms complex with BPGAP1. (Figure 3.2 B), first panel 
immunoprecipitated samples probed with anti-HA antibody showing the binding of 
LanCL1 to BPGAP1 and its mutants. wt (Wild type BPGAP1), PC (GAP and tail region) 
and NP (Proline rich, GAP, and tail region) interact with LanCL1 (lanes 1, 3 and 4) and 
BCH shows weak interaction (lane 2), but interaction with P1 and P5 which lack the 
proline rich region is relatively stronger (lanes 5, 7) and P4 and P6 fail to interact (lanes 
6, 8). Since the intensities in binding for wt, BCH, PC and NNP varied considerably 
between sets, we hypothesized that while both the BCH and the PC is required for 
interaction, the binding could depend on activation of signaling pathway, allowing  
 
 





BPGAP1 to be in the “open conformation” favoring interaction with its partners. In 
addition, presence of Proline rich region could prevent interaction by occluding the 
interaction site as P1 and P5 that lack the proline rich region interact strongly. 
 
Earlier work by our group has shown that BPGAP1 was involved in Ras/MAPK 
pathway and caused formation of protrusions in PC12 cells under EGF stimulation, 
suggesting that BPGAP1 could exist in a closed conformation prior to activation. 
BPGAP1 was also able to display intramolecular interactions (Aarthi R. PhD thesis, 
2010) which could occlude accessibility to interacting partners.  Based on the above 
findings, we hypothesized that activation by a signaling cascade may change the 
conformation of BPGAP1, facilitating interaction with its partners.  
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Figure 3.2A: Schematic representation of the various constructs used in co-
immunoprecipitation.   






     






























       
 
Figure 3.2B: LanCL1 forms complex with BPGAP1 in vivo  HEK293T cells expressing 
both Flag-tagged full length LanCL1 with HA-tagged full length or fragments of BPGAP1 
were immunoprecipitated (IP) with anti-FLAG antibody beads conjugate. Bound 
proteins were detected with anti-HA immuno blot (IB), (panel 1) immunoprecipitated 
samples probed with anti-HA antibody showing the binding of LanCL1 to BPGAP1 and 
its mutants. wt (Wild type BPGAP1), PC (GAP and tail region) and NP (Proline rich, GAP, 
and tail region) interact with LanCL1 (lanes 1, 3 and 4) and BCH shows weak interaction 
(lane 2), but interaction with P1 and P5 which lack the proline rich region is relatively 
stronger (lanes 5, 7) and P4 and P6 fail to interact (lanes 6, 8). Expression of transfected 
proteins were verified by anti-HA (panel 3) or anti–FLAG (panel 4) Western analyses of 
whole cell lysates respectively. Blots were stripped and probed with anti-FLAG antibody 










3.1.3.   BPGAP1-LanCL1 complex formation is dependent on stimulation 
 
 In light of our previous reports that BPGAP1 could exist in closed conformation 
prior to activation and its involvement in the Ras/MAPK pathway leading to ERK 
activation and protrusion formation in PC12 cells following EGF stimulation, we tested 
if its interaction with LanCL1 was dependent on stimulation. Complex formation of 
BPGAP1 and LanCL1 were also tested in PC12 cells. They would be a good model to 
study the morphological and cellular effects of these interactions, as these cells show 
distinct effects upon EGF and NGF stimulation, whereby stimulation with EGF causes 
proliferation and stimulation with NGF results in differentiation. 
 
 
3.1.3.1.   Association of BPGAP1 and LanCL1 is acute upon EGF stimulation 
 
To determine the effects of EGF on LanCL1 and BPGAP1 complex formation, 
HEK293T cells were co-transfected with Flag-tagged BPGAP1 along with HA-tagged 
LanCL1.  Cells were maintained in serum free media for a further 24 hours after 
transfection and then subjected to time course stimulation with EGF as described in 
“Materials and Methods”. Cell lysates were subjected to immunoprecipitation as 
described before. BPGAP1 interacts with LanCL1 in a time course dependant manner in 
the presence of EGF (Figure3.3). Interaction is rather weak in the absence of EGF and is 
acute at 5 min (panel 1, lanes 1 and 2).  
 




This indicates that the interaction between BPGAP1 and LanCL1 is dependent on 
the activation by the EGF signaling pathway, probably allowing BPGAP1 to change 
conformation facilitating its interaction with LanCL1. 
 
 
3.1.3.2.   LanCL1 interacts with BPGAP1 in the presence of NGF 
 
We then proceeded to determine the effects of NGF on LanCL1-BPGAP1 complex 
formation. PC12 cells were co-transfected with Flag-tagged BPGAP1 and HA-tagged 
LanCL1.  Cells were maintained in serum free media for a further 24 hours after 
transfection and then subjected to stimulation with NGF as described in “Materials and 
Methods”. Cell lysates were then subjected to immunoprecipitation as described before.  
 
BPGAP1 interacts with LanCL1 upon NGF stimulation (Figure 3.4) First panel, 
lane 2. These results not only indicate that interaction is dependent on the activation of 
the signaling pathway but, it is also not limited by the cell line used. Thus, in future PC12 
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Figure 3.3: BPGAP1 interaction with LanCL1 is acute upon EGF stimulation 
HEK293T cells expressing both Flag-tagged full length BPGAP1 and HA-tagged full 
length LanCL1 were subjected to time course stimulation with EGF prior to being 
immunoprecipitated (IP) with anti-FLAG antibody beads conjugate. Bound proteins 
were detected with anti-HA immunoblot (IB) (first panel). Expression of transfected 
proteins were verified by anti-HA (panel 3) or anti–FLAG (panel 4) Western analyses of 
whole cell lysates respectively. Blots were stripped and probed with anti-FLAG antibody 
to show amounts of precipitated proteins (panel 2). 
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Figure 3.4: BPGAP1 associates with LanCL1 upon NGF stimulation. PC12 cells 
expressing both Flag-tagged full length BPGAP1 and HA-tagged full length LanCL1 were 
subjected to stimulation with NGF prior to being immunoprecipitated (IP) with anti-
FLAG antibody beads conjugate. Bound proteins were detected with anti-myc immuno 
blot (IB) (panel 1). Expression of transfected proteins were verified by anti-myc (panel 
3) or anti–FLAG (panel 4) Western analyses of whole cell lysates respectively. Blots 
were stripped and probed with anti-FLAG antibody to show amounts of precipitated 




















3.1.3.3.   LanCL1 enhances   ERK1/2 phosphorylation upon of EGF stimulation 
 
BPGAP1 has been shown to enhance ERK1/2 phosphorylation (Lua and Low, 
2005; Soh F. L. MSc thesis, 2005; Aarthi R. PhD thesis, 2010) and association of LanCL1 
with BPGAP1 was acute in the presence of EGF. In light of these, we wanted to 
determine the effect of LanCL1 on ERK1/2 activation upon EGF stimulation. To this 
effect, HEK293T cells were transfected with Flag tagged LanCL1 and maintained in 
serum free media for a further 24 hours after transfection and then subjected to time 
course stimulation with EGF followed by Western analyses as previously described.  
 
Enhanced ERK1/2 phosphorylation was observed in lysates with LanCL1 at time 
points  5, 10 and 20 min after EGF stimulation (Figure 3.5) Second panel, (lanes 3, 4, 
and 5) as compared to Vector control (lanes 9, 10 and 11). This suggests LanCL1 acts via 





























Figure 3.5: LanCL1 enhances phosphorylation of ERK1/2 upon EGF  stimulation. 
HEK293T cells expressing Flag-tagged full length LanCL1 were subjected to time course 
EGF stimulation prior to analyses of  lysates by Western.  Blots were  probed with anti-
phospho ERK1/2 antibody to show endogenous levels of phosphorylated ERK1/2 
(panel 2),  then stripped and probed with pan ERK and tubulin antibodies to show equal 
loading (panels 3 and 4 respectively) and expression of transfected proteins were 












3.2.   Identification of BPGAP1 and LanCL1 interactions with Ras 
 
3.2.1.   BPGAP1 interacts with Ras a key activator upstream of EGF signaling 
pathway 
 
BPGAP1 and its BCH domain has been shown to act on the Ras/MAPK pathway 
and increase phosphorylation ERK1/2. The activation is inhibited by the MEK inhibitor 
U0126, showing that it acts upstream of MEK (Aarthi R. PhD thesis, 2010). BCH domain 
of other BCH domain containing proteins such as BNIP-2, BNIP-Sα, and  BNIP–XL have 
been shown to have regulatory function against small GTPases such as CDC42 (BNIP-2) 
and RhoA (BNIP-Sα, and  BNIP-XL) (Soh and Low, 2008; Zhou et al., 2002; 2005; 2006). 
These gave valuable clues that BPGAP1 might also have its effect on Ras GTPases since 
they are the key upstream regulators of the Ras/MAPK pathway. BPGAP1 targets 
upstream of MEK, and interacts with Ras. The BCH domain was specific for K-Ras, while 
BPGAP1 did not display any specificity (Aarthi  R. PhD Thesis, 2010).  
 
Current work and work by colleagues (Soh F. L. and Aarthi R.) have 
demonstrated that BPGAP1 interacted with Ras isoforms K-, N- and H-Ras. To reaffirm 
the association of BPGAP1 and Ras, co-immunoprecipitation experiments were carried 
out. HEK293T cells co-expressing HA-epitope tagged full length K-Ras, N-Ras or H-Ras 
and FLAG epitope tagged full length BPGAP1 were subjected to immunoprecipitation  
 
 





and Western analyses as previously described. BPGAP1 can indiscriminately interact 
with K-, N-, and H- Ras isoforms (Figure 3.6) lanes 2, 3 and 4.  Asterisk indicates 












































Figure 3.6: BPGAP1 inetracts with all three Ras isoforms  K- ,N-, and H-Ras. 
HEK293T cells expressing both Flag-tagged full length BPGAP1 and HA-tagged full 
length K-Ras, N-Ras or H-Ras were immunoprecipitated (IP) with anti-FLAG antibody 
beads conjugate. Bound proteins were detected with anti-HA immuno blot (IB) (first 
panel). Asterisk indicates non-specific detection of light chain (first panel; lane 1). 
Expression of transfected proteins were verified by anti-HA (panel 3) or anti–FLAG 
(panel 4) analyses of whole cell lysates respectively. Blots were stripped and probed 












3.2.2.   LanCL1 is H-Ras specific 
 
BPGAP1 and LanCL1 could independently enhance ERK1/2 phosphorylation 
upon EGF stimulation suggesting they act on similar pathways. Current work and work 
by colleagues (Soh F. L., MSc Thesis 2005; Aarthi R., PhD Thesis, 2010) have 
demonstrated that BPGAP1 interacted with Ras isoforms K-, N- and H-Ras. LanCL1 has 
been shown to increase ERK1/2 activation following EGF stimulation.  
 
Ras being one of the key upstream activators of Ras/MAPK pathway leading to 
ERK, we wanted to determine if LanCL1 was able to associate with Ras. To determine 
this HEK293T cells co-expressing HA-epitope tagged full length K-Ras, N-Ras or H-Ras 
and FLAG-epitope tagged full length LanCL1, were subjected to immunoprecipitation 
and Western analysis as described before.  
 
LanCL1 interacted strongly with H-Ras (Figure 3.7, top panel lane 3), while it 
did not interact with K-and N-Ras (lanes 1 and 2). Third panel is a longer exposure of 
the anti-HA Western blot, to ensure that the specificity shown by LanCL1 is not due to 
low exposure time.  Third panel, lane 1 shows a weak interaction with K-Ras; however, 
it is insignificant when compared to the H-Ras band on lane 3.  Thus LanCL1 interacts 
with H-Ras isoform while its interaction with other isoforms K-and N-Ras are 
nonexistent or maybe too transient to be captured by co-immunoprecipitation. 
However, BPGAP1 can interact with all three Ras isoforms K-, N-, and H- Ras.   
 





This specificity shown by LanCL1 in targeting H- 
Ras suggests that it may have an important role in directing BPGAP1 towards the 




























                                







HA-N-Ras               +                               +     
HA-K-Ras          +                               +      
 
              
Figure 3.7: LanCL1 interacts specifically with H-Ras. HEK293T cells expressing 
both Flag-tagged full length LanCL1 and HA-tagged full length K-Ras, N-Ras or H-Ras 
were immunoprecipitated (IP) with anti-FLAG antibody beads conjugate. Bound 
proteins were detected with anti-HA immuno blot (IB) (first panel; lanes 1, 2 and 3). 
Expression of transfected proteins were verified by anti-HA (first panel; lanes 5, 6 and 
7)) or anti-FLAG (third panel; lanes 5, 6 and 7) Western analyses of whole cell lysates 
respectively.  Blots were stripped and probed with anti-FLAG antibody to show 
amounts of precipitated proteins (third panel; lanes 1, 2 and 3).Very weak interaction 














3.2.2.1.   LanCL1 interacts preferentially with constitutive active H-Ras G12V 
 
On determining the specificity of LanCL1 for H-Ras, we wanted to determine if 
LanCL1 has any preference for  the dominant active G12V or dominant negative S17N 
forms of H-Ras. To investigate this, co-immunoprecipitations of LanCL1 with Wt H-Ras, 
constitutive active H-RasG12V and dominant negative H-RasS17 were carried out. 
Briefly, HEK293T cells  co-expressing HA-epitope tagged H-Ras WT (wild type), H-
RasG12V or H-RasS17N and FLAG-epitope tagged LanCL1 were subjected to 
immunoprecipitation  and Western blot analysis as described before.  
 
Wild type and G12V interacts with LanCL1 while, S17N interacts weakly (Figure 
3.8) Top panel, lanes 2, 3 and 4. The interaction of LanCL1 is stronger with the G12V 
mutant as compared to the wild type.  
 
 
3.2.2.2.    Specificity of LancL1 for H-Ras may depend on the differentia 
localization of Ras isoforms 
 
In mammalian cells, the three Ras genes encode four Ras isoforms (H-Ras, K-
Ras4A, K-Ras4B, and N-Ras) that are highly homologous but functionally distinct. 
Differences between the isoforms arise from the carboxy terminal hypervariable region 
(HVR) which differ in their post-translational modification resulting in differential  intra 
cellular sorting.   





Thus, they are proposed to recruit distinct up-stream and downstream accessory 
proteins and activate multiple signaling pathways (John F.Hancock, 2003; J.Omerovic et 
al., 2007). 
 
Individual Palmitoyl residues serve distinct roles in H-Ras trafficking, micro 
localization and signaling. Monopalmitoylation of Cys181 is required and sufficient for 
efficient trafficking of H-Ras to the plasma membrane, while monopalmitoylation of 
Cys184 does not permit efficient trafficking beyond the Golgi. Monopalmitoylation of 
Cys181 (mutating Cys184) reverses H-Ras lateral segregation and drives GTP loaded H-
Ras into cholesterol-dependant microdomains emulating the GTP-regulated 
microdomain interactions of N-Ras (Sandrine Roy et al., 2005). 
 
With the above information along with the knowledge that LanCL1 shows 
specificity towards H-Ras, it would be possible to determine the cause for its specificity 
by using H-Ras C184 mutant in co-immunoprecipitation, as the HVR region modification 
would  resemble N-Ras  (both N-Ras and H-Ras C184 would carry a single palmitoyl 
group on Cys181). HEK293T cells co-expressing HA-epitope tagged H-Ras wt (wild 
type), or its various mutants and FLAG epitope tagged LanCL1 were subjected to 










H-Ras cysteine mutant C184A failed to interact with LanCL1 (Figure 3.8) Top 
panel, lane4. This suggests that the specificity could be dependent on the microdomain 
localization of the Ras isoforms, as the post-translational modification of the C184A 
mutant now resembles N-Ras in having a single cysteine palmitoylated at position 181 
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Figure 3.8: LanCL1 preferentially interacts with H-RasG12V and does not 
interact with H-Ras S17N and H-Ras C184A. HEK293T cells co-expressing Flag- 
tagged full length LanCL1 with HA-tagged Wt-H-Ras, H-RasG12V, H-RasS17N or H-
RasC184A were immunoprecipitated (IP) with anti-FLAG antibody beads conjugate. 
Bound proteins were detected with anti-HA immuno blot (IB) (first panel). Expression 
of transfected proteins were verified by anti-HA (third panel) or anti –FLAG (fourth 
panel) Western analyses of whole cell lysates respectively. Blots were stripped and 













3.3.   Delineating the binding regions on LanCL1 for BPGAP1 and H-Ras 
 
On determining  the ability of LanCL1 to associate with BPGAP1 and H-Ras  it 
was necessary to delineate the  regions on LanCL1 important for its interaction with 
BPGAP1 and H-Ras. Various truncation and internal deletion mutants were created 
based on seconadry structure prediction. The secondary structure of LanCL1 was 
predicted  with NPS@(Network Protein Sequence analysis) consensus secondary 
prediction web server (http://www.nps@-pbil.ibcp.fr) that incorporated 10 secondary 
structure prediction methods, detailed in “Materials and Methods”.  
The concensus secondary structure obtained is provided in Appendix II. This 
prediction was used to determine the boundary for the internal and truncation 
deletions, taking care to avoid any major disruption in secondary structure. 
The mutants were created and sequenced as described in “ Materials and 
Methods” before being used in immuno precipitation reactions. (Figure 3.9) depicts a 
schematic representation of the various mutants used. 
 
3.3.1.   BPGAP1 has multiple binding sites on LanCL1 
 
To determine the binding region on LanCL1 for BPGAP1, HEK293T cells co-
expressing HA-tagged deletion mutants of LanCL1 and Flag-tagged BPGAP1 were 
subjected to immunoprecipitation and Western blot analysis as described before.  
 




All the internal deletion and truncation mutants were able to interact with 
BPGAP1. This shows that LanCL1 has more than one site involved in interaction with 
BPGAP1. (Figure 3.10) first panel - Immunoprecipitated samples probed with anti HA 
antibody showing the binding of LanCL1 mutants to BPGAP1.  
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Figure 3.9: Schematic representation of the various deletion mutants of LanCL1. 
Internal and truncation mutants used to screen the binding sites for H-Ras and BPGAP1. 
Red outline indicates region that is essential for interaction with Ras, adjacent green 




















































    
Figure 3.10: LanCL1 has multiple binding sites for BPGAP1. HEK293T cells co-
expressing Flag-tagged full length BPGAP1 and with HA-tagged fragments of 
LanCL1were immunoprecipitated (IP) with anti-FLAG antibody beads conjugate. Bound 
proteins were detected with anti-HA immunoblot (IB) (first panel). Expression of 
transfected proteins were verified by anti-HA (panel 3) or anti–FLAG (panel 4) Western 
analyses of whole cell lysates respectively. Blots were stripped and probed with anti-














3.3.2.   The 3 region on LanCL1 spanning amino acids 271-330 is essential for    
              H-RasG12V association 
 
To determine the binding region on LanCL1 for H-Ras, HEK293T cells co-
expressing HA tagged deletion mutants of LanCL1 and Flag tagged H-Ras-G12V were 
subjected to immunoprecipitation and Western blot analysis as described before. 
Figure 3.9 shows schematic representation of the various mutants used. The 
highlighted regions are  important  for interaction with H-Ras: Red box –aa 271-330; 
Green box–aa 240-270. Deleting amino acids 271-330 caused complete loss of binding 
to H-RasG12V and deleting amino acids 240-270 reduced the association between 
LanCL1 and H-RasG12V. 
 
(Figure 3.11) First panel, the immunoprecipitated samples probed with anti HA 
antibody showing the binding of H-RasG12V to LanCL1 and its mutants. The region 
spanning amino acids 271-330 are important for interaction with LanCL1, as the 3 
mutant lacking this region fails to interact with H-RasG12V (first panel, lane 3) and the 
deletion of adjacent region 230-271 (4 mutant) caused inconsistent binding 








































Figure 3.11: The 3 region on LanCL1 essential for interacting with H-Ras G12V.    
HEK293T cells expressing both Flag-tagged full length H-RasG12V with HA- tagged full 
length or fragments of LanCL1 were immunoprecipitated (IP) with anti-FLAG antibody 
beads conjugate. Bound proteins were detected with anti-HA immunoblot (IB) (first 
panel). Expression of transfected proteins were verified by anti-HA (panel 3) or anti–
FLAG (panel 4) Western analyses of whole cell lysates respectively. Blots were stripped 
and probed with anti-FLAG antibody to show amounts of precipitated proteins (panel 
2). LanCL1 binds to H-RasG12V at region 271-330, adjacent region spanning amino 











3.3.3.   Histidine 323 on LanCL1 is indispensable for interaction with H-RasG12V   
 
LanCL1 structure published by Zhang et al revealed the key residues in the active 
site; these were comparable to what was obtained in our deletion mutant screening as 
being important for association with H-RasG12V. This facilitated the designing of point 
mutants spanning this region. Thus based on the active site structure various point 
mutants were created as described in “Materials and Methods” and used in binding 
studies and later for confocal imaging. To determine the  critical residue on LanCL1 
important  for its association with H-RasG12V, HEK293T cells co-expressing various HA 
tagged point  mutants of LanCL1 and Flag tagged H-RasG12V were subjected to 
immunoprecipitation  and Western blot analysis as described before. (Figure 3.12) 
First panel - Immunoprecipitated samples probed with anti HA antibody revealing 
interacting mutants. Histidine 323 on LanCL1 is indispensable for interaction with H-
RasG12V, as mutating this residue (H232F) completely abolishes interaction with H-
RasG12V (lane 4). Mutating Histidine 219(H219F), Arginine 364, (R364E) and Lysine 
317(K317A), (lanes 1, 6 and 7) showed variable binding between experiments 
suggesting that they may play a role in stabilizing the interactions. Histidine 323 is one 
of the highly conserved amino acids among the different species (Figure1.15) as shown 










































































Figure 3.12: H323 on LanCL1 is indispensable for interaction with H-RasG12V. 
HEK293T cells co-expressing Flag-tagged full length H-RasG12V and with HA-tagged full 
length or various point mutants of LanCL1 were immunoprecipitated (IP) with anti-
FLAG antibody beads conjugate. Bound proteins were detected with anti-HA immuno 
blot (IB) (first panel). Expression of transfected proteins were verified by (anti-HA) 
panel 3 or anti–FLAG (panel 4) Western analyses of whole cell lysates respectively. 
Blots were stripped and probed with anti-FLAG antibody to show amounts of 













3.4.   LanCL1 forms complex with endogenous H-Ras 
 
Since both BPGAP1 and LanCL1 have multiple binding sites for association with 
each other, we were unable to use mutants of BPGAP1 or LanCL1 in further analyses to 
dissect and delineate the mechanism of interaction between LanCL1, BPGAP1 and H-
Ras. Thus, further characterization was carried out using full length LanCL1 and 
BPGAP1. 
 
Since LanCL1 was  shown to increase ERK1/2 phosphorylation upon EGF 
stimulation and preferentially bound to G12V mutant that mimics the active GTP bound 
form, we wanted to determine if LanCL1 was able to form complex with endogenous H-
Ras following EGF stimulation. HEK293T cells expressing Flag-epitope tagged full length 
LanCL1 were subjected to time course EGF stimulation followed by 
immunoprecipitation and Western blot analysis as described previously. LanCL1 
interacted strongly with endogenous H-Ras at 5min post EGF stimulation (Figure: 3.13) 
First panel, lane 3. Notably maximum phosphorylation of ERK1/2 occurred at a similar 
time point (sixth panel, lane 3). Thus it was evident that LanCL1 interacted with H-Ras 
following EGF stimulation leading to increased ERK1/2 activation. The observed result 
could also imply that the endogenous H-Ras associating with LanCL1 following EGF 
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Figure 3.13: LanCL1 formed physiological complex with endogenous H-Ras. 
HEK293T cells expressing Flag-tagged full length LanCL1 were subjected to stimulation 
with EGF for 0, 2, 5, 10, 20 and 30 min as described in “Materials and Methods” and the 
lysates were immunoprecipitated (IP) with anti-FLAG antibody beads conjugate. Bound 
proteins were detected with anti-H-Ras- immunoblot (IB) (first panel). Expression of 
endogenous H-Ras was verified using anti-H-Ras antibody (third panel) or expressed 
LanCL1 by anti-FLAG (fourth panel) Western analyses of whole cell lysates respectively. 
Blots were stripped and probed with anti-FLAG antibody to show amounts of 
precipitated proteins (second panel). Phosphorylation of endogenous ERK1/2 was 
detected using anti-phospho ERK1/2 antibody (fifth panel). Equal loading was 
confirmed using anti pan ERK and anti GAPDH antibodies after stripping (sixth and 









3.4.1.   Complex formation of LanCL1 with endogenous H-Ras is disrupted by     
  LanCL1-BPGAP1 association 
 
BPGAP1 and LanCL1 have been demonstrated to independently interact with H-
Ras and increase ERK1/2 activation following EGF stimulation and LanCl1 could 
independently associate with BPGAP1 and endogenous H-Ras following EGF 
stimulation. Based on these we hypothesized that a triple complex of LanCL1 BPGAP1 
and H-Ras could exist. To determine this Flag-tagged LanCL1 was used to 
immunoprecipitate endogenous H-Ras in the presence or absence of HA-BPGAP1 using 
Flag-Vector as control, following time course EGF stimulation. HEK293T cells 
expressing either FLAG epitope tagged LanCL1 or Flag-Vector alone or co-expressing 
Flag-LanCL1 and HA-BPGAP1 were subjected to immunoprecipitation following time 
course EGF stimulation and subsequent Western blot analysis as described previously. 
 
LanCL1 associated with endogenous H-Ras at 5 min (Figure 3.14) first panel, 
lane 2. Surprisingly, association was almost abrogated in the presence of BPGAP1 at 5 
min (first panel, lane 6). Interaction between H-Ras and LanCL1 is disrupted when 
LanCL1 interacts with BPGAP1 (second panel, lanes 6 and 7) and no interaction is 
observed for Vector alone (lanes 11-14). These results were surprising, as they indicate 
that  LanCL1 can interact with endogenous H-Ras upon EGF stimulation, but the 
interaction is disrupted when LanCL1 and BPGAP1 interact with each other. This 
opened up a new possibility that somehow the activity status of H-Ras could play a role 
in these interactions.  






      























Figure 3.14: Complex formation of LanCL1 with H-Ras is disrupted by BPGAP1. 
HEK293T cells expressing either FLAG-epitope tagged LanCL1, Flag- Vector alone or co-
expressing Flag-LanCL1 and HA-BPGAP1 were subjected to stimulation with EGF for 0, 
2, 5, 10, 20 and 30 min as described in “Materials and Methods”, then the lysates were 
immunoprecipitated (IP) with anti-FLAG antibody beads conjugate. Bound endogenous 
proteins were detected with anti-H-Ras immunoblot (IB) (first panel) presence 
/absence of bands highlighted by a box. BPGAP1 association with LanCL1 was verified 
by anti HA immuno blot (IB) (Second panel – bands highlighted by box).  Expression of 
endogenous H-Ras was verified by anti-H-Ras antibody (sixth panel) or expressed 
BPGAP1 by anti-HA (fourth panel) and LanCL1 by anti–FLAG (fifth panel) Western 
analyses of whole cell lysates respectively. Blots were stripped and probed with anti-
FLAG antibody to show amounts of precipitated proteins (third panel). Equal loading 
was confirmed by anti-tubulin immuno blot after stripping (sixth panel). Arrows 










3.4.2.   Complex formation of LanCL1 with H-RasG12V unaffected by BPGAP1 
 
Following the inability of LanCL1-BPGAP1 association to form physiological 
complex with endogenous H-Ras, we wanted to determine if the activity status of the H-
Ras played a role in formation of the triple complex. To address this, we decided to use 
wt H-Ras, the constitutive active mutant G12V, Dominant negative mutant S17N, along 
with C184A mutant as negative control and compare their abilities to form a complex 
with either LanCL1 or BPGAP1 and both.  Briefly, HEK293T cells were transfected with 
either Flag-tagged wild type, G12V, S17N or C184A H-Ras and either LanCL1 or BPGAP1 
or with both and the lysates were subjected to immunoprecipitation and Western blot 
analysis as described previously. 
 
LanCL1 and BPGAP1 associate with wt H-Ras, but the association of LanCL1 with 
Wt H-Ras decreased in the presence of BPGAP1. (Figure 3.15) First panel, lane 1-
LanCL1, lane 2-BPGAP1, and lane 3-(double bands) LanCL1-lower band and BPGAP1 
upper band.  Interaction of LanCL1 or BPGAP1 was unaffected when the H-RasG12V 
mutant was used (lanes 4, 5 and 6). LanCL1 interacted weakly with H-RasS17N unlike 
BPGAP1 which bound H-Ras S17N (lanes 7, 8) and the profile remained unaffected in 
the triple transfection (lane 9). The H-RasC184A mutant failed to interact with LanCL1 
as expected (lane 10) while BPGAP1 binding to H-RasC184A was unaffected either in 
the presence or absence of LanCL1 (lanes 11, 12).      
 
 





These results again suggest that the activity of H-Ras may be affected when 
LanCL1 and BPGAP1 associate, causing a drop in amount of LanCL1 associating with H-
Ras in the presence of BPGAP1. This assumption is further supported by the fact that 
LanCL1 preferentially binds H-RasG12V (the mutant that emulates the conformation of 




























HA-BPGAP1                +    +           +    +          +   +           +    +
G12V                               WT                               












Flag-H-Ras:                             
 
 
                
Figure 3.15:  BPGAP1 reduces LanCL1 interaction with Wt H-Ras but not G12V H-
Ras.  HEK293T were transfected with either Flag-tagged Wt H-Ras, G12V, S17N or 
C184A H-Ras and HA-LanCL1 or HA-BPGAP1 or both and lysates  subjected to 
immunoprecipitation with mouse anti-FLAG® M2 beads. Bound proteins were detected 
with anti-HA immuno blot (IB) (first panel). Panel 1 and 3 show bands of two molecular 
weights, the upper band corresponds to BPGAP1 and the lower band corresponds to 
LanCL1. LanCL1 binding to wt H-Ras is decreased in the presence of BPGAP1. Binding to 
G12V is unaffected and LanCL1 does not bind S17N or C184A mutant. BPGAP1 can 
interact with all – wt, G12V, S17N and C184A mutants. Expression of transfected 
proteins were verified by anti-HA (panel 3) or anti –FLAG (panel 4) Western analyses of 
whole cell lysates respectively. Blots were stripped and probed with anti-FLAG antibody 
to show amounts of precipitated proteins (panel 2). Dotted line represents sets  (wt, 










3.5.   Knockdown of LanCL1 delineates roles for LanCL1, BPGAP1, and their   
           association on H-Ras regulation 
 
Reduction in LanCL1 binding to H-Ras in the presence of BPGAP1 was 
unexpected, and  the mechanism and  function of BPGAP1–LanCL1 interaction  on H-Ras  
has to be determined. Since both LanCL1 and BPGAP1 seem to be involved in 
interaction with H-Ras and can increase ERK activation, their interaction has to be 
uncoupled to determine their individual effects on Ras/MAPK pathway leading to ERK. 
Knockdown of LanCL1 will help  to determine its function towards H-Ras. 
Simultaneously determining the action of BPGAP1 on H-Ras in the background of 
LanCL1 knockdown would provide insights into the role of BPGAP1, then their 
concerted effect on H-Ras can be better understood.  
 
Various siRNA sequences that target the human LanCL1 were selected by 
screening for overlapping target sites using four different design tools as described in 
“Materials and Methods”. Eight different target sequences, sh1 to sh8 were  chosen, 












3.5.1.   Short hairpin RNA sh1 and sh2 effectively target LanCL1 
 
To identify  pSilencer clones  that most effeciently target and knockdown 
LanCL1, GFP-tagged LanCL1 was co-transfected  with pSilencer vector at a ratio of 1:10 
into HEK293T cells for 24 hours before visualizing the transfected cells under 
fluorescence microscope  prior to lysing the cells for analysis by Immuno blotting . 
 
sh1 and sh2 sequences were the most efficient  in targeting LanCL1, resulting in 
about 80% and 90% reduction in protein expression respectively (Figure 3.16) First 
panel, lanes 1 and 2 show significantly low expressions of LanCL1 as compared to GFP-
LanCL1 co-transfected with pSilencer negative control  (lane 9) which consists of a non 



























































































Figure 3.16: sh1 and sh2 target LanCL1. HEK293T cells were co-transfected with 
GFP- tagged LanCL1 and pSilencer constructs at a ratio of 1:10 for 24 hours prior to 
analyses of cell lysates by Western. Blots were probed with anti-LanCL1 antibody to 
show endogenous levels of LanCL1 (top panel), blots were stripped and probed with 














3.5.2.   LanCL1 knockdown decreases active H-Ras 
 
In order to determine the role of LanCL1 and LanCL1-BPGAP1 interaction  on H-
Ras signaling,  transient knockdown of LanCL1 in HEK293T cells were carried out using 
two targetting sequences sh1 and sh2. Lysates were then subjected to Wesern blotting 
to determine ERK1/2 activation, as well as to determine activation of endogenous H-Ras 
by in vivo  GTP assays using GST-fusion proteins of Raf-1 RBD as described in “Materials 
and Methods” (RBD binds to the active form form of Ras thus, the amount of active Ras 
can be determined by Ras isoform  specific antibodies). HEK293T cells were transfected 
with sh1, sh2 or negative control and  stimulated with 100ng/ml EGF for 0 and 5 min 
before being lysed. The cleared lysates were then subjected to  Western blotting to 
determine ERK1/2 activation as well as to determine activation of endogenous H-Ras by 
in vivo  GTP assays  and analysed as described under “Materials and Methods”. sh1 and 
sh2  efffectively knockdown LanCL1. (Figure 3.17) First panel, lanes1-4. Knockdown of 
LanCL1 decreases amount of active H-Ras at 5min post EGF stimuation (second panel, 
lanes 2 and 4) as compared to knockdown  negative control (lane6). ERK1/2 activity 
also drops in the knockdown (third panel, lanes 2 and 4) as compared to the negative 
control (lane 6). These results complement the  observation in the semi-endogenous 
immunoprecipitation, whereby interaction of LanCL1 with H-Ras is acute following EGF 
stimulation.                                                         
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Figure3.17: Knockdown of LanCL1 decreases active H-Ras. HEK293T cells were 
transfected with sh1, sh2 or negative control and  then stimulated with 100ng/ml EGF 
for 0 and 5 min before being lysed.The cleared lysates were then subjected to Western 
blotting to determine ERK1/2 activation as well as to determine activation of 
endogenous H-Ras by in vivo  GTP assays using GST-fusion proteins of Raf-1 RBD. The 
samples were seperated by SDS-PAGE and immuno blotted with appropriate antibodies 








Active endogenous H-Ras pulled down by RBD detected with anti-H-Ras immunoblot 
(IB) (second panel, last lane (box– active H-Ras), control with GST alone shows no pull 
down (eighth panel). LanCL1 expression probed with anti-LanCL1 antibody (first 
panel); phosphorylation levels of endogenous ERK1/2 (third panel), endogenous levels 
of H-Ras (fourth panel). Blots were stripped and probed with anti-pan ERK and anti-
tubulin antibody to show equal loading (fifth and sixth panel). Amido Black staining 









 We then proceeded to determine the effect of BPGAP1 overexpression in the 
background of  LanCL1 knockdown on H-Ras ativity. HEK293T cells co-expressing  HA-
tagged BPGAP1 and sh1, sh2 or negative control were stimulated with 100ng/ml EGF 
for 0 and 5 min before being lysed. The cleared lysates were then subjected to  Western 
blotting to determine ERK1/2 activation as well as to determine activation of 
endogenous H-Ras by in vivo  GTP assays using GST-fusion proteins of Raf-1 RBD and 
analysed as described before.  
 
sh1 and sh2  efffectively knockdown LanCL1 (Figure 3.18) First panel , lanes 1-
4). BPGAP1 increases active H-Ras in the LanCL1 knockdown (second panel, lanes 1 and 
3 ) but not in the knockdown negative (lane 5). ERK1/2 activity also increases  
in the LanCL1 knockdown (third panel; lanes 1 and 3) as compared to the negative 
control (lane5). These indicate that BPGAP1 can effeciently increase the H-Ras activity 
and ERK1/2 phosphorylation  in the LanCL1 knockdown cells but not in the knockdown 
negative, suggesting that association of LanCL1 and BPGAP1 impose a negative 
regulation on H-Ras and ERK1/2 activation. 
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Figure 3.18: BPGAP1 increases  active H-Ras in LanCL1 knockdown. HEK293T cells 
co-expressing  sh1, sh2 or negative control  with HA-BPGAP1 were stimulated with 
100ng/ml EGF for 0 and 5 min before being lysed. The cleared lysate was then subjected 
to  Western blotting to determine ERK1/2 activation as well as to determine activation 
of endogenous H-Ras by in vivo  GTP assays using GST-fusion proteins of Raf-1 RBD. The 
samples were seperated by SDS-PAGE and immuno blotted with appropriate antibodies 
for  analysis.  
 




Active endogenous H-Ras pulled down by RBD detected with anti-H-Ras immuno blot 
(IB) (second panel), control with GST alone shows no pulldown (last panel). Expression 
of LanCL1 probed with anti-LanCL1 antibody (first panel), phosphorylation levels of 
endogenous ERK1/2 (third panel), and endogenous levels of H-Ras (fourth panel). 
Expression of transfected proteins were verified by anti-HA (fifth panel). Blots were 
stripped and probed with anti-pan ERK and anti-tubulin antibody to show equal loading 
(sixth and seventh panels). Amido Black staining shows equal loading of GST-Raf RBD 





3.5.4.   LanCL1 and BPGAP1 independently activate H-Ras/ERK but concerted  
 
action    down regulates activity 
 
 
The H-Ras and ERK1/2 activation levels obtained by RBD assay for the LanCL1 
knockdown and BPGAP1 expressing LanCL1 knockdown cells were then compared 
across a single blot. The results obtianed following Western analyses were quantitated 
with image J software  and the average of three independent experiments were 
represented as fold activation over zero time point control. Statistical comparison was 
made using ANOVA and Newman–Keuls multiple comparison. 
 
Amount of active H-Ras drops in the LanCL1 knockdown (Figure 3.19) column 
1, 2 as compared  to negative control (column 3).  LanCL1 increases active  H-Ras by 
about 4 fold. Active H-Ras  increases by 2-3 fold  in the presence of BPGAP1 (columms 4 
and 5)  as compared to LanCL1 knockdown (columns 1 and 2). Concerted action of 
BPGAP1 and LanCL1 (BPGAP1 expressing, LanCL1 knockdown negative) causes a 
decrease in H-Ras activation to about 5 fold lower than LanCL1 knockdown  negative 
control  alone(column 6 column 3). LanCL1 knockdown decreases  ERK1/2 activation  
 





by over 40% (Figure 3.20,  cloumns 1 and 2) as compared to negative control (column 
3). ERK1/2 activity is increased by  BPGAP1 in knockdown by about 45% (columns 4, 5)  
as compared to BPGAP1 and LanCL1 knockdown negative control (column 6). 
 
  The ERK activity is increased by BPGAP1 in LanCL1 knockdown to levels higher 
than knockdown negative (Figure 3.20, columns 4, 5 as compared to column 3). 
However, BPGAP1 is unable to significantly increase ERK1/2 activity in the absence of 
LanCL1 knockdown (column 6 ,compared to 4 and 5) suggesting that ERK1/2 activation 
by BPGAP1 is suppressed in the presence of LanCL1. H-Ras activity co-relates with the 














Figure 3.19: LanCL1 knockdown decreases H-Ras activation and BPGAP1 
increases activation in knockdown. HEK293T cells were transfected with sh1, sh2 or 
negative control alone or co-transfected with BPGAP1 and sh1, sh2 or negative vector 
control for 24 hours. Cells were then allowed to grow in  serum free media for 24 hours 
and stimulated with 100ng/ml EGF for 0 and 5 min before being lysed. The cleared 
lysates were then subjected to  Western blotting to determine ERK1/2 activation as well 
as to determine activation of endogenous H-Ras by in vivo  GTP assays using GST-fusion 
proteins of Raf-1 RBD. The samples were seperated by SDS-PAGE and and immuno 
blotted with appropriate antibodies for  analysis. The results were quantitated with 
image J software  and the average of three independent experiments were represented 
as fold activation over zero time point control. Statistical comparison was made using 
ANOVA and Newman–Keuls multiple comparison. Colums with different alphabets 
indicate a significant difference at  
p< 0.02 whereas all colums with same alphabets indicate no significant difference at p< 
0.02. 




      
 
Figure 3.20: LanCL1 knockdown decreases  ERK1/2 activity and activity in 
Knockdown is increased by BPGAP1. HEK293T cells were transfected with sh1, sh2 
or negative control  alone or co-transfected with BPGAP1 and sh1, sh2 or negative 
control for 24 hours. Cells were  allowed to grow in  serum free media for another 24 
hours, and stimulated with 100ng/ml EGF for 0 and 5 min before being lysed. Lysates 
were subjected to  Western blotting to determine ERK1/2 activation as well as to 
determine activation of endogenous H-Ras by in vivo  GTP assays using GST-fusion 
proteins of Raf-1 RBD. The samples were seperated by SDS-PAGE and immunoWestern 
blotted with appropriate antibodies for  analysis. The results were quantitated with 
image J software  and the average of three independent experiments were represented 
as fold activation over zero time point control. Statistical comparison was made using 
ANOVA and Newman–Keuls multiple comparison. Alphabets and Roman numerals 
represent sets without and with BPGAP1 respectively. Colums with different  alphabets 
or numerals indicates a significant difference at  p < 0.01 whereas all colums with same 










3.6.   PC12 cells   show distinct morphological changes for LanCL1, H-Ras and  
          their  association in response to EGF stimuation 
 
Responses of  PC12 cells are specific to EGF and NGF such that they proliferate in 
the presence of EGF and differentiate in the presence of NGF. 
We had earlier determined that interaction between LanCL1 and H-Ras was acute in the 
in the presence of  EGF and LanCL1 preferentially bound to the active G12V form, thus 
morphological changes in PC12 cells caused by LanCL1 and its asociation with H-Ras 
were investigated under EGF stimulation. 
 
3.6.1.   LanCL1 forms “starlets” upon EGF stimulation 
 
To determine the effects of LanCL1 on cell shape change, HA-epitope tagged 
LanCL1 was transiently expressed  in PC12 cells stimulated with 20ng/ml EGF for 24 
hours, processed as described in “Materials and Methods), and  examined using confocal 
fluorescence microscopy. (Figure 3.21) Cells expressing LanCL1 had extended 
morphology causing it to appear as “starlets” with punctate structures on cell periphery. 
Surrounding  untransfected cells  retained their compact circular shape. Quiescent cells 
expressing LanCL1  did not cause starlet formation. However the membrane 
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Figure 3.21: LanCL1 causes “starlet” formation upon EGF stimulation. PC12 cells 
were transfected HA-LanCL1 for 24 hours before being made quiescent by maintaining 
in 0.5% serum containing media and then stimulated with 20ng/ml EGF for 24 hours. 
Cells were then fixed, permeabilised, stained and viewed using confocal 
immunofluorescence microscopy as described under “Materials and Methods”.  Ectopic 
expression of the proteins were detected using anti-HA primary antibodies (red) 
followed by appropriate fluorophore-conjugated secondary antibodies. LanCL1 caused 










 3.6.2.   H-Ras and its mutants  display different phenotypes upon EGF  
  stimulation 
 
We then wanted to determine the effect of EGF upon Wt H-Ras and its different 
mutants G12V, S17N and C184A. To this effect Flag epitope tagged H-Ras Wt, S17N and 
C184A mutants were transiently expressed   in  PC12 cells stimulated with 20ng/ml  
EGF for 24 hours, processed and examined using confocal fluorescence microscopy as 
described in “Materials ans Methods”. 
 
Wt H-Ras differentiated unpon EGF stimulation resulting in long protrutions 
reminiscent of neurite outgrowth (greater than 2 to 3 body length), S17N expressing 
cells remained undifferentiated upon EGF stimulation and C184A mutant of H-Ras had 
rounded cell bodies and  shorter neurites compared to the wild type. (Figure 3.22) First 
panel; 1st column, H-Ras trasfected cells display neuronal outgrowth. DIC merged 
picture show untransfected cells retain circular shape (second panel, 1st column). H-
RasC184A transfected cells show rounded cell body with shorter neurites (first panel, 
2nd column). H-RasS17N transfected cells do not differentiate (first panel, 3rd column). 
Unstimulated wild type H-Ras transfected cells show short neurite like outgrowths (first 
panel, 4th column) which are absent in untransfected cells as observed in DIC merged 
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Figure 3.22: H-Ras and its mutants  display different phenotypes upon EGF 
stimulation. PC12 cells were transfected with Flag-epitope tagged wild type H-Ras, 
S17N and C184A mutants for 24 hours before being made quiescent by maintaining in 
0.5% serum containing media and stimulated with 20ng/ml EGF for 24 hours, 
unstimulated Wt H-Ras was used as control.  Cells were then fixed, permeabilised, 
stained and viewed using confocal immunofluorescence microscopy as described under 
“Materials and Methods”.  Ectopic expression of the proteins was detected using anti-
FLAG primary antibodies (green) followed by appropriate fluorophore-conjugated 
secondary antibodies. H-Ras transfected cells display neuronal outgrowth, while C184A 
have shorter neurites  and S17N transfected cells do not differentiate. Unstimulated H-
Ras control showed short neurites as compared to stimulated H-Ras transfected cells. 













3.6.3.   H-Ras and LanCL1 association increases soma size in PC12 cells 
 
LanCL1 could increase amount of active H-Ras  as knocking down LanCL1 caused 
a drop in the amount of active H-Ras.   To determine how its association with H-Ras 
would alter the morphology of PC12 cells, Flag- epitope tagged H-Ras was co-expressed 
with HA-eitope tagged LanCL1  and stimulated with 20ng/ml  EGF for 24 hours and 
examined using confocal fluorescence microscopy. Cells co-expresing LanCL1 and H-Ras 
showed shortening of neurites with increased membrane protrusions and expanded 
soma (increased size of cell body). 
 
(Figure 3.23) Morphological change characterised by expanded soma in  double 
transfected cells treated with EGF (first panel, 1st column), single trasfection of H-Ras 
observed in the background retains Wt H-Ras phenotype with neurites greater than 2-3 
times body length. Merged picture shows untransfected cells retaining undiffrentaited 
phenotype (first panel, 3rd column). The morphological change is only observed upon 
EGF stimulation as unstimulated cells retain morphology of unstimulated Wt-H-Ras 
(Second panel). These results indicate that LanCL1 is able to exert its effects on H-Ras in 
the presence of EGF resulting in morphological changes in PC12 cells that are distinct 
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Figure 3.23: LanCL1 caused distinct morphological changes in H-Ras transfected 
cells. PC12 cells were co-transfected with Flag-H-Ras and HA-LanCL1 for 24 hours 
before being made quiescent by maintaining in 0.5% serum containing media and 
stimulated with 20ng/ml EGF for 24 hours. Cells were then fixed, permeabilised, stained 
and viewed using confocal immunofluorescence microscopy as described under 
“Materials and Methods”.  Ectopic expression of the proteins was detected using anti-
Flag (green) or anti-HA primary antibodies (red) followed by appropriate fluorophore-
conjugated secondary antibodies. LanCL1 caused distinct morphological changes in H-
Ras transfected cells upon EGF stimulation, these were not observed in H-Ras single 












3.6.4.   Expansion of soma and shortening of nerites caused by H-RasG12V and   
LanCL1 co-transfection is  blocked by dominant negative  S17N 
 
We wanted to determine if the phenotype observed in the co-transfections of Wt 
H-Ras and LanCL1were due to the activity status of H-Ras. To test this, we co-expressed 
H-RasG12V with Wt LanCL1. Co-transfections of H-RasS17N  and Wt LancL1  and co-
transfections of Flag aad HA vectors were used as negative and vector control 
respectively. Flag epitope tagged H-RasG12V or H-RasS17N were co-expressed with HA-
eitope tagged wt LanCL1, along with co-tranfections of Flag and HA vectors (control) in  
PC12 cells and stimulated with 20ng/ml  EGF for 24 hours and examined using confocal 
fluorescence microscopy. 
 
(Figure 3.34) First panel, Co-expressing H-RasG12V and LanCL1 causes 
expasion of soma and increased membrane protrusions, but the neurite shortening was 
not as marked as those obserevd in wt H-Ras and wt-LanCL1 co-transfections. Co-
expressing H-Ras S17N and LanCL1 blocks the phenotype change (second panel). Co-
expressing  FLAG and HA  vectors causes no morphological changes upon EGF 
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Figure 3.24: H-RasG12V and LanCL1 cause expansion of soma and increased 
membrane protrusions. PC12 cells were co-transfected with Flag-H-RasG12V, Flag-H-
RasS17N and HA-LanCL1 or FLAG and HA-vectors for 24 hours before being made 
quiescent by maintaining in 0.5% serum containing media and stimulated with 20ng/ml 
EGF for 24 hours. Cells were then fixed, permeabilised, stained and viewed using 
confocal immunofluorescence microscopy as described under “Materials and Methods”. 
Ectopic expression of the proteins were detected using anti-Flag (green) or anti-HA 
primary antibodies (red) followed by appropriate fluorophore-conjugated secondary 
antibodies. H-RasG12V and LanCL1 caused increase in soma size and membrane 
protrusions and these were not observed in co-transfections of H-Ras S17N and LanCL1, 










3.6.5.   Phenotype of H-RasC184A unaltered by co-expressing LanCL1 and H-  
              RasC184A 
 
  H-RasC184A, the non-interacting mutant was also co-expressed  with LanCL1 to 
determine if it had any effect on the morphology. Flag epitope tagged H-RasC184A was 
co-expressed with HA-eitope tagged wt LanCL1 in  PC12 cells and stimulated with 
20ng/ml  EGF for 24 hours and examined using confocal fluorescence microscopy. Cells 
co-expresing  H-RasC184A and  wt LanCL1  showed short neurites (less than 2 cell body 
lenght) and retained morphology of stimulated single transfected H-RasC184A cells.   
 
(Figure 3.25), First panel, double transfected cells treated with EGF retain  phenotype 
of H-RasC184A.  Thus the mutant H-RasC184A is also unable to cause morphological 
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Figure 3.25: H-RasC184A  and LanCL1 expressing cells retain phenotype of single 
H-RasC184A tranfections. PC12 cells were co-transfected with Flag-H-Ras C184A and 
HA-LanCL1 for 24 hours before being made quiescent by maintaining in 0.5% serum 
containing media and stimulated with 20ng/ml EGF for 24 hours. Cells were then fixed, 
permeabilised, stained and viewed using confocal immunofluorescence microscopy as 
described under “Materials and Methods”.  Ectopic expression of the proteins were 
detected using anti-Flag (green) or anti-HA primary antibodies (red) followed by 
appropriate fluorophore-conjugated secondary antibodies. Co-expressing LanCL1 and 
H-RasC184A caused no morphological changes and cells retained morphology of 













3.6.5.  Non-interacting  LanCL1-H323F mutant  blocks expanded phenotype   
 of LanCL1 and H-Ras expressing cells  
 
 To confirm if the observed phenotype in PC12 cells, characterised by increased 
soma size  when LanCL1 and H-Ras are co-expressed are due to the  association of 
LanCL1 and H-Ras,  LanCL1 mutant H323F  (does not interact with H-Ras) was co-
expressed with wt-H-Ras and imaged by confocal microscopy. Flag epitope tagged H-
Ras was co-expressed with HA-eitope tagged LanCL1-H323F  in  PC12 cells and 
stimulated with 20ng/ml  EGF for 24 hours and examined using confocal fluorescence 
microscopy. 
 
Cells co-expresing H323F and H-Ras showed long neurites (2-3 cell body length) 
and retained morphology of stimulated Wt H-Ras transfected cells.  (Figure 3.26) First 
panel,  double transfected cells treated with EGF retaining phenotype of wt H-Ras.  The 
mutant H323F is unable to cause morphological change in H-Ras expressing cells as 
observed with wt LanCL1. These results indicate that the morphological changes 
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Figure 3.26: Distinct morphological change characterized by expansion of soma 
caused by LanCL1-H-Ras association is blocked by LanCL1-H323F mutant. PC12 
cells were co-transfected with Flag-H-Ras and HA-H323F-LanCL1 for 24 hours before 
being made quiescent by maintaining in 0.5% serum containing media and stimulated 
with 20ng/ml EGF for 24 hours. Cells were then fixed, permeabilised, stained and 
viewed using confocal immunofluorescence microscopy as described under “Materials 
and Methods”.  Ectopic expression of the proteins were detected using anti-Flag (green) 
or anti-HA primary antibodies (red) followed by appropriate fluorophore-conjugated 
secondary antibodies. H323F mutant was able to block the morphological changes 










Collectively these results (Figures 3.21 to 3.26) show that the morphological 
changes observed when wt LanCL1 and wt-H-Ras are co-expressed require their 
association. In summary, the confocal results indicate that LanCL1 is able to exert its 
effects on H-Ras in the presence of EGF resulting in morphological changes in PC12 cells 
that are distinct from unstimulated control or single transfections of H-Ras or LanCL1. 
This effect requires interaction between LanCL1 and H-Ras as the non-interacting 
mutants of H-Ras and LanCL1 are unable to cause this effect.  
 
 
3.7.   BPGAP1 and  its association with LanCL1 differentially modulate     
           neuronal differentiation in PC12 cells 
 
BPGAP1 had been implicated in causing differentiation of PC12 cells upon EGF 
stimulation, although LanCL1 caused morphological changes upon EGF stimulation it 
did not result in differentiation. LanCL1 and BPGAP1 interaction was also enhanced by 
NGF and both  could independently activate H-Ras while their concerted action 
downregulates H-Ras and ERK activity. We wanted to determine the effects of these 
interactions on  PC12  neuronal differentiation.  NGF stimulation was done at 
suboptimal concentrations of 5ng/ml, this suboptimal stimulation ensured that the 
physiological phenomena observed were due to the proteins under study and not a 
result of NGF per se, as under such conditions vector or untransfected cells would not  
show  morphological difference. 
 





Briefly, PC12 were seeded on poly D-Lysine coated 6-well culture plates  for 24 
hours before they  were transfected with suitable constructs  using Lipofectamine 2000 
as described in “Materials and Methods”.  The cells were then made quiescent by 
maintaining cells in 0.5% serum containing media for 24 hours. Prior to live imaging 
using Olympus live imaging system, the cells  were stimulated with suboptimal 
concentrations of 5ng/ml NGF. Six different positions  were imaged for every well in a 
six well plate and images captured every 30 minutes for 24 hours using the auto focus 
system on the microscope. The captured images were converted to movie using image J 
software and analysed. 
 
Since the movies cannot be compared in synchronised manner and using the 
autofocus for fluorescent images for 24 hours  caused bleaching  and small changes in 
focus planes resulted in  poor quality images, the different positions were captured 
manually   at 1, 4 ,8 and 12 hours after stimulation with NGF. Following   analysis of the 
24 hour movie to determine the best time points, 1, 4, 8 and 12 hour time points were 













3.7.1.   BPGAP1 potentiates neuronal differentiation 
 
To determine the effect of BPGAP1 overexpression on PC12 morphology under 
suboptimal levels of 5ng/ml NGF stimulation, mCherry-BPGAP1 was transfected into 
 PC12 cells  and time lapse live imaging was carried out as described before. (Figure 
3.27) Fluorescent images in panel 1 show that BPGAP1 transfected cells show neurite 
potentiation, and neurite length increases progressively from 1 hr onwards till it 
reaches a maximum at about 8 to 12 hrs post stimulation. Second, third and fourth  
panels show images obtained at 4, 8 and 12 hours respectively. Comaparison of 
fluorescent and  Phase contrast images (panels 1 and  2 respectively)  show that neurite 
outgrowth is characteristic of BPGAP1 transfected cells and untransfected cells do not 












































Figure 3.27: BPGAP1 potentiates neurite outgrowth at suboptimal NGF 
stimulation. PC12 were seeded on poly D-Lysine coated 6-well culture plates  for 24 
hours before they  were transfected with mCherry-BPGAP1 using Lipofectamine 2000 
as described in “Materials and Methods”.  The cells were then made quiescent by  
maintaining cells in 0.5% serum containing media for 24 hours. Prior to live imaging 
using Olympus live imaging system, the cells  were stimulated with suboptimal 
concentrations of 5ng/ml NGF. Representative fluorescent and phase contrast  images 
captured on the Olympus live imaging system using manual focus fuction at times points  
1 hour, 4 hour, 8 hour and 12 hours for cells transfected with mCherry-BPGAP1 are 
shown. Fluorescent images (First column,  panels 1 to 4) and phase contrast images 
(second column, panels 1 to 4). Arrows indicate position of  neurites. 
 





3.7.2.   LanCL1 shows  initiation of neurite outgrowth 
 
Neurite potentiation under suboptimal NGF stimulation of 5ng/ml in  LanCL1 
transfected cells  was not as significant as observed with BPGAP1 transfected cells. 
Neurite outgrowth slowly increased but does not reach maximum between 8 and 12 
hours as observed for BPGAP1 transfected cells. However cells had “starlet” like 
appearance. 
 
(Figure 3.28) Fluorescent images, (panel 1) shows that LanCL1 transfected cells show 
initiation of neurite like outgrowths, giving a starlet like appearence and progresses 
slowly with time and fails to reach maximun between 8 and 12 hours. Second, third and 
fourth  panels show images obtained at 4, 8 and 12 hours respectively. Comparison of 
Fluorescent and Phase contrast images clearly show that untransfected cells do not 
show significant morphological changes. 
 
mCherry and GFP-Vectors served as controls in the NGF neurite potentiation 
experiment. mCherry and GFP-vector transfected cells show no potentiation or 
initiation of neurite outgrowth even at 12 hours when stimulated with suboptimal 
concentrations of 5ng/ml NGF. Figures are included in Appendix III. 






























Figure 3.28:  LanCL1 causes formation of starlet like phenotype with slow neurite 
outgrowth. PC12 were seeded on poly D-Lysine coated 6-well culture plates  for 24 
hours before they  were transfected with  and GFP-LanCL1 using Lipofectamine 2000 as 
described in the “Materials and Methods”.  Prior to live imaging using Olympus live 
imaging system, the cells  were stimulated with suboptimal concentrations of 5ng/ml 
NGF. Representative fluorescent and phase contrast   images captured on the live 
imaging system using manual focus fuction at times points 1 hour, 4 hour, 8 hour and 12 
hours  for cells transfected with GFP LanCL1are shown. Fluorescent images (First 
column,  panels 1 to 4) and phase contrast images (second column, panels 1 to 4). 









3.7.3.  Concerted action of LanCL1 and BPGAP1 modulate neuronal  
differentiation 
 
Concerted action of LanCL1 and BPGAP1 has been known to downregulate H-Ras 
activation. We then wanted to determine the effect of co-expressing lanCL1 and BPGAP1 
on the morphology of PC12 cells. To this effect PC12 cells were co-transfected with GFP-
LanCL1 and mCherry-BPGAP1 and subjected to live imaging as described before. 
 
Co-transfection of  GFP LanCL1 and mCherry BPGAP delays the potentiation 
mediated by BPGAP1. No potentiation is observed at 4 or even 8 hours. BPAGP1 and 
LanCL1 co-transfected cells start differentiation only at about 12 hours after stimulation 
with suboptimal concentrations of NGF.  
 
(Figure 3.29) Fluorescent image from, panel1,  mCherry-BPGAP1  and GFP-
LanCL1  co-transfected cells show no significant morphological changes. Second, third 
and fourth  panels showing images obtained at 4, 8 and 12 hours respectively reveal 
that co-transfected cells show delayed differentiation and initiation of neurite 
outgrowth is only observed around 12 hours post stimulation. Comparison of 
Fluorescent and Phase contrast images clearly show that  no significant difference 
occurs between co-transfected and untransfected cells until 8 hours after stimulation, 
neurite outgrowth is observed in co-transfected cells only at 12 hours after stimulation. 
  
 





These results indicate that the potentiation mediated by BPGAP1 is delayed by 
co-expressing BPGAP1 in the presence of LanCL1. The concerted inhibition of PC12 
differentiation,  along with the results obtained in the knockdown in the HEK293T cells 
(with regard  to drop in amount of active H-Ras in  BPGAP1 expressing, LanCL1 
knockdown negative cells ) suggests that the concerted action of BPGAP1 and LanCL1 

















































Figure 3.29: Concerted action of LanCL1 and BPGAP1 delays neuronal 
differentiation.  PC12 were seeded on poly D-Lysine coated 6-well culture plates  for 
24 hours before they  were co-transfected with mCherry-BPGAP1 and GFP-LanCL1 
using Lipofectamine 2000 as described in the Materials and Methods.  The cells were 
then made quiescent by replacing cells in 0.5% serum containing media for 24 hours. 
Prior to live imaging using Olympus live imaging system, the cells  were stimulated with 
suboptimal concentrations of 5ng/ml NGF. Representative fluorescent and phase 
contrast   images captured on the live imaging system using manual focus fuction at 
times points 1 hour, 4 hour, 8 hour and 12 hours for cells transfected with mCherry-
BPGAP1and GFP-LanCL1 (Fluorescent images; First and second columns,  panels 1 to 4) 









3.7.4.   BPGAP1 mediated  neurite potentiation  does not require  GAP activity   
             of  BPGAP1 
 
The GAP domain of BPGAP1 has been known to control various signaling events 
leading to morphological changes and motility of cells. BPGAP1 plays a key role in 
RhoGTPase signaling involving Cdc42, Rac1 and RhoA, where its BCH and GAP  domains 
are required for formation of pseudopodia by Cdc42 and Rac1, and the GAP domain 
inactivates RhoA. The GAP domain of BPGAP1 causes formation of pseusopodia by 
inactivating Rho A,  while its Proline rich region interacts and  with cortactin,  resulting 
in enhanced cell migration. Thus BPGAP1 was able to couple morphological changes to 
enhanced cell migration (Shang et al., 2003; Lua and Low , 2005).  
 
To test the involvement of GAP activity of BPGAP1 in regulating neurite 
outgrowth, live imaging was carried out using mCherry BPGAP1-R232A, the GAP 
insensitive mutant of BPGAP1. PC12  cells were seeded and transfected as described 
previously. R232A mutant also potentiates neurite outgrowth  comparable to BPGAP1 
under suboptimal conditions of 5ng/ml. R232A mutant can also potentiate neurite 
outgrowth as early as 4 hours  similar to wild type BPGAP1, and neurite growth reaches 
maximum between 8-12 hours  to about 3 times cell body length and untransfected cells 
show no neurite outgrowth even after 12 hours. (Figure 3.30) Fluorescent images, 
panel 1, BPGAP1-R232A transfected cells show neurite potentiation, and neurite length 
increases progressively from 1 hr onwards till it  
 
 





reaches a maximum at about 8 to 12 hrs post stimulation. Second, third and fourth  
panels show images obtained at 4, 8 and 12 hours respectively. Comparison of 
Fluorescent and Phase contrast images (panels 1 and 2 respectively) show that 
untransfected cells do not have neurites and neurite outgrowth is characteristic of 
transfected cells. The neurite potentiation is comparable at all time points  to wild type 



































Figure 3.30: GAP muatant of BPGAP1, BPGAP1-R232A also potentiates neurite 
outgrowth at suboptimal NGF stimulation. PC12 were seeded on poly D-Lysine 
coated 6-well culture plates  for 24 hours before they  were transfected with mCherry-
BPGAP1R232A using Lipofectamine 2000 as described in “Materials and Methods”. 
Prior to live imaging using Olympus live imaging system, the cells  were stimulated with 
suboptimal concentrations of 5ng/ml NGF. Representative  fluorescent and phase 
contrast images captured on the live imaging system using manual focus fuction at 
times points 1 hour, 4 hour, 8 hour and 12 hours for cells transfected with mCherry- 
BPGAP1-R232A are shown. Fluorescent images (First column,  panels 1 to 4) and phase 









3.7.5.   GAP activity of BPGAP1 required for concerted modulation of  neuronal   
             differentiation 
   
To test the involvement of GAP activity of BPGAP1 in concerted modulation of  
neurite outgrowth, live imaging was carried out using BPGAP1-R232A, the GAP 
insensitive mutant of BPGAP1 along with LanCL1. Co-expressing  GFPLanCL1 and 
mCherry BPGAP-R232A caused no  delay in  the potentiation and neurite outgrowth 
remained comparable to wild type BPGAP1  or R232A mutant transfected cells. (Figure 
3.31) Fluorescent images, panel 1, BPGAP1-R232A and LanCL1 co-transfected cells 
show neurite potentiation and neurite length increases progressively from 1 hour 
onwards, till it reaches a maximum at about 8 to 12 hrs post stimulation. Second, third 
and fourth  panels show images obtained at 4, 8 and 12 hours respectively. 
 
 A steady increase in neurite outgrowth was observed over time from 1 to 12 
hours post stimulation and was comparable to single transfections of BPGAP1 (Figure 
3.27) or BPGAP1-R232A (Figure 3.30) for the time points observed. Comparison of 
Fluorescent and Phase contrast images (Panels 1 and 2 respectively) show that 











Thus the delay in differentiation observed while co-expressing LanCL1 and 
BPGAP1 is blocked when LanCL1 and BPGAP1-R232A are co-expressed. These results 
indicate that the potentiation delay mediated by the concerted action of LanCL1 and 



















































Figure3.31: Potentiation delay mediated by concerted action of LanCL1 and 
BPGAP1 is blocked by  association of LanCL1 and BPGAP1-R232A. PC12 cells  were 
seeded on poly D-Lysine coated 6-well culture plates  for 24 hours before they  were co-
transfected with mCherry-BPGAP1-R232A and GFP-LanCL1 using Lipofectamine 2000 
as described in “Materials and Methods”. Prior to live imaging using Olympus live 
imaging system, the cells  were stimulated with suboptimal concentrations of 5ng/ml 
NGF. Representative fluorescent and phase contrast  images captured on the live 
imaging system using manual focus fuction at times points  1, 4, 8 and 12 hours for cells 
co-expressing  mCherry-R232A and GFP-LanCL1 are shown. Fluorescent images (First 
and second columns,  panels 1 to 4) and phase contrast images (third column, panels 1 
to 4). Yellow arrows indicate neurite positions. 
 





3.7.6.    H-Ras activity co-relates with  length of neurite outgrowth in PC12 cells 
 
  To determine if the morphological changes  observed with BPGAP1 over- 
expression resulting in potentiation of  neurite outgrowth was linked to amount of 
endogenous active H-Ras, pull down experiments using Raf1RBD bound to GST fusion 
proteins  were carried out as described in “Materials and Methods”. To link the 
potentiation of neurite outgrowth in PC12 to the amount of active H-Ras , the  pull-down 
assays were carried out in PC12 cells under similar conditions as for the live imaging 
using 5ng/ml NGF and amounts of active H-Ras was determined at similar time points.  
 
PC12 cells expressing  Flag-tagged LanCL1, Flag-tagged BPGAP1 or Flag Vector 
alone or co-expresing Flag-tagged LanCL1 and Flag-tagged BPGAP1 were stimulated 
with 5ng/ml NGF for 1, 4 and 12 hours  before being lysed for estimation of H-Ras 
activity. Lysates were subjected to  Western blotting to determine the amount of active 
endogenous H-Ras by in vivo  GTP assays using GST-fusion proteins of Raf-1 RBD. The 
samples were seperated by SDS-PAGE and immunoblotted with appropriate antibodies 
for  analysis as described before. 
 
(Figure 3.32) First panel, RBD-Raf pull down of endogenous active H-Ras probed with 
anti-H-Ras antibody. Increased active H-Ras is observed in BPGAP1 transfected samples 
at 4 and 12 hour time points ( lanes 5 and 6, highlighted by box).  
 
 





Significant increase in active H-Ras in LanCL1 transfected samples is observed 
only at 12 hours (lane3). Samples co-transfected with LanCL1 and BPGAP1 have no 
increase in  active H-Ras at 4 hours (lane 8) and weak activity appears only at 12 hour 
(lane  9), Vector control shows no significant increase in active H-Ras  at all time points 
(lanes 10 and 11).  
 
Thus amounts of active H-Ras in BPGAP1 transfected cells is increased, and co-
expressing LanCL1 and BPGAP1 decreases amount of active H-Ras. Though increase in 
active  H-Ras is observed at 12 hour in LanL1 and BPGAP1 co-transfected cells, the 
amount is not significant and is only comparable to that of 4 hour activity observed in 
the presence of BPGAP1 alone. Increased ERK1/2 activation is also obsevered at the 
time points when H-Ras activity is increased (fifth and sixth panels). ERK1/2 activation 
complements H-Ras activity suggesting that the signalling from  H-Ras occurs via ERK, 
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Figure 3.32: H-Ras activity co-relates with  length of neurite outgrowth in PC12 
cells. PC12 cells expressing  Flag-tagged LanCL1, Flag- tagged BPGAP1 or Flag Vector 
alone or co-expressing Flag-tagged LanCL1 and Flag-tagged BPGAP1 were stimulated 
with 5ng/ml NGF for 1, 4 and 12 hours  before being lysed. Lysates were subjected to  
Western blotting to determine amount of active endogenous H-Ras by in vivo  GTP 
assays using GST-fusion proteins of Raf-1 RBD. The samples were sepetared by SDS-
PAGE and immunoblotted with appropriate antibodies for  analysis.  
RBD pulldown of active endogenous H-Ras was detected with anti-H-Ras immunoblot 
(IB) (first panel), control with GST alone shows no pull down (ninth panel).  
Endogenous levels of total H-Ras determined by anti–H-Ras antibody (second panel).  









Endogenous phosphorylation levels of ERK1/2 determined by anti-phospho ERK1/2 
antibody (fourth panel). Blots were stripped and probed with anti-pan ERK and anti-
tubulin antibodies to show equal loading (fifth and sixth panels). Amido Black staining 






3.7.7.   Concerted action of LanCL1 and BPGAP1 modulate neuronal     
              differentiation by regulating H-Ras 
 
The results obtained with Raf-RBD pull down in PC12 cells at 1, 4 and 12 hr 
timepoints were quantitated with image J software  and the average of three 
independent experiments were represented as fold activation of H-Ras over zero time 
point control. Different colours represent different time points as indicated in the graph. 
  
(Figure 3.33)  No significant increase in active H-Ras  at 1 hour time point, except for 
BPGAP1 which shows  over  ½ fold increase as compared to vector (Blue Bars).  
BPGAP1 increases amount of active H-Ras by over 2 .5 folds as compared to Vector at 4 
hours, no significant increase in active H-Ras  was observed for the others (Brown 
Bars). BPGAP1 increases active H-Ras close to 3.5 folds as compared to vector at 12 
hour while  LanCL1 shows more than ½ fold over vector at 4hours and over 1.5 folds  at 
12 hours. Co-tranfection of LanCL1 and BPGAP1 show about 1 fold increase over vector 
at 12 hours (Green bars). Vector shows no significant increase in active H-Ras at all 
times. This shows that the concerted action of BPGAP1 and LanCL1 can delay or 
suppress BPGAP1 mediated neurite potentiation by modulating H-Ras activity. 
 







Figure 3.33: Concerted action of LanCL1 and BPGAP1 modulate neuronal 
differentiation by regulating H-Ras. PC12 cells expressing  Flag-tagged LanCL1, Flag 
tagged BPGAP1 or Flag Vector alone or co-expressing Flag-tagged LanCL1 and Flag-
tagged BPGAP1 were stimulated with 5ng/ml NGF for 1, 4 and 12 hours  before being 
lysed. Lysates were subjected to  Western blotting to determine amount of active 
endogenous H-Ras by in vivo  GTP assays using GST-fusion proteins of Raf-1 RBD. The 
samples were seperated by SDS-PAGE and immunoblotted with appropriate antibodies 
for  analysis. The signals from  Western blots were quantitated with image J software  
and the average of three independent experiments are represented as fold activation 
over vector at 1 hr timepoint. Statistical comparison was made using ANOVA and 
Newman–Keuls multiple comparison. Columns with same alphabets indicate same time 
points. Columns with different number of asterisks indicates a significant difference at p 
< 0.05 whereas all colums with same number of asterisks indicate no significant 










4       DISCUSSION 
 
4.1.   LanCL1 : a novel interacting partner for BPGAP1 requires stimulation   
          for  association   LanCL1 was identified as an interacting partner for BPGAP1 by proteomics based affinity pull down. We have demonstrated the interaction of BPGAP1 and LanCL1 in 293T and PC12 cells. However, the interaction intensities varied suggesting that the interactions are too transient or required cues from upstream activators following stimulation to form stable complexes. In addition, BPGAP1 has been observed to have intramolecular interactions since its identification and characterization by Shang et al from our group.  Full length BPGAP1 interacted weakly with the BCH domain of Cdc42GAP3 and did not interact with the BCH domain of BNIP-2 (Bcl2/adenovirus E1B 19KD interacting Protein 2). Conversely, the BCH domain of BPGAP1 interacted strongly with both BCH domain of Cdc42Gap and BCH domain of BNIP-2 (Shang et al., 2003). Also, full length BPGAP1 could not precipitate endogenous K-Ras while the BCH domain of BPGAP1 interacted strongly with endogenous K-Ras (Soh F. L. MSc thesis, 2005). There have been many reports of proteins exhibiting intramolecular interactions, mostly through protein–protein interactions, phosphorylation and post-translational modification (Schmidt and Hall, 2002). Many regulators of GTPases have been shown to demonstrate intermolecular inhibitory effect. Auto-inhibitory effect in p115 RhoGEF is released by   
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 the binding of GM130 (or) Giatin to its acidic domain, allowing p115 RhoGEF to interact  with Rab1 (Beard et al., 2005). In addition, the N-terminus of p115 RhoGEF may impose an autoinihibition on the GEF activity of the DH-PH module towards RhoA (Hart et al., 1998). P120GAP is inhibited by the binding of its N-terminal PH domain to the catalytic GAP domain, preventing interaction of Ras with the GAP domain (Drugan et al., 2000). The first 48 amino acids of p50 RhoGAP interacts with the C-terminal GAP domain causing self-inhibition which is released upon interaction with Rac1 (Moskwa et al., 2005).  BNIP–H (BNIP-2 Homology) a BCH domain containing protein also exhibits intramolecular interaction that is disrupted by NGF stimulation, allowing BNIP-H to interact and localize with Pin 1 to the tips of differentiating neurites (Buschdorf et al., 2008). BPGAP1 has been shown to have intramolecular interaction by deletion mutant analysis, whereby N-terminal BCH domain (amino acids 34-74) interacts with C-terminal region (amino acids 389-433) (Aarthi R. PhD Thesis, 2010). The existence of such intramolecular interaction could also be the reason for the decreased binding between LanCL1 and BPGAP1.  The binding of the various mutants of BPGAP1 to LanCL1 also revealed that a composite BPGAP1 is necessary for interaction, as the domains showed weak binding. Proline rich region imposes a negative regulation on interaction as mutants P1 and P5 that lack this region showed very strong affinity for LanCL1 (Figure 3.2). The proline rich region may occlude the binding site that could become available following   
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 stimulation with EGF or NGF. Alternatively, the presence of intermolecular interactions  of BPGAP1, (whereby N-terminal BCH domain amino acids 34-74 interact with C-terminal region amino acids 389-433)  or allosteric regulation  could prevent interaction. Stimulation with EGF or NGF  could release these inhibitions by conformational change, favoring interaction with its partners. We have shown that the association of LanCL1 and BPGAP1 require stimulation and their interaction is promoted by EGF or NGF. 
 
 
4.2.   Significance of interaction with Ras  Our group has extensively studied BCH domain containing proteins. One common characteristic of BCH domain containing proteins is their ability to interact with small GTPases, suggesting that they may function as regulators of small GTPases. BCH domain of BNIP 2 interacts with Cdc42, while the BCH domains of BNIP- Sα and BNIP-XL targets Rho A and specifically regulates its activity either directly or by interacting with Rho GAPs and GEFs (Zhou et al., 2002; 2005; 2006; Soh and Low, 2008). The ability of BCH domain to regulate Rho GTPases strongly suggested that BPGAP1 might also be involved in regulating Ras subfamily of small GTPases. Following this, the BCH domain of BPGAP1 has been shown to interact with K-Ras (Soh  F. L. MSc thesis, 2005; Aarthi R. PhD thesis, 2010).    
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 However, current work and work by colleagues Soh and Aarthi have revealed that full length BPGAP1 can interact with all three Ras isoforms- K, N, and H-Ras (Figure 
3.6). This ability of BPGAP1 to target different Ras isoforms suggests that the BCH domain, proline rich region and GAP domain can be involved in interacting with the different isoforms either through their specific domains or as composite BPGAP1. The proline rich region (PRR) and the GAP domains may serve as anchor points that facilitate binding of H and N-Ras or they may recruit other interacting partners that stabilize the interaction of BCH domain with H and N-Ras respectively. Alternatively, the PRR and GAP domains may be involved in interaction with H-Ras and N-Ras by an uncharacterized mechanism.  Interestingly, LanCL1 interacted with BPGAP1 upon stimulation with EGF or NGF, and LanCL1 increased phosphorylation of ERK 1/2 upon EGF stimulation. Also, BPGAP1 increases ERK1/2 activation following EGF stimulation (Soh F. L., MSc thesis, 2005), suggesting that LanCL1 might play also a role in the Ras/MAPK pathway leading to ERK. This led us to determine if LanCL1 was able to interact with the Ras isoforms, one of the key upstream activators of the Ras/MAPK pathway leading to ERK. Surprisingly LanCL1 showed specificity in its interaction with Ras isoforms, it specifically interacted with H-Ras but not with K or N-Ras (Figure 3.7)  The specificity of LanCL1 towards H-Ras is significant as there are few reports of proteins exhibiting isoform specificity, as the Ras isoforms are highly homologous. H, K and N-Ras are expressed ubiquitously and almost identical in terms of structural,   
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 biophysical and biochemical properties but have differing functions in various tissues. These differences are proposed to be mediated by differential localization, enabling isoforms to interact with different sub cellular pools of effectors and activators (Daniels 
et al., 2006; Onken et al., 2006; Rocks et al., 2006).   The main divergence among Ras isoforms are restricted to the 24 C-terminal amino acids, termed the hypervariable region  with less than 15% identity except  cysteine at position 186. This hypervariable region undergoes distinct post-translational modification allowing differential intracellular sorting.  Ras isoforms in different sub cellular locations are proposed to recruit distinct up-stream and downstream accessory proteins and activate multiple signaling pathways. Thus in addition to regulatory proteins, post-translational modification on the C termini determines their sub–cellular localization providing an additional level of regulation.  There have been reports of protein demonstrating isoform specific interaction with H-Ras. Galectin-1, a lectin implicated in human tumors, is a selective binding partner of oncogenic H-Ras(12V) (Paz, A. et al., 2001). Ras-GRF1 has been shown to selectively activate H-Ras rather than K or N-Ras  and induces morohological changes in PC12 cells (Huibin Yang et al., 2006). The cyclopentenone 15-deoxy-12,14-prostaglandin J2 (15d-PGJ2) induces cell proliferation and mitogen-activated protein kinase activation by activating H-Ras activation. The specific effect of 15d-PGJ2 on H-Ras is mediated by its interaction with the cysteine residue at the 184 position, which exists in H-Ras but not in N-Ras or K-Ras suggesting that this site may be an important   
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 determinant in the homologue-specific roles of Ras proteins (Jose Luis Oliva et al., 2003).  H-Ras isoform was specifically required for mechanorepression of RANKL gene expression. This Ras isoform is located within lipid rafts (Prior i. A. et al 2001; Niv et al., 2002) and thus organization of membrane microdomains may be critical to the specific mechanical response (Janet Rubin et al., 2005). RGS12 is a selective scaffold regulating prolonged ERK activation, it  is  specific for  NGF, activated H-Ras  and B-Raf. Differential post-translational modifications, known to sequester these Ras family members to distinct cellular locales (Ashery et al, 2006), may dictate in part, the functional differences seen among Ras isoforms for RGS12 association (MD Willard et al., 2007).  Based on existing knowledge we speculated that the specificity of LanCL1 towards H-Ras could be due its localization. H-Ras laterally segregates into specific  microdomains that are distinct from K and N-Ras (Sandrine Roy et al., 2005). Based on previous studies showing that different modifications on the C-terminus can target H-Ras to different microdomains (Sandrine Roy et al., 2005), mutational analysis of C-terminus region was carried out to determine the nature of specificity displayed by LanCL1.   H-Ras is anchored to the plasma membrane by two palmitoylated cysteine residues, Cys181 and Cys184, operating in concert with a C-terminal S-farnesyl cysteine  whereas N-Ras lacks cysteine at 184. Previous work has shown the two palmitates serve   
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 distinct biological roles, monopalmitoylation of Cys181 is required and sufficient for efficient trafficking of H-Ras to the plasma membrane (when Cysteine at 184 is mutated), whereas monopalmitoylation of Cys184  (when cysteine at 181 is mutated) does not permit efficient trafficking beyond the Golgi apparatus. Thus, HRasC184S is effectively targeted to the plasma membrane but  segregates into microdomains that are unique to GTP loaded N-Ras (Sandrine Roy et al., 2005).  
 We hypothesized that mutating cysteine 184 on H-Ras would abolish interaction with LanCL1 as the mutant would resemble GTP loaded N-Ras, which does not  interact with LanCL1. Our data shows that the cysteine at position 184 on H-Ras is indeed essential for interaction with LanCL1, as mutating this residue completely abolishes interaction (Figure3.8). Thus, absence of interaction could be attributed to different microdomain localization, as Cys181 monopalmitoylated H-Ras (when C184 is mutated) anchor emulates the GTP-regulated microdomain interactions of N-Ras and LanCL1 does not interact with N-Ras.  Also, plasmamembrane affinities of the monopalmitoylated anchor Cys181-palmitate (C184 is mutated) is equivalent to the dually palmitoylated wild-type anchor, whereas Cys184-palmitate (C181 mutated) is weaker (Sandrine Roy et al., 2005). Since LanCL1 fails to interact with C184A mutant, loss of binding to LanCL1 cannot be attributed to weak membrane associations but rather differential localization, as the mutant now mimics N-Ras on GTP loading.  Alternatively, the cysteine at 184 could be in direct interaction with LanCL1,  possibly regulating post-translational modifications on H-Ras. This is highly unlikely   
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 based on the crystal structure of LanCL1. Seven conserved GXXG motifs are located at the N-termini of the inner helices and are a signature feature of the LanCL1 family of proteins, as they are absent in other double helix containing proteins such as the  farnesyl transferases (Park et al., 1997). These bulged loops reduce the entry size of the central cavity formed by the inner helix barrel by about one-third relative to other known double helix barrel proteins such as Farnesyl transferases (Figure 1.16), making it unlikely a substrate-binding site (Zhang et al., 2009). Thus, LanCL1 is unlikely to use the central cavity as a substrate binding for posttranslational modification as proposed for the farnesyl transferases.  
 
4.3.   BPGAP1 has multiple sites that associate with LanCL1 but H323 on  
          LanCL1 is indispensable for interaction with H-Ras 
 Co-immunoprecipitations using deletion and truncation mutants of LanCL1 with  either BPGAP1 or H-RasG12V enabled us to map the regions involved in association.  BPGAP1 was able to interact with all the mutants (Figure 3.9). Thus, more than one site on LanCL1 may be involved in association with BPGAP1, and removing one site does not affect its interaction, as the other site/sites may be available for association. Though the 
∆3 mutant shows weak association with BPGAP1, it can be considered significant because the expression as revealed by Western shows a very weak expression for the 
∆3 mutant (Figure 3.10) while the immunoblot for the corresponding band shows a stronger band than the whole cell lysate.   
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 The binding region on LanCL1 for H-Ras lies between amino acids 271 and  330 as deleting this region completely abolished interaction and deleting the adjacent amino acids 240-270 also affected association but was unstable between different experimental sets, suggesting that this region may contribute to the stability of the interaction  preventing it from being captured every time. (Figure3.27). The crystal structure of LanCL1 (Figure 1.17) being published by Zhang et al around a similar time greatly facilitated the designing of point mutants. The key amino acids involved in forming the active site greatly matched the binding region determined as by our deletion analysis.   Thus, various point mutants that span this region were generated to determine key residue/residues involved in interaction with H-Ras and binding region was determined by employing co-immunoprecipitation studies (Fig 3.11). H219F, R364E and K317A mutant showed differential binding between experimental sets, suggesting that these residues are not indispensable but contribute to the stability of association with H-Ras.  LanCL1 has a small but detectable dimer population as measured by analytical ultracentrifugation and displayed an interaction with itself as determined by surface Plasmon resonance (SPR) and this dimerisation  significantly reduced by R364E mutation of LanCL1 (Zhang et al., 2009). However, the biological significance of this with respect to interaction with H-Ras remains to be demonstrated.     
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 R4A, K317A, C322A and R364E mutants of LanCL1 completely abolished interaction with GSH. In addition, Arginine at position 4 is essential for interaction with GSH and Eps8 (Zhang et al., 2009).   However mutating residues cysteine 276, cysteine 322 which are highly conserved across the different species and thought to be the putative active site for Zn2+ co-ordination did not affect interaction with H-Ras, ,  also R4E  mutant( does not bind Eps 8) still interacted with H-Ras suggesting  that the mechanism of LanCL1 interaction with H-Ras   is quiet   distinct from Eps8 and GSH.  Histidine 323 is another amino acid that is highly conserved in LanCL1 proteins across different species (Figure 1.15). This conservation suggests that this residue could be of significant importance. This histidine in conjunction with cysteine 276 and 322, co-ordinates Zn2+ (Zhang et al., 2009). Mutating histidine 323 to phenylalanine completely abolishes interaction with H-Ras, thus this histidine plays a crucial role in interacting with H-Ras. However, Zn2+ co-ordination might not play a key role in interaction with H-Ras, as two other residues Cysteine 276 and cysteine 322, which are indispensable for such a mechanism, do not seem to be important for interaction with H-Ras. (Figure 3.12). The crystal structure shows that this histidine  residue lies close to R364 and K317 (which show differential binding) thus a coordination of these three residues could contribute to interaction with H-Ras, with H323 being indispensable (Figure 1.17). 
 
 




4.4.   Significance of BPGAP1 and LanCL1 association on H-Ras regulation   Association of LanCL1 and BPGAP1 could direct  its activity towards distinct nanocluters, leading to distinct signal outputs. LanCL1 also preferentially interacts with H-Ras G12V (Figure 3.8), thus it could be an effector of H-Ras, or a regulator that either directly inactivates or recruits an unknown protein X that regulates H-Ras. It could also facilitate the binding and activity of specific downstream effectors that are specific for given pathways by recruiting them to H-Ras specific domains. The BCH domain is specific for K-Ras and increases its activity and it interacts strongly with the dominant negative K-RasS17N (Aarthi R. PhD thesis, 2010). The interaction of BPGAP1 with LanCL1 would allow BPGAP1 to exert its effect on H-Ras in a mechanism that is distinct from K-Ras, as LanCL1 preferentially binds G12V form of H-Ras. Although BPGAP1 can bind to all Ras isoforms, its interaction with different partners not only  allows specificity towards particular isoforms   they target, but also provide diversity in the mechanisms and cellular effects  resulting from such interactions, contributing further to the multifunctional nature of BPGAP1.   
 
4.4.1.   BPGAP1-LanCL1-H-Ras Triple complex formation is dependent on H- 
Ras activity   LanCL1  increases ERK1/2 activity following EGF stimulation (Figure 3.5) and it associates with H-Ras, indicating that it may play a role in activation of the Ras/MAPK   
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 pathway leading to ERK. BPGAP1 also increases ERK activation following EGF stimulation and is capable of interacting with Ras isoforms. Work by colleagues, Soh F. L. and Aarthi R. have shown the involvement of BCH domain of BPGAP1 in the activation of the Ras/MAPK pathway leading to ERK phosphorylation. Thus, LanCL1 and BPGAP1 seem to act in parallel on similar pathways.  We have demonstrated that  BPGAP1 and LanCL1 can independently interact with H-Ras (Figures 3.6 and 3.7).  LanCL1 also forms complex with endogenous H-Ras following EGF stimulation, suggesting that an activation of the signaling pathway is required for interaction (Figure 3.9).   The activation profile of ERK matches the binding profile of H-Ras to LanCL1, with highest interaction occurring when ERK1/2 activity is at the maximum. This further suggests that the binding of LanCL1 to H-Ras may depend on its activity with LanCL1 binding strongly to the GTP loaded form following stimulation. Since BPGAP1 has also been implicated in Ras/MAPK pathway we wanted to determine if LanCL1, BPGAP1 and endogenous H-Ras could form a triple complex.  Surprisingly LanCL1-BPGAP1 complex formation almost completely abrogated interaction of LanCL1 with endogenous H-Ras (Figure 3.10).  To determine if the complex formation was indeed dependant on the activity of H-Ras we compared triple binding of Wild type, G12V and S17N  H-Ras to LanCL1 in the presence and absence of BPGAP1. LanCL1 interacted with wt-H-Ras and G12V but not S17N, while BPGAP1 could interact with all three forms. However, we observed that the amount of LanCL1   
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 interacting with Wt- H-Ras decreased when BPGAP1 was co-expressed, but was unaffected by G12V which mimics the active conformation (Fig 3.11). This suggests that the activity of H-Ras could be affected when LanCL1 and BPGAP1 associate, whereby H-Ras loses its GTP for GDP preventing LanCL1 from associating with it.   On the other hand, interaction of BPGAP1 with H-Ras is independent of its  H-Ras activity, as binding affinities are not altered in the presence or absence of LanCL1. This  suggests that BPGAP1 binding to H-Ras is not limited by its activity and this corroborates with the finding that BPGAP1 is able to interact with Wt, G12V and S17N H-Ras. It also suggests that BPGAP1 may play a multifunctional role in H-Ras regulation, as it may bind to active and inactive forms in context dependant manner or BCH and GAP domains  could be   independently  interacting  with S17N or G12V forms respectively, thereby regulating it.  Work by colleague has shown that the BCH domain has been shown to bind K-Ras S17N strongly and has the ability to activate K-Ras implicating BCH domain as a positive regulator of K-Ras (Aarthi R. Ph D thesis, 2010).   
4.4.2.   BPGAP1 and LanCL1 regulate H-Ras activity 
 To better understand the individual roles of LanCL1 and BPGAP1 on the Ras/MAPK signaling cascade, we decided to uncouple the effects of LanCL1 and BPGAP1 and their association by knocking down LanCL1 and  determining the effects on the Ras/MAPK pathway. Fold activities of endogenous  H-Ras and ERK were used as   
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 readouts to determine the activation or the inactivation of the pathway.  Transient knockdown down LanCL1 caused a drop in amount of active H-Ras at 5  min after EGF stimulation to about 4 fold lower than knockdown negative control (Figure 3.19).  The ERK activation also dropped in the LanCL1 knockdown by about 1 - 1.5 fold as compared to the knockdown negative control .This confirms that LanCL1 is involved in the activation of the Ras/MAPK pathway leading to ERK1/2 phosphorylation.(Figure 3.20).  The effect of BPGAP1 on the Ras/MAPK pathway in the background of LanCL1  knockdown revealed that BPGAP1 was able to increase the amount of active H-Ras in the LanCL1 knockdown cells (Figure 3.19). The ERK activation also increased by about 3 fold over in LanCL1 knock down- BPGAP1 expressing cells as compared to LanCL1 knockdown negative- BPGAP1 expressing cells.(Figure 3.20).  This suggests that LanCl1 and BPGAP1 can independently activate the Ras/MAPK pathway leading to ERK1/2 activation. Surprisingly, in the absence of LanCL1 knockdown, BPGAP1 is unable to significantly increase the amount of active H-Ras and ERK1/2. This suggests that the association of LanCL1 and BPGAP1 is under regulation, preventing a concerted action of LanCL1 and BPGAP1 on activating the Ras/MAPK pathway.  This could explain the observation that LanCL1 failed to interact with endogenous H-Ras when it was in complex with BPGAP1 and a triple complex between LanCL1, BPGAP1 and endogenous H-Ras could not be captured (Figure3.10). The   
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 interaction also decreased in the over-expression system in the presence of wild type H-Ras but was unaffected  by constitutively active (G12V) form. (Figure 3.11). However,  the precise mechanism and the physiological impact of BPGAP1 and LanCL1 association on H-Ras activity are yet to be determined. 
 
4.5    Association of H-Ras and LanCL1 causes morphological changes in PC12    
          cells upon EGF stimulation 
 EGF is a mitogen that is best known to regulate multiple cellular processes including proliferation, survival, and differentiation. Although it has not been as widely emphasized, EGF is also known to exert neurotrophic and/or neuromodulatory effects, thereby regulating neurite extension and neuronal activity as shown in studies of primary neurons  (Rosenberg A, Noble EP, 1989; Goldshmit Y. et al., 2004)  and PC12 cells( Kasai A. et al., 2005;  Takebayashi  M.et al., 2004). EGF markedly stimulates neuritogenesis in Sigma -1 receptor-overexpressing PC12 cells (σ-1R OE cells) (Minrou Takebayashi et al., 2004). Sigma-1 receptors potentiate epidermal growth factor signaling towards neuritogenesis in PC12 cells through lipid raft reconstitution (Tsai et 
al., 2010).  Microinjection of the Ras oncogene protein promoted the morphological differentiation of PC12 cells into neuron-like cells (Dafna Bar-Sagi and James R. Feramisco, 1985). Expression of oncogenic ras proteins in PC12 cells also caused neurite outgrowth and acquisition of other neuron like characteristics similar to those   
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 observed after NGF treatment (Bar-Sagi et al., 1985; Noda et al., 1985). Also, dominant Inhibitory Mutation on Ha-Ras inhibited neuronal differentiation of PC12 cells without  affecting its growth (Jozsef Szebertnyi et al., 1990) , while H-RasG12V is potent than K-RasG12V in driving differentiation of PC12 cells (Sandrine Roy et al., 2002). In addition, it has been reported that microinjection of PC12 cells with anti-p21 monoclonal antibody blocks neuronal differentiation induced by NGF, suggesting that ras proto-oncogene proteins may normally be involved in the NGF signal transduction pathway (Hagag et al., 1986). Thus, activation of H-Ras has been shown to be associated with neuronal differentiation. Though there has been compelling evidence for EGF mediated neurite differentiation, none of the studies had been conducted with H-Ras and  if so differentiation was either studied using the dominant active G12V form or under stimulation with NGF, if wild type H-Ras was used.  LanCL1 has been shown to associate with endogenous H-Ras following EGF stimulation in 293T cells  and LanCL1 knockdown causes a decrease in  active H-Ras upon EGF stimulation, hence wanted to explore the effects of LanCL1 and H-Ras on PC12 morphology upon EGF stimulation. Results showed that LanCL1 expression caused formation of “starlets” in the presence of EGF and the cell body has an expanded shape with punctuate structures along the periphery (Figure 3.21). Expanded cell body has been observed when activated H-Ras V12 from synapsin promoter in adult CNS is expressed in cortical neurons (Arendt et al., 2004). Thus increased soma size can be attributed to increased endogenous H-Ras activity in the presence of LanCL1.   
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 On the other hand, H-Ras expression caused formation of neurites about 4-5 times cell body length in the presence of EGF. However, the H-RasC184A mutants had shorter neurites and were only about 2 times body length. Unstimulated counterparts  had the shortest neurites and the presence of short neurites in the absence of growth factors can be attributed to background activity of H-Ras. Thus, stimulation with EGF  causes marked neurite outgrowth in H-Ras transfected cells as compared to the C184A mutant, unstimulated H-Ras transfected or untransfected cells (Figure 3.22).  H-Ras requires co-expression of LanCL1 to induce novel morphology  in PC12 cells, characterized by increased soma,  shortening and widening of neurites. This change in morphology requires EGF stimulation as unstimulated control cells retain morphology of  unstimulated  wild type H-Ras cells (Figure 3.23, panels 1 and 2 respectively). Single H-Ras transfected cell in the background having long neurites shows that co-expression of LanCL1 is required for the morphological change observed.  Ras-GRF1 confers exchange factor activity towards Ras (Cen et al., 1993) and for Rac1 (Kiyono et al., 1999). Ras-GRF1 selectively activates H-Ras rather than K or N-Ras and induces morphological changes in PC12 cells, which was characterized by a 10-fold increase in soma size and by neurite extension. The Ras GEF domain of Ras-GRF1 was essential for neurite formation, but did not expand the soma. This neurite extension was blocked by inhibition of MAP kinase activation, but was independent of dominant-negative Rac1 or RhoA showing that activation of the MAPK pathway caused neurite extension. The Rac GEF domain of Ras-GRF1 produced the expanded phenotype when   
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4.5.1.   Significance of H-Ras activation and soma size Activation of H-Ras is significant, as this isoform of Ras is strongly linked to regulation of long-term potentiation, neuronal morphology, and memory. Knockout mice deficient in H-Ras have aberrant NMDA receptor-dependent long-term    potentiation (Manabe et al., 2000). Further, transgenic expression of an activated H-RasV12 from a synapsin promoter in adult CNS neurons increases soma size and  dendritic spine density of cortical neurons (Arendt et al., 2004) and was also protective against neural degeneration (Heumann et al., 2000). Soma size of prefrontal and hippocampal neurons are reduced in major depression (Rajkowska et al., 1999; Stockmeier et al., 2004).   Thus is it important to understand signaling pathways that regulate this morphology. The significance of Ras induced increases in cell size is not clear, but in addition to the study on PC12 cells expressing Ras-GRF1 and H-Ras, and the  observations on cortical neurons expressing H-Ras V12 (Arendt et al., 2004), there is also evidence for this phenomenon in hypertrophy of cardiomyocytes (Ramirez et al., 1997). Expression of constitutively-activated Rac2 (Daniels et al., 1998) or stimulation of PC12 cells that overexpress the TrkB receptor with brain-derived neurotrophic factor (Iwasaki et al., 1997) have been reported to produce some soma expansion. In the latter case, expansion of the soma took 7 days to occur and was preceded by an apparent thickening of neurite extensions in comparison to those stimulated by NGF treatment   
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 (Iwasaki et al., 1997). In our case, the morphological change occurred in 24 hours with 20ng/ml EGF,  showing it to be potent.    Modification of dendritic shape is thought to be a morphological correlate of long-term potentiation and memory (Carlisle and Kennedy, 2005). The modification of PC12 cell morphology by Ras GRF1 could be a parallel phenomenon to that process (H.  Yang et al., 2006). In the adult brain, where cell proliferation does not normally occur, the H-Ras gene was dominantly expressed, and analysis of H-Ras deficient mice revealed an important role for H-Ras in synaptic transmission (Manabe et al., 2000). These along with the fact that LanCL1 specifically interacts with H-Ras and  has the highest expression in the brain (Mayer, et al., 1998; Bauer et al., 2000; Mayer et al., 2001), causes us to speculate that effect of LanCL1 on H-Ras resulting in changes on neuron morphology might be of physiological relevance. 
 
 
4.6.   BPGAP1 and LanCL1 modulate neuronal differentiation  The rat pheochromocytoma PC12 cell line has been an invaluable model system for studying neuritogenesis. Nerve growth factor (NGF) elicits multiple aspects of neurite outgrowth in PC12 cells (Jingnan Xiao et al., 2003). Studies in PC12 cells have demonstrated an important role for ERK in NGF-dependent neuronal differentiation and  neuritogenesis (Fukuda et al., 1995; Pang et al., 1995). ERK is essential in all aspects of neuritogenesis, i.e. initiation, rapid neurite elongation, and branching/contact  
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  formation, JNK is involved in the later stages of neuritogenesis when the cells form extensive networks and establish contacts (Jingnan Xiao et al., 2003).   Previous studies have demonstrated that oncogenic ras proteins induce morphological and biochemical changes in PC12 cells that mimic the events of NGF-induced neuronal differentiation (Sugimoto et al., 1988; Hagag et al., 1986; Sassone-Corsi et al., 1989; Bar-Sagi et al., 1985). The possible involvement of normal Ras proteins in NGF-induced differentiation of PC12 cells has also been suggested by experiments in which microinjection of an anti-p21 monoclonal antibody was found to block NGF-induced neurite outgrowth (Hagag et al., 1986). This effect caused by Ras proteins could be attributed to the activation of Ras upon stimulation with NGF leading to neuronal differentiation.   During axonal growth, new neurofilament subunits are incorporated all along the axon in a dynamic process. The level of neurofilament gene expression directly controls axonal diameter, which in turn controls how fast electrical signals travel down the axon (Alberts and Bruce, 2002). NO (NGF-induced neuronal outgrowth) and NF-L (neurofilament) mRNA expression in PC12 cells increase monotonously with time when the cells were incubated with NGF at a concentration of 50 ng/ml, leading to a good correlation between the two endpoints. At sub-optimal NGF concentration (5 ng/ml), marked differences in the kinetics of NO and NF-L mRNA expression were observed. Although mRNA levels up to day 3 were nearly the same as with 50 ng/ml NGF, NO was delayed until day 2. Overall, the degree of NO was considerably lower at 5 ng/ml NGF when compared to 50 ng/ml (Schimmelpfeng et al., 2004). 
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 BPGAP1 and LanCL1 has been shown to increase active H-Ras and cause ERK1/2 activation independently and they can form complex in PC12 cells upon NGF stimulation. We wanted to determine if we could recapitulate the effects of H-Ras regulation by LanCL1 and BPGAP1, and co-relate neuronal outgrowth as a readout of H- Ras activity leading to ERK activation in the presence of NGF. Therefore, we wanted to determine the effects BPGAP1 and LanCL1, and their association on neurite outgrowth  in PC12 cells, at suboptimal concentrations of 5ng/ml whereby no significant NO would occur for control cells, and any differences observed in transfected cells can be entirely attributed to the proteins under study.  
 
 
4.6.1. BPGAP1 mediated neurite outgrowth is under stringent regulation by  
concerted action of BPGAP1 and LanCL1  Live imaging revealed that BPGAP1 caused significant neurite outgrowth in PC12 cells under suboptimal conditions of 5ng/ml. Initiation occurred as early as after 1 hour of stimulation and marked increase in neurite length occurred from 4 hours and progressed steadily until 8 and 12 hours reaching 3-4 cell body length (Figure 3.17). Control untransfected cells or Vector control did not show any potentiation at these concentrations for the time points observed, correlating with the observation that stimulation of PC12 cells with 5ng/ml NGF causes no neurite outgrowth until day 2 of stimulation (Schimmelpfeng et al., 2004).   
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 LanCL1 mediated neurite outgrowth progressed slowly at suboptimal NGF stimulation (Figure 3.21). Thus, BPGAP1 seems to potentiate neurite outgrowth much earlier and more potently than LanCL1 at suboptimal NGF concentrations.   Differentiation was delayed when BPGAP1 and LanCL1 were co-expressed and no significant neurite outgrowth occurred until 12 hours after stimulation.   This could be of physiological relevance, whereby differentiation is under stringent regulation and  neurite potentiation occurs only when cells are subjected to stimulation for extended periods before they respond to signaling cues at suboptimal levels. Thus, concerted action of LanCL1 and BPGAP1 modulate the neurite potentiation exhibited by BPGAP1 but the precise mechanism awaits further characterisation. 
 
 
4.6.2.   GAP activity of BPGAP1 required for concerted modulation of neuronal  
             differentiation by BPGAP1 and LanCL1  BPGAP1 causes morphological changes in MCF7 cells in a process that involves activation of Rac1 and Cdc42 and inactivation of RhoA. These effects are brought about by the concerted action of the BCH domain and the GAP domain. The BCH domain is responsible for the formation of short pseudopodia and the GAP domain is responsible for the formation of long pseudopodia. The formation of long pseudopodia by the GAP domain requires inactivation of RhoA (Shang et al., 2003).   
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4.6.3.   BPGAP1 and LanCL1 modulate neuronal differentiation by regulating  
H-Ras activity   To determine the involvement of H-Ras activation in BPGAP1 mediated neurite outgrowth, RBD assays were performed at the time points when neurite potentiation was observed during live imaging. (Figure 3.23) shows a robust increase in H-Ras  activation in the presence of BPGAP1 as compared to BPGAP1 and LanCL1 co-transfected cells or Vector control. H-Ras activation increased progressively in BPGAP1 transfected cells from about t 1 fold at 1hr to 3 fold at 4 hour and 4 fold at 12 hour as compared to vector control.   There was no significant increase in active H-Ras for LanCL1 expressing cells at 1 hr, and more than ½ fold at 4 hours and about 1.5 fold at 12 hour. LanCL1-BPGAP1 co-transfected cells show no significant increase in H-Ras until  12 hours which  was only comparable to 4 hour time point for BPGAP1 expressing cells (Figure 3.24). ERK analysis also revealed enhanced ERK phosphorylation profile at time points when there was an increase in active H-Ras. Thus the neuronal differentiation mediated by BPGAP1 and the concerted modulation by LanCL1 and BPGAP1 can be attributed to the amount of active H-Ras available for activating the Ras/MAPK pathway leading to ERK.     
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4.7.   BPGAP1 interaction with LanCL1 modulates Ras/ERK activation and  
          neuronal differentiation – a Model  LanCL1 expression caused increased H-Ras activity and ERK activation resulting in novel morphology of H-Ras transfected PC12 cells, characterized by  increased soma size, and shorter but broader neurites. (Figure 3.31) BPGAP1 also interacts with and increases active H-Ras leading to enhanced ERK activation resulting  in potentiation of neurite outgrowth (Figures 3.17). H-Ras has the ability to bind both BPGAP1 and LanCL1. ERK activation is increased when LanCL1 or BPGAP1 was expressed, this could be mediated by interacting with and increasing active H-Ras, resulting in sustained ERK activation following EGF stimulation. This co-relates with the finding that LanCL1 knockdown decreases active H-Ras and BPGAP1 expression increases H-Ras activity and ERK phosphorylation in the LanCL1 knockdown.   BPGAP1 has been proposed to exist in closed conformation and upon stimulation with EGF or NGF its structure opens up facilitating interaction with interacting partners (Figure 3.2, 3.3, 3.4). Though LanCL1 and BPGAP1 association is dependent on stimulation, their association decreases the amount of active H-Ras. Similarly, BPGAP1 potentiated PC12 differentiation is delayed in the presence of LanCL1 (Figure 3.17; 
3.18 respectively) and  the amount  of active H-Ras co-relates well with the extent of neurite outgrowth, with increased H-Ras activity leading to neurite outgrowth, which is delayed when LanCL1 and BPGAP1 are co-expressed  with a concomitant drop in amounts  of active H-Ras  (Figure 3.23).   
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Figure 4.1 BPGAP1 interaction with LanCL1 modulates Ras/ERK activation and 
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CONCLUSION AND FUTURE PERSPECTIVES 
 
5.1. Conclusion  
 
This work has confirmed the interaction between LanCL1 and BPGAP1 and has 
shown that the interaction is dependent on stimulation by EGF or NGF. This could be 
due to intramolecular interaction of BPGAP1, preventing it from associating with 
LanCL1. Alternatively, BPGAP1 could be under allosteric regulation requiring change in 
conformation.  Activation by EGF or NGF releases the intramolecular interaction or 
causes changes in conformation of  BPGAP1 facilitating interaction with LanCL1. We 
were unable to determine the binding site for BPGAP1 and LanCL1 as more than one 
sites are involved in the interaction. LanCL1 also requires a composite BPGAP1 for 
interaction and proline rich region imposes a negative regulation, possibly by occluding 
the binding site and preventing interaction.  
  
BPGAP1 interacts with K, H and N-Ras while LanCL1 is specific for H-Ras. 
Mutational analysis on H-Ras, revealed that the microdomain localization of the 
different Ras isoforms may contribute to the specificity exhibited by LanCL1. BPGAP1 
and LanCL1 can independently act on the Ras/MAPK pathway leading to ERK1/2 
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Knocking down LanCL1 decreased the amount of active H-Ras and ERK1/2 
activation and BPGAP1 overexpression increased the H-Ras activity/ ERK1/2 activity in 
the LanCL1 knockdown, showing that LanCL1 and BPGAP1 can independently act on the 
Ras/MAPK pathway leading to ERK1/2 activation through their interaction with and H-
Ras. 
 
LanCL1 interacts preferentially with active H-Ras as it binds G12V form stronger 
while BPGAP1 interaction with H-Ras is not activity dependant. However, triple 
complex formation occurs only when H-Ras is in the active form as observed with G12V 
mutant, suggesting that H-Ras activity plays a key role in interaction between the trio, 
LanCL1, BPGAP1 and H-Ras. Association of BPGAP1 and LanCL1 regulates H-Ras activity 
negatively, as loss of interaction or drop in interaction with the wt H-Ras or endogenous 
H-Ras occurs when BPGAP1 is co-expressed with LanCL1. This is also corroborates with 
the findings in the LanCL1 knockdown. 
 
Extensive work has been done by our group in establishing the role of BPGAP1 in 
Rho GTPase signaling. It was characterized as a GAP towards Rho A (Shang et al., 2003). 
Its Rho GAP activity is important in mediating cell migration and enhanced ERK 
phosphorylation by enhancing EGF receptor mediated endocytosis (Lua and Low, 
2005). 
 
We have now established a role for BPGAP1 and LanCL1 in neuronal 
differentiation. BPGAP1 can activate Ras/MAPK pathway by activating H-Ras leading to 
enhanced ERK1/2 phosphorylation resulting in neurite potentiation in PC12 cells under  
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suboptimal NGF stimulation. We have also demonstrated a role for LanCL1 in EGF 
mediated activation of H-Ras causing morphological changes in PC12 cells resulting in 
increased soma size, which is blocked by the non interfering mutants, H323F LanCL1 
and HRasC184A. Thus we have identified the critical residues on LanCL1 and H-Ras that 
are essential for their interaction by mutational studies and confirmed their cellular 
effects by confocal microscopy. 
 
Also a novel mechanism of H-Ras regulation has been demonstrated whereby; 
BPGAP1 and LanCL1 can independently activate H-Ras/ERK and potentiate PC12 
differentiation or cause morphological changes. For BPGAP1, this induction was GAP-
independent. However, such a stimulative effect was delayed when they were both co-
expressed.  And such mutual neutralizing effect required the GAP activity of BPGAP1, 
possibly providing a mechanism for cross talk with Rho signaling pathway. Collectively, 
despite acting separately as inducer for Ras/ERK, timely BPGAP1-LanC1 interaction 
could act as a feedback loop to modulate their signaling output, the detailed molecular 
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5.2. Future perspectives 
 
Our work has revealed novel functions of BPGAP1 and LanCL1 in Ras GTPase 
signaling, specifically towards H-Ras and these are consistent with the hypothetical 
model described in Figure 4.1.  
Determining the binding region between LanCL1 and BPGAP1 would give clues 
to the possible mechanism involved but this still remains elusive as the binding region 
between BPGAP1 and LanCL1 involves more than one binding site on each. Solving the 
structure of BPGAP1 or its domains would enable us to determine the key residues and 
the possible mechanism. This would also provide insight into the mechanism of 
interaction between BPGAP1 and H-Ras, and enable us to determine the precise 
mechanism of BPGAP1 regulation on H-Ras activity mediated by LanCL1.  
 
Our work has shown that this regulation requires the GAP activity of BPGAP1. 
BPGAP1 has GAP activity towards Rho and has been shown to regulate pseudopodia 
formation and cell migration by the concerted action of the BCH domain, proline rich 
region and GAP domain in a mechanism that requires Rho A inactivation. Though we 
have demonstrated that LanCL1 mediated BPGAP1 regulation on H-Ras requires the 
GAP activity of BPGAP1, the underlying mechanism is yet to be determined. 
 
Determining how the GAP activity of BPGAP1 is involved in LanCL1 mediated H-
Ras regulation would enable us to understand if the regulation is brought about by cross 
talk with Rho, and if so how this would modulate H-Ras activity. This can be determined  
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by employing simultaneous RBD assays using Rho-RBD  to pull down Rho and Raf-RBD 
to pull down H-Ras in the presence of LanCL1 and BPGAP1.  
 
Alternatively, BPGAP1 could act as Ras GAP towards H-Ras and causing its 
inactivation in the presence of LanCL1. Though it is highly unlikely as BPGAP1 has been 
shown to be specific towards Rho A. However, it is essential that this option not be ruled 
out, and the underlying mechanism of GAP domain mediated regulation by BPGAP1 
need to be addressed by employing GAP assays. Also, in vitro GTP loading assays should 
be employed to validate the findings in the in vivo RBD assays. 
 
Apart  from delineating the underlying mechanism of BPGAP1 and LanCL1 
mediated regulation on H-Ras, it would essential to determine the spatio- temporal 
dynamics of these interactions. Live imaging using GFP based Fluorescence resonance 
energy transfer (FRET) probes can be used to study the spatio-temporal regulation of 
small GTPases (Nakamura et al., 2006). Probes for Rho and Ras GTPases have been used 
to study the precise regulation of cell dynamics in a  spatio-temporal context (Yokono et 
al., 2006; Wu et al., 2009; Machacek et al., 2009). Multiple probes were used 
simultaneously to show coordination of Rac1, RhoA  and Cdc42 Rho GTPase activities in 
cell protrusions (Machacek et al., 2009) and the coordination of Rac1 and RhoA in cell 
motility (Wu et al., 2009). 
 
BGPAP1 being able to  interact with both Ras and RhoGTPases and LanCL1 being 
specific for H-Ras, the spatio temporal regulation of such complex and intricate  
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signaling pathways can better understood by employing live imaging using Ras and Rho 
biosensors. 
 
Furthermore, human and rat isoforms of LanCL1 are highly homologous and the 
sh RNA target sites on human LanCL1 differ in sequence from the rat sequence by only 
two nucleotides, hence rat sh RNA sequences generated from  corresponding  sites on 
human LanCL1 should be able to knockdown rat LancL1 efficiently. Stable cell lines can 
be created for LanCL1 in PC12 cells. Stable cell lines for BPGAP1 is also being created in 
our group. These knockdown stable lines can be used to not only address  the 
importance of LanCL1 and BPGAP1 on Ras signaling but also their impact on neuronal 
morphology using PC12 as a model. 
  
Current work also revealed the BPGAP1 is phosphorylated. (Figure 5.1) Protein 
phosphorylation plays a significant role in a wide range of cellular processes. Reversible 
phosphorylation of proteins is an important regulatory mechanism. (Cozzone A. J et 
al.,1988; Stock JB, 1989; Chang C, Stewart RC, 1998; Barford D. et al., 1998).  
 
 Many enzymes and receptors are regulated by phosphorylation and  
dephosphorylation, whereby they act as binary switches regulating their activation or  
inactivation. Phosphorylation usually occurs on serine, threonine, and tyrosine residues 
in eukaryotic proteins. In addition, phosphorylation occurs on the basic amino acid 
residues histidine, arginine or lysine in prokaryotic proteins (Cozzone AJ et al., 1988; 
Stock JB, 1989).  
 
         Chapter 5       Conclusions and Future Perspectives 
 
  210 
 
 
The addition of a phosphate (PO4) molecule to a polar R group of an amino acid 
residue can turn a hydrophobic portion of a protein into a polar and extremely 
hydrophilic portion. In this way, it can introduce a conformational change in the 
structure of the protein via interaction with other hydrophobic and hydrophilic 
residues in the protein. One such example of the regulatory role played by 
phosphorylation is the p53 tumor suppressor protein. The p53 protein is heavily 
regulated (Ashcroft M et al., 1999) and contains more than 18 different phosphorylation 
sites (Bates S and Vousden KH, 1996). 
 
   BPGAP1 has also been shown to have intramolecular interactions which  could 
be released upon stimulation. Alternatively, a phosphorylation dependant allosteric 
regulation could cause a conformational change upon stimulation, enabling BPGAP1 to 
interact with its partners resulting in signal specific cellular responses. The mechanism 
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HA-aMEK2                          +            +    +          +     +          +    +         +
CIP                                                                                                          +     +    +    
37º C                                                                  +     +    +    +   +   +    +     +      +
Na2VO3                                                                                                                          - - - - - -
1      2    3      4      5      6     7      8     9   10     11  12   13  
FLAG-BPGAP1 +     +     +     +      +      +     +      +     +    +      +    +     +        













Figure 5.1:BPGAP1 is phosphorylated.  Immunoblot probed with anti PY20 (detects 
tyrosine phosphorylation) reveals that BPGAP1 is phosphorylated. Phosphorylation is 
removed by treatment with CIAP (Calf intestinal alkaline phosphatase) (lanes 11-13) or 
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Nucleotide  sequence of human p40 cDNA  corresponding to LanCL1 obtained from 
EMBL that was used to design primers for cloning of human LanCL1 cDNA.The 
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CLUSTAL W (1.83) multiple sequence alignment (forward primer) 
 
 
ori             ------------------------------------ATGGCTCAAAGGGCCTTCCCGAAT 
SJ2             CTGAAGAGGACNTGATTGCGGAAACATATGNCATCCATGGCTCAAAGGGCCTTCCCGAAT 
                                                    ************************ 
 
ori             CCTTATGCTGATTATAACAAATCCCTGGCCGAAGGCTACTTTGATGCTGCCGGGAGGCTG 
SJ2             CCTTATGCTGATTATAACAAATCCCTGGCCGAAGGCTACTTTGATGCTGCCGGGAGGCTG 
                ************************************************************ 
 
ori             ACTCCTGAGTTCTCACAACGCTTGACCAATAAGATTCGGGAGCTTCTTCAGCAAATGGAG 
SJ2             ACTCCTGAGTTCTCACAACGCTTGACCAATAAGATTCGGGAGCTTCTTCAGCAAATGGAG 
                ************************************************************ 
 
ori             AGAGGCCTGAAATCAGCAGACCCTCGGGATGGCACCGGTTACACTGGCTGGGCAGGTATT 
SJ2             AGAGGCCTGAAATCAGCAGACCCTCGGGATGGCACCGGTTACACTGGCTGGGCAGGTATT 
                ************************************************************ 
 
ori             GCTGTGCTTTACTTACATCTTTATGATGTATTTGGGGACCCTGCCTACCTACAGTTAGCA 
SJ2             GCTGTGCTTTACTTACATCTTTATGATGTATTTGGGGACCCTGCCTACCTACAGTTAGCA 
                ************************************************************ 
 
ori             CATGGCTATGTAAAGCAAAGTCTGAACTGCTTAACCAAGCGCTCCATCACCTTCCTTTGT 
SJ2             CATGGCTATGTAAAGCAAAGTCTGAACTGCTTAACCAAGCGCTCCATCACCTTCCTTTGT 
                ************************************************************ 
 
ori             GGGGATGCAGGCCCCCTGGCAGTGGCCGCTGTGCTATATCACAAGATGAACAATGAGAAG 
SJ2             GGGGATGCAGGCCCCCTGGCAGTGGCCGCTGTGCTATATCACAAGATGAACAATGAGAAG 
                ************************************************************ 
 
ori             CAGGCAGAAGATTGCATCACACGGCTAATTCACCTAAATAAGATTGATCCTCATGCTCCA 
SJ2             CAGGCAGAAGATTGCATCACACGGCTAATTCACCTAAATAAGATTGATCCTCATGCTCCA 
                ************************************************************ 
 
ori             AATGAAATGCTCTATGGGCGAATAGGCTACATCTATGCTCTTCTTTTTGTCAATAAGAAC 
SJ2             AATGAAATGCTCTATGGGCGAATAGGCTACATCTATGCTCTTCTTTTTGTCAATAAGAAC 
                ************************************************************ 
 
ori             TTTGGAGTGGAAAAGATTCCTCAAAGCCATATTCAGCAGATTTGTGAAACAATTTTAACC 
SJ2             TTTGGAGTGGAAAAGATTCCTCAAAGCCATATTCAGCAGATTTGTGAAACAATTTTAACC 
                ************************************************************ 
 
ori             TCTGGAGAAAAC 
SJ2             TCTGGAGAAAAC 




CLUSTAL W (1.83) multiple sequence alignment(internal forwards primer) 
 
 
ori                         TGCTCTATGGGCGAATAGGCTACATCTAT 
seqsj3                      TGCTCTATGGGCGAATAGGCTACATCTAT 
                                               ***************************** 
 
ori             GCTCTTCTTTTTGTCAATAAGAACTTTGGAGTGGAAAAGATTCCTCAAAGCCATATTCAG 
seqsj3          GCTCTTCTTTTTGTCAATAAGAACTTTGGAGTGGAAAAGATTCCTCAAAGCCATATTCAG 
                ************************************************************ 
 
ori             CAGATTTGTGAAACAATTTTAACCTCTGGAGAAAACCTAGCTAGGAAGAGAAACTTCACG 
seqsj3          CAGATTTGTGAAACAATTTTAACCTCTGGAGAAAACCTAGCTAGGAAGAGAAACTTCACG 
                ************************************************************ 
 
ori             GCAAAGTCTCCACTGATGTATGAATGGTACCAGGAATATTATGTAGGGGCTGCTCATGGC 
seqsj3          GCAAAGTCTCCACTGATGTATGAATGGTACCAGGAATATTATGTAGGGGCTGCTCATGGC 
                ************************************************************ 
 
ori             CTGGCTGGAATTTATTACTACCTGATGCAGCCCAGCCTTCAAGTGAGCCAAGGGAAGTTA 
seqsj3          CTGGCTGGAATTTATTACTACCTGATGCAGCCCAGCCTTCAAGTGAGCCAAGGGAAGTTA 
                ************************************************************ 
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ori             CATAGTTTGGTCAAGCCCAGTGTAGACTACGTCTGCCAGCTGAAATTCCCTTCTGGCAAT 
seqsj3          CATAGTTTGGTCAAGCCCAGTGTAGACTACGTCTGCCAGCTGAAATTCCCTTCTGGCAAT 
                ************************************************************ 
 
ori             TACCCTCCATGTATAGGTGATAATCGAGATCTGCTTGTCCATTGGTGCCATGGCGCCCCT 
seqsj3          TACCCTCCATGTATAGGTGATAATCGAGATCTGCTTGTCCATTGGTGCCATGGCGCCCCT 
                ************************************************************ 
 
ori             GGGGTAATCTACATGCTCATCCAGGCCTATAAGGTATTCAGAGAGGAAAAGTATCTCTGT 
seqsj3          GGGGTAATCTACATGCTCATCCAGGCCTATAAGGTATTCAGAGAGGAAAAGTATCTCTGT 
                ************************************************************ 
 
ori             GATGCCTATCAGTGTGCTGATGTGATCTGGCAATATGGGTTGCTGAAGAAGGGATATGGG 
seqsj3          GATGCCTATCAGTGTGCTGATGTGATCTGGCAATATGGGTTGCTGAAGAAGGGATATGGG 
                ************************************************************ 
 
ori             CTGTGCCACGGTTCTGCAGGGAATGCCTATGCCTTCCTGACACTCTACAACCTCACACAG 
seqsj3          CTGTGCCACGGTTCTGCAGGGAATGCCTATGCCTTCCTGACACTCTACAACCTCACACAG 
                ************************************************************ 
 
ori             GACATGAAGTACCTGTATAGGGCCTGTAAGTTTGCTGAATGGTGCTTAGAGTATGGAGAA 
seqsj3          GACATGAAGTACCTGTATAGGGCCTGTAAGTTTGCTGAATGGTGCTTAGAGTATGGAGAA 
                ************************************************************ 
 
ori             CATGG 








ori                  TAGGGCCTGTAAGTTTGCTGAATGGTGCTTAGAGTATGGAGAACATGGATGCA 
seqsj4                 TAGGGCCTGTAAGTTTGCTGAATGGTGCTTAGAGTATGGAGAACATGGATGCA 
                       ***************************************************** 
 
ori             GAACACCAGACACCCCTTTCTCTCTCTTTGAAGGAATGGCTGGAACAATATATTTCCTGG 
seqsj4          GAACACCAGACACCCCTTTCTCTCTCTTTGAAGGAATGGCTGGAACAATATATTTCCTGG 
                ************************************************************ 
 
ori             CTGACCTGCTAGTCCCCACAAAAGCCAGGTTCCCTGCATTTGAACTCTGA---------- 
seqsj4          CTGACCTGCTAGTCCCCACAAAAGCCAGGTTCCCTGCATTTGAACTCTGACTCGAGGCGG 
                **************************************************           
 
ori             ------------------------------------------------------------ 
seqsj4          CCGCCCCGGGCTGCAGGAGCTCGGTACCAGATCTTATTAAAGCAGAACTTGTTTATTGCA 
                                                                             
 
                                                                      
The clustal W alignment of the LanCL1 clone. The sequencing was carried out 
using three Forward primers and three reverse primers at various positions to 
ensure complete sequencing . The results obtained with forward primers are 
depicted here. Green colour indicates vector backbone, overlapping regions 
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The secondary structure of LancL1 (This structure was based on the protein 
sequence CAA72205 predicted with the NPS@ (Network Protein Sequence 
@nalysis) consensus secondary structure prediction web server 
(http://www.npsa-pbil.ibcp.fr) that incorporated 10 secondary structure 
prediction methods. The blue highlighted region indicates the amino acids 
deleted in the 3 mutant . 
 
 






























mCherry and GFP Vectors unable to potentiate neurite outgrowth at 
suboptimal NGF stimulation. PC12 cells  were seeded on poly D-Lysine coated 
6-well culture plates  for 24 hours before they  were co-transfected with 
pmCherry and GFP Vectors using Lipofectamine 2000 as described in “Materials 
and Methods”. Prior to live imaging using Olympus live imaging system, the cells  
were stimulated with suboptimal concentrations of 5ng/ml NGF. Representative 
fluorescent and phase contrast  images captured on the live imaging system 
using manual focus fuction at times points  1, 4, 8 and 12 hours for cells co-
expressing  pmCherry and GFP-vector are shown. Fluorescent images (First and 
second columns;  panels 1 to 4) and phase contrast images (third column; panels 
1 to4). Yellow arrows indicate neurite positions. 
 
